

ONUR BAŞER

Office Address
Boğaziçi University
Faculty of Economics and Administrative Sciences
Washburn Hall #407
Bebek 34342 Istanbul/Turkey

EDUCATION

Doctor of Philosophy, Economics May 2002
Michigan State University, East Lansing, MI
THESIS: Estimation from Censored Medical Cost Data
ADVISOR: Jeffrey M. Wooldridge

Master of Science, Statistics May 2001
Michigan State University, East Lansing, MI

Master of Arts, Applied Economics May 1998
Michigan State University, East Lansing, MI

Master of Science, Economics May 1996
Middle East Technical University, Ankara, Turkey

Bachelor of Science, Economics May 1994
Middle East Technical University, Ankara, Turkey

ACADEMIC EXPERIENCE

Boğaziçi University, Istanbul, Turkey Sep 2023 – Present

Graduate School of Public Health, CUNY, New York Jul 2022 – Present

University of Michigan, Ann Arbor, MI Aug 2006 – Sep 2023
Adjunct Professor of Internal Medicine Aug 2010 – Aug 2023
Associate Professor of Surgical Sciences Aug 2006 – Aug 2010

John D. Dingell VA Medical Center, Detroit, MI Jun 2018 – Sep 2023
Research Data Scientist of VA Data Systems

MEF University, Istanbul, Turkey Sep 2015 – Sep 2023
Professor of Economics, Department of Economics 2015 – 2023
Department Chair, Department of Economics 2015 – 2021

Columbia University, New York, NY Sep 2015 – Jun 2018
Assistant Professor of Surgery (Research tract) 2015 – 2017
Associate Professor of Surgery (in Surgical Science) (Research tract) 2017 – 2018

Michigan State University, East Lansing, MI Aug 1997 – May 2002
Teaching Assistant, Department of Mathematics 1997 – 2002
Teaching Assistant, Department of Economics 1998 – 2002
Mathematics Program Developer, Office of Supportive Service 1998 – 2002
Research Associate, Department of Family Practice 2000 – 2002

Middle East Technical University, Ankara, Turkey Aug 1993 – Aug 1996
Student Assistant, Department of Economics 1993 – 1994
Teaching Assistant, Economics 1994 – 1996

NON-ACADEMIC EXPERIENCE

Milliman, Inc., New York, NY
Head of Data Analytics, Senior Scientist Sep 2022 – Jan 2023

STATinMED Research, Ann Arbor, MI
Founder and Chief Executive Officer Apr 2007 – Sep 2018

IBM Watson, Ann Arbor, MI
Health Economist Aug 2002 – Apr 2007

Michigan Economics Development Corporation, East Lansing, MI
Database Management Expert May 1998 – May 2002

OYAK, Ankara, Turkey
Auditor May 1995 – Apr 1996

OTHER SERVICES

Boğaziçi University
Interim Dean, Faculty of Economics and Administrative Sciences Feb 2025 – Present
Member of University Executive Board Jan 2024 – Present
Member of the University Senate Jan 2024 – Present
Dean, Faculty of Managerial Sciences Jan 2024 – Feb 2025

Journal of Health Economics and Outcomes Research
Editor in Chief May 2015 – Present

New York City College of Technology
Professional Development Advisory Board Member Aug 2010 – Present

International Society of Pharmaceuticals and Outcomes Research
Professor of Distance Learning Program Aug 2008 – Present

New Jersey District Court
Litigation Expert, Amgen v Ortho Biotech (Antitrust Litigation)

Aug 2007 – Jul 2008

TEACHING EXPERIENCE

Boğaziçi University

ECON 102, Introduction to Macroeconomics

ECON 101, Introduction to Microeconomics

Graduate School of Public Health

CUNYPUBH 698, Capstone Project

PUB 635, Economics of Happiness and Wellbeing

HPAM 621, Health Economics

HPAM 621, Behavioral Economics

MEF University, Istanbul, Turkey

ECON 301, Econometrics

ECON 405, Seminar in Quantitative Methods

ECON 445, Managerial Economics

ECON 203, Statistics for Economics and Business

ECON 302, Time Series Models

ECON 503, Quantitative Methods for Economics and Finance

ECON 503, Panel Data Analysis – Graduate Program

A.

PUBLISHED ARTICLES

2026

A.1. Law AW, Mayer DC, Zakeri M, Yapar N, Passarelli A, Baser O, MacDonald PDM. Administration timing of respiratory syncytial virus preventatives among commercially insured populations in the United States: 2024 – 2025 RSV season. *Vaccines*. 2026, forthcoming.

A.2. Zakeri M, Wagner S, Guo W, Baser O. Brexpiprazole and behavioral suicidality in MDD: A real-world advantage over other oral atypical antipsychotics. *Pharmacoeconomics and Drug Safety*. 2026, forthcoming.

A.3. Zakeri M, Wagner S, Baser E, Baser O. Beyond weight loss: Semaglutide and tirzepatide cut sleep apnea risk in older adults. *Obesity*. 2026, forthcoming.

A.4. Baser O, Nchekwube P, Guo W. Safety of medication abortion: analysis of insurance claims, 2017-2024. *Women's Health Issues*. 2026, forthcoming.

A.5. Mollard E, Burkhard J, Johnson D, Joo E, Baser O, Mohamed M, Nguyen V, Vera T, Toubouti Y, Koch M, Tan R. Evaluating the relationship between maternal healthcare policies and practices on postpartum depression (PPD) diagnosis incidence in the US. *Women's Health Issues*. 2026, forthcoming.

A.6. Baser O, Waters HC, Yapar N, Samayoa G, Han X, Freedman D, Isenman L, Patel R. The effect of Medicaid reimbursement policies on serious mental illness outcomes. *American Journal of Managed Care*. 2026, forthcoming.

A.7. Zakeri M, Zhu X, Wagner S, Baser O. Analysis of treatment patterns in patients with mucosal melanoma using real-world data in the SEER-Medicare-linked database. *Cancer*. 2026, forthcoming.

A.8. Baser O, Sepulveda F, Lu Y, Endrizal A. Socioeconomic status and postpartum depression risk after the Dobbs v Jackson Women's Health Organization Decision, based on state trigger laws. *The Journal of American Medical Association*. Network Open. 2026;9(2):e2557337. <https://doi.org/10.1001/jamanetworkopen.2025.57337>.

A.9. Hussein M, Wu L, Soliman A, Healey M, Baser O. Prevalence, economic burden, and healthcare utilization among Medicare and commercially insured oropharyngeal cancer patients. *Cancer Epidemiol Biomarkers Prevent*. 2026;35(3):406-414. <https://doi.org/10.1158/1055-9965.epi-25-1267>.

2025

A.10. Baser O, Waters HC, Yapar N, Rodchenko K, Isenman L, Han X, Freedman D, Patel R. Impact of Medicaid Institution for Mental Diseases Exclusion on serious mental illness outcomes. *American Journal of Managed Care*. 2025; 31(12):e364-e370. <https://doi.org/10.37765/ajmc.2025.89841>.

A.11. Baser O, Rodchenko K, Waters HC, Sullivan M, Wu L, Shurleff M, Bigley C, Patel R. The impact of copay accumulators and maximizers on treatment patterns, adherence, and costs among patients with major depressive and bipolar disorders treated with branded therapies. *J Mark Health Access Policy*. 2025;13(4):55. <https://doi.org/10.3390/jmahp13040055>

- A.12. Baser O, Waters HC, Huang D, Morrissey L, Rodchenko K, Samayoa G, Patel R. Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness. *J Health Econ Outcomes Res.* 2025;12(1):222-229. <https://doi.org/10.36469/001c.137909>
- A.13. Baser O, Lu Y. External control arm with real-world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. *Expert Opinion on Pharmacotherapy.* 2025, online ahead of print. <https://doi.org/10.1080/14656566.2025.2518329>
- A.14. Baser O, Yuce H, Samayoa G. Analysis of rare events in healthcare intervention using Department of Defense data: Intravenous immune globulin therapy for bullous pemphigoid. *BMC Research Methodology.* 2025;25(1):114. <https://doi.org/10.1186/s12874-025-02559-5>
- A.15. Baser O, Lu Y, Chen S, Baser E. Tirzepatide and semaglutide for the treatment of obstructive sleep apnea and obesity: A retrospective analysis. *Medical Research Archives.* 2025;13(1)25. <https://doi.org/10.18103/mra.v13i1.6236>
- A.16. Baser O, Zeng Y, Baser I. Prevalence and risk factors among patients with alcohol use disorder during COVID-19: National Survey on Drug Use and Health Analysis. *Medical Research Archives.* 2025;13(2). ISSN 2375-1924. <https://doi.org/10.18103/mra.v13i2.6329>
- A.17. Baser O, Lu Y, Sepulveda F, Alemzadeh A, Endrizal A. The Effect of Dobbs v. Jackson Women's Health Organization on clinical diagnosis of postpartum depression. *J Health Econ Outcomes Res.* 2025;12(1):86–96. <https://doi.org/10.36469/001c.129633>.

2024

- A.18. Baser O, Samayoa G., Yapar N., Baser, E. Artificial intelligence in identifying patients with undiagnosed nonalcoholic steatohepatitis. *J Health Econ Outcomes Res.* 2024;11(2):86–94. <https://doi.org/10.36469/001c.123645>.
- A.19. Baser O, Isenman L, Baser E, Li W, Cigdem B. Neighborhood socioeconomic status and postpartum depression among commercial health insurance enrollees: A retrospective cohort study. *BMC Pregnancy Childbirth.* 2024;24(732). <https://doi.org/10.1186/s12884-024-06882-5>.
- A.20. Baser O, Alsaleh S, Zeng Y, Baser I. Behind the sadness of teen girls: A retrospective survey analysis amidst the COVID-19 crisis of 2021. *Adolescents.* 2024;4(3):410-425. <https://doi.org/10.3390/adolescents4030029>.
- A.21. Baser O, Rodchenko K, Vivier E, Baser I, Lu Y. The impact of newly approved anti-obesity medications on osteoarthritis. *Expert Opin Pharmacother.* 2024;25(11):1565-73. <https://doi.org/10.1080/14656566.2024.2391524>.
- A.22. Baser O, Mohamed M, Samayoa G, Sarioglu S. Semaglutide and tirzepatide use and reduction of cardiovascular risks in adults with overweight and obesity. *Med Res Arch.* 2024;12(8). <https://doi.org/10.18103/mra.v12i8.0000>.

- A.23. Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. *Obesity*. 2024;32(7):1401-1409. <https://doi.org/10.1002/oby.24037>
- A.24. Baser O, Isenman L, Baser S, Samayoa G. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study. *Obes Sci Pract*. 2024;e762. <https://doi.org/10.1002/osp4.762>.
- A.25. Baser O, Samayoa G, Dwivedi A, AlSaleh S, Cigdem B, Kizilkaya E. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide. *Acta Oncologica*. 2024;63(1)137-146. <https://doi.org/10.2340/1651-226X.2024.20337>
- A.26. Baser O, Rodchenko K, Zeng Y, Endrizal A. Mental health disparities in young adults with arrest history: A survey-based, cross-sectional analysis. *Health Justice*. 2024;12:1. <https://doi.org/10.1186/s40352-023-00257-2>.

2023

- A.27. Baser O, Rodchenko K, Chen L, Yapar N. Short-term and long-term behavioral effects of vaccination mandates. *Human Vaccines Immunotherapeutics*. 2023;19:3. <https://doi.org/10.1080/21645515.2023.2294525>.
- A.28. Baser O, Zeng Y, Alsaleh S, Baser I. Factors associated with the prevalence and treatment of depression in adolescent males in the US during the period of COVID-19 pandemic. *Adolescents*. 2023;3(4):640-50. <https://doi.org/10.3390/adolescents3040045>.
- A.29. Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. *J Health Econ Outcomes Res*. 2023;10(2):44-52. <https://doi.org/10.36469/001c.87538>.
- A.30. Baser O, Baser E, Samayoa G. Relationship between body mass index and diagnosis of overweight or obesity in Veterans Administration population. *Healthcare*. 2023;11(11):1529. <https://doi.org/10.3390/healthcare11111529>.

2021

- A.31. Baser, O. Population density index and its use for distribution of Covid-19: A case study using Turkish data. *Health Policy*. 2021;125(2)148-54. <https://doi.org/10.1016/j.healthpol.2020.10.003>.
- A.32. Schuler CF 4th, Volertas S, Khokhar D, Yuce H, Chen L, Baser O, Montejo JM, Akin C. Prevalence of mastocytosis and Hymenoptera venom allergy in the United States. *J Allergy Clin Immunol*. 2021;148(5):1316-23. <https://doi.org/10.1016/j.jaci.2021.04.013>.

2020

- A.33. Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US Medicaid beneficiaries. *AIDS Res Ther*. 2020;17(12). <https://doi.org/10.1186/s12981-020-00268-1>.

A.34. Ramaswamy K, Lechpammer S, Mardekian J, Huang A, Schultz NM, Sandin R, Wang L, Baser O, George DJ. Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone. *Adv Ther.* 2020;37(5):2083-97. <https://doi.org/10.1007/s12325-020-01260-x>.

A.35. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *Clin Lymphoma Myeloma Leuk.* 2020;20(2):63-9. <https://doi.org/10.1016/j.clml.2019.11.010>.

2019

A.36. Cinaroglu S, Baser O. Network among HTA ecosystem. *Health Technol.* 2019;9:153–66. <http://doi.org/10.1007/s12553-018-0266-y>.

A.37. Cinaroglu S, Baser O. Does the unification of health financing affect the distribution pattern of out-of-pocket health expenses in Turkey? *Int J Soc Welfare.* 2019;28:293-306. <https://doi.org/10.1111/ijsw.12389>.

A.38. Coleman CI, Pandya S, Wang L, Baser O, Cai J, Ingham M, Bookhart B. Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. *J Comp Eff Res.* 2019;8(11):889-905. <https://doi.org/10.2217/cer-2019-0002>.

A.39. Wang L, Baser O, Wells P, et al. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *J Health Econ Outcomes Res.* 2019;6(2):84-94. <https://doi.org/10.36469/9744>.

A.40. Pandya S, Baser O, Wan G, Lovelace B, Potenziano J, Pham AT, Huang X, Wang L. The burden of hypoxic respiratory failure in preterm and term/near-term infants in the United States 2011-2015. *J Health Econ Outcomes Res.* 2019;6(3):130-41. <https://doi.org/10.36469/001c.9682>.

A.41. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: A retrospective cohort study. *BMC Cardiovasc Disord.* 2019;19(1):19. <https://doi.org/10.1186/s12872-018-0991-1>.

A.42. Smilowitz NR, Zhao Q, Wang L, Shrestha S, Baser O, Berger JS. Risk of venous thromboembolism after new onset heart failure. *Sci Rep.* 2019;9(1):17415. <https://doi.org/10.1038/s41598-019-53641-0>.

A.43. Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K. Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: An observational retrospective analysis. *Adv Ther.* 2019;36(10):2941-53. <https://doi.org/10.1007/s12325-019-01039-9>.

A.44. Hyde LZ, Baser O, Mehendale S, Guo D, Shah M, Kiran RP. Impact of surgical approach on short-term oncological outcomes and recovery following low anterior resection for rectal cancer. *Colorectal Dis.* 2019;21(8):932-42. <https://doi.org/10.1111/codi.14677>.

A.45. Fu RH, Baser O, Li L, Kurlansky P, Means J, Rohde CH. The effect of the breast cancer provider discussion law on breast reconstruction rates in New York state. *Plast Reconstr Surg.* 2019;144(3):560-8. <https://doi.org/10.1097/prs.0000000000005904>.

A.46. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. *J Thromb Thrombolysis.* 2019;48(1):149-57. <https://doi.org/10.1007/s11239-019-01814-z>.

A.47. Kuritzkes BA, Cao Y, Baser O, Thomas N, Forde KA, Kiran RP. New barrier attire regulations in the operating room: A mandate without basis? *Am J Surg.* 2019;218(3):447- 51. <https://doi.org/10.1016/j.amjsurg.2019.02.002>.

A.48. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Hematocrit levels and thrombotic events in patients with polycythemia vera: An analysis of Veterans Health Administration data. *Ann Hematol.* 2019;98(11):2533-39. <https://doi.org/10.1007/s00277-019-03793-w>.

2018

A.49. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients: The ARISTOPHANES Study. *Stroke.* 2018;49(12):2933-44. <https://doi.org/10.1161/STROKEAHA.118.020232>.

A.50. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the effect of treatment persistence on the economic burden of moderate to severe psoriasis and/or psoriatic arthritis patients in the U.S. Department of Defense population. *J Manag Care Spec Pharm.* 2018;24(7):654-63. <https://doi.org/10.18553/jmcp.2018.24.7.654>.

A.51. Cinaroglu S, Baser O. The relationship between medical innovation and health expenditure before and after health reform. *Health Policy Technol.* 2018;20:30. <https://doi.org/10.1016/j.hlpt.2018.10.001>.

A.52. Kuritzkes BA, Pappou EP, Kiran RP, Baser O, Fan L, Guo X, Zhao B, Bentley-Hibbert S. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *Int J Colorectal Dis.* 2018;33(8):1019- 28. <https://doi.org/10.1007/s00384-018-3038-2>.

A.53. Sietsema D, Araujo A, Wang L, Boytsov N, Pandya S, Haynes V, Faries D, Taylor K, Baser O, Jones C. Effectiveness of a private, orthopedic practice-based osteoporosis management program to reduce the risk of subsequent fractures. *J Bone Joint Surg.* 2018;100(21):1819-28. <https://doi.org/10.2106/jbjs.17.01388>.

A.54. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton H, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. *Am J Med.* 2018;131(9):1075-85. <https://doi.org/10.1016/j.amjmed.2018.05.007>.

- A.55. Cinaroglu S, Baser O. Understanding the relationship between effectiveness and outcome indicators to improve quality in healthcare. *Total Qual Manag Bus.* 2018;29 (11- 12):1294-311. <https://doi.org/10.1080/14783363.2016.1253467>.
- A.56. Kalfa D, Belli E, Bacha E, Lambert V, di Carlo D, Kostolny M, Nosal M, Horer J, Salminen J, Rubay J, Yemets I, Hazekamp M, Maruszewski B, Sarris G, Berggren H, Ebels T, Baser O, Lacour-Gayet F; European Congenital Heart Surgeons Association. Outcomes and prognostic factors for postsurgical pulmonary vein stenosis in the current era. *J Thorac Cardiovasc Surg.* 2018;156(1):278-86. <https://doi.org/10.1016/j.jtcvs.2018.02.038>.
- A.57. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. A real-world observational study of hospitalization and health care costs among non-valvular atrial fibrillation patients prescribed oral anticoagulants in the United States Medicare population. *J Manag Care Pharm.* 2018;24(9):911-20. <https://doi.org/10.18553/jmcp.2020.26.5.639>.
- A.58. Al-Mazrou AM, Baser O, Kiran RP. Alvimopan, regardless of ileus risk, significantly impacts ileus, length of stay, and readmission after intestinal surgery. *J Gastrointestinal Surg.* 2018 22 (12): 2104-16. <https://doi.org/10.1007/s11605-018-3846-2>.
- A.59. Keshishian A, Greenberg SA, Agashivala N, Baser O, Johnson K. Health care costs and comorbidities for patients with inclusion body myositis. *Curr Med Res Opin.* 2018;34(9):1679-85. <https://doi.org/10.1080/03007995.2018.1486294>.
- A.60. Fu RH, Toyoda Y, Li L, Baser O, Rohde C H, Otterburn D M. Smoking and postoperative complications in plastic and general surgical procedures: A propensity-score matched analysis of 294,903 patients from the NSQIP database from 2005-2014. *Plastic Reconstruct Surg.* 2018;141(1):226-36. <https://doi.org/10.1097/prs.0000000000005008>.
- A.61. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Cytoreductive treatment patterns among US veterans with polycythemia vera. *BMC Cancer.* 2018;18(1):528. <https://doi.org/10.1186/s12885-018-4422-6>.
- A.62. Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. *Leuk Lymphoma.* 2018;59(12):2880-7. <https://doi.org/10.1080/10428194.2018.1459613>.
- A.63. Soo-Hoo S, Nemeth S, Baser O, Argenziano M, Kurlansky P. East meets West: the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *Heart Asia.* 2018;10: e010995. <https://doi.org/10.1136/heartasia-2017-010995>.
- A.64. Sonpavde G, Huang A, Wang L, Baser O, Miao R. Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer. *BJU Int.* 2018;121(6):871-79. <https://doi.org/10.1111/bju.14152>.
- A.65. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Med Econ.* 2018;21(6):564-70. <https://doi.org/10.1080/13696998.2018.1431921>.

A.66. Al-Mazrou AM, Baser O, Kiran RP. The effect of hospital familiarity with complex procedures on overall healthcare burden. *Am J Surg.* 2018;216(2):204-12. <https://doi.org/10.1016/j.amjsurg.2018.01.026>.

A.67. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Managed Care Specialty Pharm.* 2018;24(7):654-63. <https://doi.org/10.18553/jmcp.2018.24.7.654>.

A.68. Khandker RK, Black CM, Xie L, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Fillit H. Analysis of episodes of care in Medicare beneficiaries newly diagnosed with Alzheimer's disease. *J Am Geriatr Soc.* 2018;66(5):864-70. <https://doi.org/10.1111/jgs.15281>.

A.69. Black CM, Fillit H, Xie L, Hu X, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Khandker RK. Economic burden, mortality and institutionalization in patients newly diagnosed with Alzheimer's disease. *J Alzheimers Dis.* 2018;61(1):185-93. <https://doi.org/10.3233/jad-170518>.

A.70. Al-Mazrou AM, Baser O, Kiran RP. The effect of hospital familiarity with complex procedures on overall healthcare burden. *Am J Surg.* 2018;216(2):204-12. <https://doi.org/10.1016/j.amjsurg.2018.01.026>.

A.71. Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K-antagonist direct oral anticoagulants among patients with non-valvular atrial fibrillation. *Ann Pharmacother.* 2018;52(2):147-1533. <https://doi.org/10.1177/1060028017728295>.

A.72. Cohen J, Beaubrun A, Bashyal R, Huang A, Huang T, Baser O. Real-world persistence for newly prescribed HIV-1 treatment: Single versus multiple tablet regimen comparison. *Pharmacoepidemiol Drug Saf.* 2018; 27: 3– 521. <https://doi.org/10.1002/pds.4629>.

A.73. Mendes S, O'Neal W, Baser O, Wang L, Cramer JA. Adherence with extended-release oxcarbazepine (Oxtellar XR[®]) vs immediate-release oxcarbazepine: Analysis of pooled data from four national pharmacy claims databases (P6.293). *Neurology.* 2018;90(15Supplement)P6.293. https://doi.org/10.1212/WNL.90.15_supplement.P6.293.

A.74. Al-Mazrou AM, Baser O, Kiran RP. Propensity score-matched analysis of clinical and financial outcomes after robotic and laparoscopic colorectal resection. *J Gastrointest Surg.* 2018;22(6):1043-1051. <https://doi.org/10.1007/s11605-018-3699-8>.

2017

A.75. Cinaroglu S, Baser O. Socio-economic status and self-rated health: Are they good predictors of income? An analysis of survey panel data from Turkey. *Int J Med Science Public Health.* 2017;6(10)1-9. <http://dx.doi.org/10.5455/ijmsph.2017.0720417082017>.

A.76. Cinaroglu S, Baser O. Spatial distribution of total number of medical devices in Turkey: A classification analysis. *Int J Med Public Health.* 2017;7(2):102-6. <http://dx.doi.org/10.5530/ijmedph.2017.2.20>.

- A.77. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents: A retrospective study utilizing two large US claims databases. *Prim Care Companion CNS Disord.* 2017;19(6). <https://doi.org/10.4088/pcc.17m02200>.
- A.78. Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baser O, Wei W. The use of decomposition methods in real-world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: Findings from the INITIATOR study. *Value Health.* 2017;20(10):1252-1259. <https://doi.org/10.1016/j.jval.2017.05.019>.
- A.79. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism. *PLoS One.* 2017;12(10):e0185022. <https://doi.org/10.1371/journal.pone.0185022>.
- A.80. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the US Medicare population. *J Manag Care Spec Pharm.* 2017;28(8):2485-2494. <https://doi.org/10.18553/jmcp.2017.17054>.
- A.81. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population. *Curr Med Res Opin.* 2017;33(9):1595-1604. <https://doi.org/10.1080/03007995.2017.1345729>.
- A.82. Bent-Ennakhil N, Coste F, Xie L, Sanon Aigbogun M, Wang Y, Kariburyo F, Hartry A, Baser O, Neumann P, Fillit H. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer's disease patients. *Neurol Ther.* 2017;6(1):131-144. <https://doi.org/10.1007/s40120-017-0067-7>.
- A.83. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Overall effectiveness of rivaroxaban in patients with pulmonary embolism. *Clin Ther.* 2017;39(7):1426-1436.e2. <https://doi.org/10.1016/j.clinthera.2017.06.002>,
- A.84. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. *Osteoporos Int.* 2017;28(8):2485-2494. <https://doi.org/10.1007/s00198-017-4072-6>.
- A.85. Al-Mazrou AM, Baser O, Kiran RP. Failure of efforts to contain costs of care after colorectal procedures: Nationwide trends in length of stay, costs and post-acute care utilization. *Am J Surg.* 2017;214(5):804-810. <https://doi.org/10.1016/j.amjsurg.2017.03.046>.
- A.86. Kohn CG, Weeda ER, Kumar N, Wells PS, Peacock WF, Fermann GJ, Wang L, Baser O, Schein JR, Crivera C, Coleman CI. External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. *Intern Emerg Med.* 2017;12(5):613-619. <https://doi.org/10.1007/s11739-017-1625-9>.

A.87. Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Healthcare resource utilization and costs of California- Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. *Curr Med Res Opin.* 2017;33(4):723-31. <https://doi.org/10.1080/03007995.2016.1278202>.

2016

A.88. Baser O, Wang L, Maguire J. Creating national weights for a patient-level longitudinal database. *J Health Econ Outcomes Res.* 2016;4(1):80-9. <https://doi.org/10.36469/9828>.

A.89. Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: A population-based cohort study. *BMC Geriatrics.* 2016;16:193. <https://doi.org/10.1186/s12877-016-0367-2>.

A.90. Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and costs in Clostridium difficile infection disease among the elderly in the US. *Infect Control Hosp Epidemiol.* 2016;37(11):1331-6. <https://doi.org/10.1017/ice.2016.188>.

A.91. Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. *J Med Econ.* 2016;19(12):1175-86. <https://doi.org/10.1080/13696998.2016.1208208>.

A.92. Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and validation of a risk score for clostridium difficile infection in Medicare beneficiaries: A population-based cohort study. *J Am Geriatr Soc.* 2016;64(8):1690-5. <https://doi.org/10.1111/jgs.14236>.

A.93. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. *J Med Econ.* 2016;19(8):769-76. <https://doi.org/10.3111/13696998.2016.1171774>.

A.94. Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju CV, Schein JR. Patterns of international normalized ratio values among new warfarin patients with non- valvular atrial fibrillation. *Blood Coagul Fibrinolysis.* 2016;27(8):899-906. <https://doi.org/10.1097/mbc.0000000000000515>.

A.95. Fox K, Wang L, Gandra S, Quek R, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: A retrospective cohort study. *BMC Cardiovasc Disord.* 2016;16(1):13. <https://doi.org/10.1186/s12872-016-0190-x>.

A.96. Keshishian A, Wang Y, Xie L, Baser O. The economic impact of symptomatic menopause among low-socioeconomic women in the United States. *Expert Rev Pharmacoecon Outcomes Res.* 2016;16(2):305-13. <https://doi.org/10.1586/14737167.2015.1073589>.

A.97. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large U.S. insurance database analysis. *Am J Ther.* 2016;23(6):e1744-53. <https://doi.org/10.1097/mjt.0000000000000167>.

A.98. Huntington SF, Keshishian A, Xie L, Baser O, et al. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. *Blood*. 2016;128:3574. <https://doi.org/10.1182/blood.V128.22.3574.3574>.

2015

A.99. Dasta J, Waikar SS, Xie L, Boklage S, Baser O, et al. Patterns of treatment and correction of hyponatremia in intensive care-unit patients. *J Crit Care*. 2015;30(5):1072-9. <https://doi.org/10.1016/j.jcrc.2015.06.016>.

A.100. Baser O, Altinbas A, Baser E, Kariburyo F. Economic burden and complications of treated and un-treated hepatitis C virus patients in Turkey. *Value Health Regional Issues*. 2015;7C:42-8. <https://doi.org/10.1016/j.vhri.2015.08.004>.

A.101. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo MF, Baser O, Murrelle L. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans Health Administration patients. *Pain Med*. 2015;16(8):1566-79. <https://doi.org/10.1111/pme.12777>.

A.102. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation. *J Med Econ*. 2015;18(5):333-40. <https://doi.org/10.3111/13696998.2014.1001851>.

A.103. Baser O, Ganguli A, Roy S, Xie L, Cifaldi M. Impact of switching from an initial tumor necrosis factor-inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. *Clin Ther*. 2015;37(7):1454-65. <https://doi.org/10.1016/j.clinthera.2015.04.012>.

A.104. Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer*. 2015;23(11):3131-40. <https://doi.org/10.1007/s00520-015-2686-9>.

A.105. Zhong L, Chung KC, Baser O, Fox DA, Yuce H, Waljee JF. Variation in rheumatoid hand and wrist surgery among Medicare beneficiaries: A population-based cohort study. *J Rheumatol*. 2015;42(3):429-36. <https://doi.org/10.3899/jrheum.140658>.

A.106. Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. *J Med Econ*. 2015;18(5):357-65. <https://doi.org/10.3111/13696998.2014.1001514>.

A.107. Waljee J, Zhong L, Baser O, Fox DA, Chung KC, Yuce H. The incidence of upper and lower extremity surgery for rheumatoid arthritis: A national, population-based longitudinal cohort study. *J Bone Joint Surg*. 2015;97(5):403-10. <https://doi.org/10.2106/JBJS.N.00802>.

A.108. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. *Int J Clin Pharm*. 2015;37(1):53-9. <https://doi.org/10.1007/s11096-014-0038-3>.

- A.109. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. *Diabetes Obes Metab.* 2015;17(3):245-53. <https://doi.org/10.1111/dom.12407>.
- A.110. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo F, Baser O, Murrelle L. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans' Health Administration patients. *Pain Med.* 2015;16(8):1566-79. <https://doi.org/10.1111/pme.12777>.
- A.111. Dalal MR, Xie L, Baser O, DiGenio A. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: Outcomes in a community setting. *Endocr Pract.* 2015;21(1):68-76. <https://doi.org/10.4158/ep14290.or>.
- A.112. Alpesh AN, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Early comparison of major bleeding, stroke and associated medical costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. *Blood.* 2015;123(23):745. <https://doi.org/10.1182/blood.V126.23.745.745>.
- A.113. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson KN. HIV economic burden of illness in the Veterans Health Administration population. *AIDS Care.* 2015;27(1):123-31. <https://doi.org/10.1080/09540121.2014.947237>.

2014

- A.114. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. *Clin Infect Dis.* 2014;59(7):1027-31. <https://doi.org/10.1093/cid/ciu476>.
- A.115. Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J. Much ado about nothing? A real-world study of patients with type 2 diabetes switching basal insulin analogs. *Adv Ther.* 2014;31(5):539-60. <https://doi.org/10.1007/s12325-014-0120-1>.
- A.116. Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F, Rajan P, Baser O, Murrelle L. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med.* 2014;15(11):1911-29. <https://doi.org/10.1111/pme.12480>.
- A.117. Levin P, Lin J, Wei W, Vlajnic A, Pan C, Xie L, Baser O. Initiating injectable therapy in US managed care patients with diabetes. *Am J Pharm Benefits.* 2014;6(4):e93-e102.
- A.118. Altinbas A, Baser E, Burkan A, Ertugay E, Kariburyo MF, Baser O. Retrospective analysis of total direct medical costs of hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey. *J Viral Hepat.* 2014;21(11):794-801. <https://doi.org/10.1111/jvh.12206>.

- A.119. Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: A claims database analysis. *Diabetes Technol Ther.* 2014;16(9):567-75. <https://doi.org/10.1089/dia.2013.0312>.
- A.120. Levin PA, Wei W, Zhou S, Xie L, Baser O. Outcomes and treatment patterns of adding a third agent to 2OADs in patients with type 2 diabetes. *J Manag Care Pharm.* 2014;20(5):501-12. <https://doi.org/10.18553/jmcp.2014.20.5.501>.
- A.121. Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin glargine treatment among elderly patients with type 2 diabetes. *J Diabetes Sci Technol.* 2014;8(1):150-8. <https://doi.org/10.1177/1932296813516956>.
- A.122. Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes: Measures, predictors and outcomes. *Endocr Pract.* 2014;20(1):52-61. <https://doi.org/10.4158/ep13159.or>.
- A.123. Baser O, Xie L, Mardekian J, Schaaf D, Wang L, Joshi AV. Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration. *Pain Pract.* 2014;14(5):437-45. <https://doi.org/10.1111/papr.12097>.
- A.124. Xie L, Joshi AV, Schaaf D, Mardekian J, Harnett J, Shah ND, Baser O. Differences in healthcare utilization and associated costs between patients prescribed versus not prescribed opioids during an inpatient or emergency department visit. *Pain Pract.* 2014;14(5):446-56. <https://doi.org/10.1111/papr.12098>.
- A.125. Xie L, Frech-Tamas F, Marrett E, Baser O. A medication and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. *Curr Med Res Opin.* 2014;30(12):2415-22. <https://doi.org/10.1185/03007995.2014.964853>.
- A.126. Bui CN, Wang L, Baser O. Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities. *Curr Med Res Opin.* 2014;30(11):2355-64. <https://doi.org/10.1185/03007995.2014.955170>.
- A.127. Wang L, Barron R, Baser O, Langeberg WJ, Dale DC. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. *Value Health.* 2014;17(6):739-43. <https://doi.org/10.1016/j.jval.2014.06.009>.

2013

- A.128. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. *Clinicoecon Outcomes Res.* 2013;5:497-505. <https://doi.org/10.2147/ccor.s49279>.
- A.129. Xie L, Wei W, Pan C, Baser O. Real-world rates, predictors and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: Results of a pooled analysis of six retrospective observational studies. *J Med Econ.* 2013;16(9):1137-45. <https://doi.org/10.3111/13696998.2013.824458>.

- A.130. Wang L, Fritschel E, Baser O. Economic and clinical impact of stroke and warfarin use for patients with non-valvular atrial fibrillation. *J Health Econ Outcomes Res.* 2013;1(1):42-53. <https://doi.org/10.36469/9852>.
- A.131. Wang L, Lewis-Beck C, Fritschel E, Baser E, Baser O. Applied comparison of meta- analysis techniques. *J Health Econ Outcomes Res.* 2013;1(1):14-22. <https://doi.org/10.36469/9848>.
- A.132. Baser O. Generalized propensity score matching with multilevel treatment options. *J Health Econ Outcomes Res.* 2013;1(1):1-13. <https://doi.org/10.36469/9847>.
- A.133. Baser O, Xie L, Du J, Smith Y. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women's registry and claims data. *Int J Stats Med Res.* 2013;2:34-9. <https://doi.org/10.1016/j.jval.2012.03.1047>.
- A.134. Baser O, Verpillat P, Gabriel S, Wang L. Prevalence, incidence, and outcomes of critical limb ischemia in the U.S. Medicare population. *Vasc Dis Man.* 2013;10(2):1-9. <http://dx.doi.org/10.1016/j.respe.2011.08.018>.
- A.135. Miao R, Wei W, Baser O, Xie L. Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. *Patient Prefer Adherence.* 2013;7:951-60. <https://doi.org/10.2147/ppa.s49287>.
- A.136. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Coronary angiography utilization and costs for coronary artery bypass graft surgery in Turkey. *Cardiol Ther.* 2013;2:151-63. <https://doi.org/10.1007/s40119-013-0018-z>.
- A.137. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from national claims data. *Rheumatol Int.* 2013;33(10):2577-84. <https://doi.org/10.1007/s00296-013-2782-4>.
- A.138. Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: A comparative retrospective database study. *BMJ Open.* 2013;3(4):1-9. <https://doi.org/10.1136/bmjopen-2012-002348>.
- A.139. Baser O, Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. *Health Econ Rev.* 2013;3(5):1-7. <https://doi.org/10.1186/2191-1991-3-5>.
- A.140. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. *Diabetes Technol Ther.* 2013;15(3):1-7. <https://doi.org/10.1089/dia.2012.0253>.
- A.141. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Health care costs associated with ankylosing spondylitis in Turkey: Analysis from nationwide real-world data. *Int J Rheumatol.* 2013;2013:1-7. <https://doi.org/10.1155/2013/139608>.

A.142. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. *Patient Prefer Adher.* 2013;7:199-205. <https://doi.org/10.2147/ppa.s39887>.

A.143. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. *Am J Therapeut.* 2013;20(2):132-42. <https://doi.org/10.1097/mjt.0b013e31826910dd>.

A.144. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High cost patients for cardiac surgery and hospital quality in Turkey. *Health Policy.* 2013;109(2):143-9. <https://doi.org/10.1016/j.healthpol.2012.09.015>.

2012

A.145. Baser O, Wang L, Sengupta N, Dysinger AH. Thromboembolism prophylaxis in medical inpatients: Effect on outcomes and costs. *Am J Man Care.* 2012;18(6):294-302. <https://pubmed.ncbi.nlm.nih.gov/22774997/>.

A.146. Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L. Burden of early stage triple-negative breast cancer in a U.S. managed care plan. *Health Outcomes Res Med.* 2012;3(2):e57-e65. <https://doi.org/10.1016/j.chrm.2012.03.001>.

A.147. Baser O, Du J, Xie L, Wang H, Dysinger AH, Wang L. Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes. *J Med Econ.* 2012;15(5):918-24. <https://doi.org/10.3111/13696998.2012.688905>.

A.148. Baser O, Wei W, Xie L, Henk HJ, Teitelbaum A. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. *Commun Oncol.* 2012;9:8-14. <https://doi.org/10.1016/J.CMONC.2011.10.002>.

A.149. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. *Arthritis Care Res.* 2012;64(9):1282-91. <https://doi.org/10.1002/acr.21693>.

A.150. Baser O, Wei W, Henk H, Teitelbaum A, Xie L. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. *Curr Med Res Opin.* 2012;28(3):419-28. <https://doi.org/10.1185/03007995.2011.628649>.

A.151. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. *Curr Med Res Opin.* 2012;28(3):439-46. <https://doi.org/10.1185/03007995.2012.654850>.

2011

A.152. Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and prophylaxis use in hospitalized medically ill US patients in 180 days post-hospital discharge. *Thrombosis J.* 2011;13(1):15. <https://doi.org/10.1186/1477-9560-9-15>.

- A.153. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, health care utilization, and costs for valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium-channel blocker free combination therapy. *J Med Econ.* 2011;14(5):576-83. <https://doi.org/10.3111/13696998.2011.596873>.
- A.154. Baser O, Spalding J, Kothari S, Yuce H, Monsalvo ML. Cost and clinical consequences of stress/single photon emission computed tomography testing when combined with specific medications. *J Med Econ.* 2011;14(4):433-9. <https://doi.org/10.3111/13696998.2011.584357>.
- A.155. Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs. exenatide BID. *J Med Econ.* 2011;14(6):673-80. <https://doi.org/10.3111/13696998.2011.605818>.
- A.156. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid dependence treatments. *Am J Manag Care.* 2011;17:S235-48. <https://pubmed.ncbi.nlm.nih.gov/21761950/>.
- A.157. Baser O, Chalk M, Rawson R, Gastfriend DR. Alcohol dependence treatments: Comprehensive health care costs, utilization outcomes and pharmacotherapy persistence. *Am J Manag Care.* 2011;17:S222-34. <https://pubmed.ncbi.nlm.nih.gov/21761948/>.
- A.158. Baser O, Supina D, Wang L, Sengupta N. Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery. *Curr Med Res Opin.* 2011;27(2):423-9. <https://doi.org/10.1185/03007995.2010.545940>.
- A.159. Baser O. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty. *Am J Manag Care.* 2011;17:S6-8. <https://pubmed.ncbi.nlm.nih.gov/21517654/>.
- A.160. Chung KC, Shauver MJ, Yin H, Kim HM, Baser O, Birkmeyer JD. Variations in the use of internal fixation for distal radius fracture in the United States Medicare population. *J Bone Joint Surg.* 2011;93(23):2154-62. <https://doi.org/10.2106/jbjs.j.012802>.
- A.161. Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. *Adv Ther.* 2011;28(11):1000-11. <https://doi.org/10.1007/s12325-011-0074-5>.
- A.162. Baser O, Wang L, Supina D, Sengupta N. Anticoagulation prophylaxis practice patterns in patients undergoing total hip or total knee replacement in a US health plan. *Formulary.* 2011;46:486-500. [Anticoagulation prophylaxis practice patterns in patients having total hip, total knee replacement in a US health plan.](#)
- A.163. Baser O, Supina D, Sengupta N, Wang L. Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a US health plan: Real-world observations and implications. *Am Health Drug Ben.* 2011;4(4):240-8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4125758/>.

2010

- A.164. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and health care costs of insulin device (Flexpen) versus conventional vial/syringe. *Adv Ther.* 2010;27(2):94-104. <https://doi.org/10.1007/s12325-010-0009-6>.
- A.165. Baser O, Supina D, Sengupta N, Wang L, Kwong L. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery. *Am J Health-Syst Pharm.* 2010;67:1438-45. <https://doi.org/10.2146/ajhp090572>.
- A.166. Birkmeyer NJ, Share D, Baser O, et al. Preoperative placement of inferior vena cava filters and out-comes after gastric bypass surgery. *Ann Surg.* 2010;252(2):313-8. <https://doi.org/10.1097/sla.0b013e3181e61e4f>.
- A.167. Birkmeyer JD, Gust C, Baser O, Dimick J, Skinner J, Sutherland JM. Medicare payments for common inpatient procedures, implications for episode-based payment bundling. *Health Serv Res.* 2010;45(6 Pt 1):1783-95. <https://doi.org/10.1111/j.1475-6773.2010.01150.x>.

2009

- A.168. Englesbe M, Fan Z, Baser O, Birkmeyer J. Mortality in Medicare patients undergoing surgery in July in teaching hospitals. *Ann Surg.* 2009;249:871-6. <https://doi.org/10.1097/sla.0b013e3181a501bd>.
- A.169. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Associations statement on antipsychotic drugs and diabetes. *Diabetes Care.* 2009;32(6):1037-42. <https://doi.org/10.2337/dc08-1720>.
- A.170. Staiger DO, Dimick JB, Baser O, Fan Z, Birkmeyer JD. Empirically derived composite measures of surgical performance. *Med Care.* 2009;47(2):226-33. <https://doi.org/10.1097/mlr.0b013e3181847574>.
- A.171. Baser O, Fan Z, Dimick JB, Staiger D, Birkmeyer JD. Outlier payments for cardiac surgery and hospital quality. *Health Affairs.* 2009;28(4):1154-60. <https://doi.org/10.1377/hlthaff.28.4.1154>.
- A.172. Baser O. Too much ado about instrumental variable approach: Is the cure worse than the disease? *Value Health.* 2009;12(8):1201-9. <https://doi.org/10.1111/j.1524-4733.2009.00567.x>.
- A.173. Sihler KC, Baser O, Birkmeyer NJ, Birkmeyer JD. Statin use reduces the risk of post-operative infections and respiratory complications from non-cardiac general surgery. *J Surg Res.* 2009;151(2):173-5. <https://doi.org/10.1016/j.jss.2008.11.022>.
- A.174. Dimick JB, Baser O, Staiger DO, Birkmeyer JD. Composite measures for predicting surgical mortality in the hospital. *Health Affairs.* 2009;28(4):1189-98. <https://doi.org/10.1377/hlthaff.28.4.1189>.
- A.175. Englesbe MJ, Dimick JB, Fan Z, Baser O, Birkmeyer JD. Case mix, quality and high- cost kidney transplant patients. *Am J Transplant.* 2009;9(5):1108-14. <https://doi.org/10.1111/j.1600-6143.2009.02592.x>.

2008

- A.176. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on healthcare costs and utilization. *Osteoporosis Int.* 2008;19(10):1421-9. <https://doi.org/10.1007/s00198-008-0586-2>.
- A.177. Baser O, Palmer L, Stephen J. The estimation power of alternative comorbidity indices. *Value Health.* 2008;11:946-55. <https://doi.org/10.1111/j.1524-4733.2008.00343.x>.
- A.178. Birkmeyer N, Baser O, Arden M, Gu N, Birkmeyer JD. Socioeconomic status and surgical mortality in the elderly. *Med Care.* 2008;46(9):893-9. <https://doi.org/10.1097/mlr.0b013e31817925b0>.

2007

- A.179. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. *J Am Geriatr Soc.* 2007;55(8):1168-75. <https://doi.org/10.1111/j.1532-5415.2007.01231.x>.
- A.180. Baser O. Choosing propensity score matching over regression adjustment for causal inference: When, why and how it makes sense. *J Med Econ.* 2007;10:379-91. <https://doi.org/10.3111/13696990701646577>.
- A.181. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care costs associated with prostate cancer, androgen deprivation therapy, and bone complications. *J Urol.* 2007;178(4):1423-8. <https://doi.org/10.1016/j.juro.2007.05.135>.
- A.182. Hutchings A, Calloway M, Choy E, Hooper M, Hunter D, Jorday J, Zhang Y, Baser O, Palmer L. The longitudinal examination of arthritis pain (LEAP) study: Relationship between weekly fluctuations in participant-rated joint pain and health outcomes. *J Rheum.* 2007;34(11):2291-300. <https://www.jrheum.org/content/34/11/2291>.
- A.183. Foley K, Foster SA, Meadows ES, Baser O, Long SR. Assessment of clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Med Care.* 2007;45(9):902-6. <https://doi.org/10.1097/mlr.0b013e3180536764>.
- A.184. Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD. Hospital lymph node examination rates and survival after resection for colon cancer. *JAMA.* 2007;298(18):2149-54. <https://doi.org/10.1001/jama.298.18.2149>.
- A.185. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. The spectrum of healthcare costs associated with herpes zoster: Acute pain vs postherpetic neuralgia. *J Am Geriatr Soc.* 2007;55(8):1168-75. [http://dx.doi.org/10.1016/S1098-3015\(10\)69066-3](http://dx.doi.org/10.1016/S1098-3015(10)69066-3).
- A.186. Baser O. Propensity score matching with limited overlap. *Econ Bulletin.* 2007;(9)8:1-8. <http://economicsbulletin.vanderbilt.edu/2007/volume9/EB-07110005A.pdf>.
- A.187. Baser O. Modeling transformed health care costs with unknown heteroskedasticity. *Appl Econ Res Bull.* 2007;1:1-6. [https://doi.org/10.1016/s1098-3015\(10\)72874-6](https://doi.org/10.1016/s1098-3015(10)72874-6).

2006

- A.188. Baser O, Crown HW, Pollicino C. Guidelines for selecting among different types of bootstraps. *Curr Med Res Opin.* 2006;22(4):799-808. <https://doi.org/10.1185/030079906x100230>.
- A.189. Baser O, Gardiner J, Bradley C, Yuce H, Given B. Longitudinal analysis of censored medical cost data. *Health Econ.* 2006;15(5):513-25. <https://doi.org/10.1002/hecc.1087>.
- A.190. Baser O. Using propensity score matching techniques for average treatment effects: Application to triptan use. *J Am Stat Assoc.* 2006;4334-39.
- A.191. Gibson TB, Mark TL, Axelsen K, Baser O, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. *Am J Managed Care.* 2006;12(12):11-19. <https://pubmed.ncbi.nlm.nih.gov/17173486/>.
- A.192. Baser O. Too much ado about propensity score models? Comparing the methods of propensity score matching. *Value Health.* 2006;9(6):377-85. <https://doi.org/10.1111/j.1524-4733.2006.00130.x>.
- A.193. Curtice TG, Long SR, Baser O, Montejano LB, Lobo F. Economic burden of restless legs syndrome in a privately-insured population. *Value Health.* 2006;9(3):A85. [http://dx.doi.org/10.1016/S1098-3015\(10\)64568-8](http://dx.doi.org/10.1016/S1098-3015(10)64568-8).
- A.194. Robinson RL, Long SR, Chang S, Able S, Baser O, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *J Managed Care Pharm.* 2006;12(1):43-54. <https://doi.org/10.18553/jmcp.2006.12.1.43>.
- A.195. Ozminkowski R, Goetzel R, Shechter D, Stapleton CD, Baser O, Lapin PJ. Predictors of preventive services use among Medicare beneficiaries. *Health Care Financ Rev.* 2006;27(3):5-23. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4194948/>.

2005

- A.196. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L. Risperidone treatment in elderly dementia patients: Relative risk of cardiovascular adverse events versus other antipsychotics. *Int Psychogeriatr.* 2005;17(4):1-13. <https://doi.org/10.1017/S1041610205002280>.

2004

- A.197. Crown WH, Berndt ER, Baser O, et al. Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Front Health Policy Res.* 2004;7:95-127. <https://doi.org/10.2202/1558-9544.1053>.
- A.198. Baser O, Gardiner J, Bradley C, Given C. Estimation from censored medical cost data. *Biometrical J.* 2004; 46:351-63. <https://mpra.ub.uni-muenchen.de/102198/>.

A.199. Baser O, Pema E. Publications over the academic life-cycle: Evidence for academic economists. *Econ Bulletin*. 2004;1(1):1-8. <http://www.economicsbulletin.com/2004/volume1/EB-04A10001A.pdf>.

2003

A.200. Bradley JC, Given C, Baser O, Gardiner J. Influence of surgical and treatment choices on the cost of breast cancer care. *Eur J Health Econ*. 2003;4:96-101. <https://doi.org/10.1007/s10198-002-0150-5>.

A.201. Baser O, Pema E. The returns of publications for economics faculty. *Econ Bulletin*. 2003;1(1)1-13. <http://www.economicsbulletin.com/2003/volume1/EB-03A10001A.pdf>.

A.202. Baser O, Bradley C, Gardiner J, et al. Testing and correcting non-random selection bias due to censoring: Application to medical costs. *Health Serv Outcomes Res Methodol*. 2003;4:93-107. <http://dx.doi.org/10.1023/B:HSOR.0000027922.32776.62>.

B. BOOKS and CHAPTERS in BOOKS

B.1. Baser O. Modeling Healthcare Costs. A2 Publications: 2012:82.

B.2. Crown HC, Berndt ER, Baser O, Finkelstein SN, Witt PW, Maguire J, Haver KE. Benefit plan design and prescription drug utilization among asthmatics: Do patient co-payments matter? *Frontiers in Health Policy Research*. MIT Press; 2004; 7:95-127.

C. CONFERENCE PRESENTATIONS

2026

C.1. Yapar N, Onder S, Arıkan E, Baser O. Early identification of postpartum depression risk using artificial intelligence. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.

C.2. Baser O, Nchekwube P, Yapar N, He J. Real-world impact of anti-amyloid therapy in Alzheimer's disease: An integrated analysis of 100% Medicare FFS claims linked with laboratory, electronic medical records, and patient-reported outcomes measures. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.

C.3. Baser O, Yapar N, Rodchenko K, Chen S, Wu L. Targeted therapy, immunotherapy, and molecular testing in advanced solid tumors: A 2021–2025 Medicare analysis. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.

C.4. Baser O, Sun Y, Yapar N, Lu Y, Chen S. Real-world effectiveness of anti-obesity pharmacotherapy in Medicare: Integrated 100% fee-for-service claims and EMR analysis of BMI reduction and cardiovascular outcomes. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026. PODIUM PRESENTATION.

- C.5. Baser O, Yuce H, Samayoa G, Chen S, Yapar N. Modeling rare events in health intervention: An application from the Department of War dataset. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.6. Baser O, Zhu X, Lu Y, Yapar N, Wu L, Guo W. Real-world safety and outcomes of bispecific antibodies in older adults. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.7. Baser O, Rodchenko K, Yapar N, Zhu X, Wu L. Real-world impact of modern obesity pharmacotherapy on liver outcomes in Medicare-enhanced lab and demographics data: 2021–2025. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.8. Baser O, Nchekwube P, Wu L, Yapar N, Guo W, Zhu X. Projected impact of personalized mRNA neoantigen cancer vaccines in Medicare: A scenario analysis using trial efficacy and linked data population estimates. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.9. Gandhi H, He J, Nchekwube P, Wagner S. Healthcare resource use in rare disease clinical trials: A systematic review. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026. Top 5% Finalist.
- C.10. Baser O, Yapar N, Chen S, Guo W. Laboratory markers and short-term outcomes in respiratory syncytial virus among older adults: Medicare-enhanced and laboratory data analysis 2021–2025. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.11. Baser O, Rodchenko K, Wu L, Chen S, Yapar N. Real-world multiple myeloma treatment responses: Evaluation of frontline regimens in MELDTM linked Medicare, laboratory and electronic medical records. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.12. Baser O, Rodchenko K, Nchekwube P, Yapar N, Chen S, He J. Prevalence and incidence of obesity and budget impact of the MOVE! weight management program in US veterans. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.13. Baser O, Rodchenko K, He J, Zhu X, Yapar N. Real-world perioperative immunotherapy and cellular therapy in older adults with solid tumors: A 2021–2025 Medicare-EMR linked analysis. Top 5% Finalist RIBBON. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.14. Zakeri M, Guo W, Baser O. Comparative risk of suicidal ideation and self-harm among patients with major depressive disorder treated with brexpiprazole versus other oral atypical antipsychotics: A propensity score-matched cohort analysis. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.15. Baser O, Rodchenko K, Yuce H. Inflation reduction act “Pill Penalty” and small-molecule innovation: Signals from investment, pipelines, and post-approval research. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.16. Baser O, Nchekwube P, Azmoudeh Y, Guo W. Timing of serious adverse events following mifepristone abortion in US commercial and Medicaid populations. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.

- C.17. Zakeri M, Baser O, Zhu X, Wagner S. Treatment patterns and gaps in resectable mucosal melanoma care for Medicare beneficiaries in the United States. *ISPOR 2026 Annual Meeting*. Philadelphia, PA: May 17-10, 2026.
- C.18. Marte EJ, Evans-Molina C, Edelman SV, Baser O, Rodchenko K, Yapar N, Kim D, Dunne JL, Bleibdrey N. Evaluating prevalence and incidence of type 1 diabetes in the US Department of War population. *AMSUS – The Society of Federal Health Professionals Annual Meeting*. National Harbor, MD: March 2-5, 2026.
- C.19. Mayer DC, Passarelli A, MacDonald PDM, Yapar N, Mohamed M, Baser O, Law AW. Administration timing of respiratory syncytial virus (RSV) preventives for infants in the United States: A descriptive retrospective observational study of the 2024 – 2025 RSV season. *RSVW'26 – A Global Conference on Novel RSV Preventive Therapeutic Interventions*. Rome, Italy: February 17-20, 2026.

2025

- C.20. Baser O, Yapar N, Baser E, Mohamed M, Passarelli A, Chen S, Lu Y, Rodchenko K. Comparative prevalence of suicidal ideation and self-harm history: Rextulti vs other oral atypical antipsychotics. *ISPOR Europe*, November 9-12, 2025: Glasgow, Scotland, UK.
- C.21. Baser O, Guo W, Yapar N. Does the abortion pill harm women? Serious adverse events following mifepristone abortion in US commercial and Medicaid populations. *ISPOR Europe*, November 9-12, 2025: Glasgow, Scotland, UK.
- C.22. Baser O, Rodchenko K, Yuce H, Yapar N. Effect of the Inflation Reduction Act on drug innovation. *ISPOR Europe*, November 9-12, 2025: Glasgow, Scotland, UK.
- C.23. Wagner S, Passarelli A, Zhu X, Baser O. Overall treatment landscape of mucosal melanoma. *ISPOR Europe*, November 9-12, 2025: Glasgow, Scotland, UK.
- C.24. Baser O, Rodchenko K, Wu L, Yapar N. Socioeconomic disparities in access to treatment for major depressive disorder: The role of accumulator and maximizer insurance plans. *ISPOR Europe*, November 9-12, 2025: Glasgow, Scotland, UK.
- C.25. Sepulveda F, Baser O, Lu Y, Endrizal A. Socioeconomic disparities in postpartum depression following abortion restrictions: A difference-in-differences analysis of Medicaid data post-Dobbs. *ISPOR Europe*. November 9-12, 2025: Glasgow, Scotland, UK.
- C.26. Baser O, Endrizal A, Lu Y, Sepulveda F. Socioeconomic vulnerabilities and postpartum depression: Assessing the aftermath of Dobbs v Jackson in trigger and non-trigger states. *AMCP Nexus*. Baltimore, MD: Oct 27-30, 2025.
- C.27. Baser O, Waters H, Rodchenko K, Sullivan M, Shurtleff M, Chen S, Wu L, Baser E, Bigley C, Patel R. The impact of copay accumulators and maximizers on treatment patterns and costs among patients with major depressive and bipolar disorders treated with branded mental health treatments. *AMCP Nexus*. Baltimore, MD: Oct 27-30, 2025.

- C.28. Passarelli A, Yapar N, Sun Y, Rodchenko K, Baser O, Phillips A, Chen X. Improved outcomes in patients with multiple sclerosis initiating cladribine tablets compared with those denied health insurance coverage in the United States. *AMCP Nexus*. Baltimore, MD: Oct 27-30, 2025.
- C.29. Nag S, Urganus A, Awasthi S, Bell Lynum KS, Atkins, Jr N, Baser O, Rodchenko K, Harrsen K. Real-world healthcare resource utilization and costs among US individuals living with bipolar-I disorder who transitioned to aripiprazole 2-month ready-to-use formulation. *Psych Congress*. San Diego, CA: Sept 17-21, 2025.
- C.30. Urganus A, Nag S, Awasthi S, Yildirim M, Bell Lynum KS, Atkins Jr N, Baser O, Rodchenko K, Harrsen K. Real-world healthcare resource utilization and costs among US individuals living with schizophrenia who transitioned to aripiprazole 2-month ready-to-use formulation. *Psych Congress*. San Diego, CA: Sept 17-21, 2025.
- C.31. Harrsen K, Awasthi S, Yildirim M, Beckham C, Bell Lynum KS, Atkins Jr. N, Baser O, Rodchenko K, Urganus A, Nag S. Real-world impact of transitioning from oral or once-monthly injectable aripiprazole to a 2-month ready-to-use aripiprazole formulation on adherence and healthcare utilization in US adults diagnosed with schizophrenia. *Psych Congress*. San Diego, CA: Sept 17-21, 2025.
- C.32. Johnson D, Mollard E, Koch M, Joo E, Nguyen V, Baser O, Tan R. Evaluating the association between Medicaid postpartum depression (PPD) screening and coverage policies with PPD diagnosis incidence in the US. *National Network of Depression Centers 17th Annual Conference*. Cincinnati, OH: September 10-11, 2025.
- C.33. Thompson S, Hansen R, Franzenburg KR, Luo W, Phatak A, Baser O, Patel R, Nehir Yapar N. Real-world clinical outcomes among patients receiving the long-acting injectable antipsychotic TV-46000 versus second-generation oral antipsychotics. *Psych Elevate 2025 Congress*. Las Vegas, NV: May 28-31, 2025.
- C.34. Thompson S, Hansen R, Franzenburg KR, Luo W, Phatak A, Baser O, Patel R, Nehir Yapar N. Treatment patterns and healthcare resource utilization among patients receiving the long-acting injectable antipsychotic TV-46000 versus second-generation oral antipsychotics. *Psych Elevate 2025 Congress*. Las Vegas, NV: May 28-31, 2025.
- C.35. Mollard E, Koch M, Joo E, Nguyen V, Baser O, Tan R. Evaluating the relationship between Medicaid postpartum depression (PPD) screening and coverage policies on PPD diagnosis incidence in the US. *ACOG Annual Clinical & Scientific Meeting*. Minneapolis, MN: May 16-18, 2025.
- C.36. Baser O, Yapar N, Baser E, Mohamed M, Passarelli A, Chen S, Lu Y, Rodchenko K. Comparison of suicidal ideation or personal history of self harm among patients with use of Rexulti and all antipsychotics. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.
- C.37. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N. Socioeconomic status and anti-obesity medications: Impact on cardiovascular risk in Medicare patients with obesity. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.

- C.38. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N, Baser E. Machine learning algorithms for identifying undiagnosed nonalcoholic steatohepatitis: A Veterans Affairs health system study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.
- C.39. Baser O, Yapar N, Rodchenko K, Mohamed M, Passarelli A, Chen S, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.
- C.40. Baser O, Lu Y, Sepulveda F, Yapar N, Endrizal A. Postpartum depression: Assessing the aftermath of Dobbs v. Jackson in trigger and non-trigger states. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.
- C.41. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N. Shades of blue: Investigating racial, socioeconomic, and family dynamics in depression among teen girls. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting*. Montreal, Quebec, Canada: May 13-16, 2025.
- C.42. Johnson D, Mollard E, Young M, Jiang X, Gannu L, Nguyen V, Mohamed M, Baser O, Tan R. Real-world treatment patterns, healthcare resource utilization and costs for Medicaid patients with a postpartum depression diagnosis. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*, Houston, TX: March 31 - April 3, 2025.
- C.43. Waters H, Huang D, Morrissey L, Patel R, Rodchenko K, Samayoa G, Yapar N, Freedman D, Baser O. Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*, Houston, TX: March 31 - April 3, 2025.

2024

- C.44. Baser O, Mohamed M, Samayoa G, Baser E. A retrospective analysis of the impact of approved anti-obesity medications on the risk of cardiovascular disease in patients with obesity. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024.
- C.45. Baser O, Samayoa G, Baser E, Mohamed M. The impact of approved anti-obesity medications on the incidence of cardiovascular disease, healthcare resource use and costs among patients with obesity: A retrospective cohort study. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024.
- C.46. Baser O, Mohamed M, Samayoa G, Baser E. The impact of approved anti-obesity medications on the incidence of osteoarthritis, healthcare resource use and costs among patients with obesity: A retrospective cohort study. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024. FINALIST AWARD
- C.47. Baser O, Samayoa G, Mohamed M, Baser E. Anti-obesity medications and related osteoarthritis risk among patients with obesity. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024.
- C.48. Baser O, Samayoa G, Baser E. The impact of approved anti-obesity medications on the risk of obstructive sleep apnea in patients with obesity: A retrospective cohort study. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024.

- C.49. Baser O, Mohamed M, Samayoa G, Baser E. The impact of approved anti-obesity medications on the incidence of obstructive sleep apnea, healthcare resource utilization and costs among patients with obesity: A retrospective cohort study. *ISPOR Europe*. Barcelona, Spain: Nov 17-20, 2024. FINALIST AWARD
- C.50. Baser O, Rodchenko K, Kuclo A, Yapar N, Mohamed M. Measuring the cardiovascular benefits of anti-obesity medications. *Obesity Week*. San Antonio, TX: Nov 3-6, 2024.
- C.51. Baser O, Budhu A, Kuclo A, Li W, Mohamed M. Head-to-head comparison of healthcare costs and utilization among patients with semaglutide vs tirzepatide use. *Obesity Week*. San Antonio, TX: Nov 3-6, 2024.
- C.52. Baser O, Rodchenko K, Baser I, Lu Y, Yapar N, Mohammed M. Likelihood of osteoarthritis among users of anti-obesity medications. *Obesity Week*. San Antonio, TX: Nov 3-6, 2024.
- C.53. Baser O, Yapar N, Kuclo A, Budhu A, Li W, Mohamed M. Likelihood of obstructive sleep apnea among patients with obesity and anti-obesity medication use. *Obesity Week*. San Antonio, TX: Nov 3-6, 2024.
- C.54. Waters HC, Huang D, Yapar N, Patel R, Samayoa G, Rodchenko K, Freedman D, Baser O. Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness. *Psych Congress*. Boston, MA: Oct 29 - Nov 2, 2024.
- C.55. Baser O, Waters HC, Samayoa G, Yapar N, Freedman D, Han S, Patel R. The effect of Medicaid reimbursement policies on serious mental illness outcomes. *Psych Congress*. Boston, MA: Oct 29 - Nov 2, 2024.
- C.56. Baser O, Waters HC, Samayoa G, Yapar N, Freedman D, Han S, Isenman L, Patel R. The effect of the Medicaid institutions for mental disease exception on serious mental illness outcomes. *Psych Congress*. Boston, MA: Oct 29 - Nov 2, 2024.
- C.57. Law A, Samayoa G, Fell D, Yapar N, Laguerre R, Judy J, Atwell J, Parrish R, Pugh S, Isenman L, Baser O. The association between socioeconomic status and the likelihood and severity of RSV-attributable lower respiratory infections in infants. *American Public Health Association (APHA)*. Minneapolis, MN: Oct 27-30, 2024.
- C.58. Baser O, Kuclo A, Budhu A, Yapar N. Effect of anti-obesity medications on cardiovascular events in the Veterans Affairs patient population. *AMCP Nexus*. Las Vegas, NV: Oct 14-17, 2024.
- C.59. Baser O, Kuclo A, Samayoa G, Baser E, Yapar N. Effect of weight loss medications on cardiovascular risk among active US military personnel. *AMCP Nexus*. Las Vegas, NV: Oct 14-17, 2024. (Bronze Ribbon Award)
- C.60. Baser O, Samayoa G, Rodchenko K. Cardiovascular benefits of weight loss medications: An analysis of Mounjaro and Wegovy in the US Medicare population. *AMCP Nexus*. Las Vegas, NV: Oct 14-17, 2024.

- C.61. Law A, Samayoa G, Fell D, Yapar N, Laguerre R, Judy J, Atwell J, Alexander-Parrish R, Pugh S, Baser O, Isenman L, Baser E. The association between socioeconomic status and maternal risk factors on the likelihood and severity of RSV-attributable lower respiratory infections from MarketScan data. *Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting*. Portland, OR: Aug 1-3, 2024.
- C.62. Baser O, Baser E, Samayoa G. The cardiovascular effect of abiraterone and enzalutamide among Veterans Affairs' metastatic castration resistant prostate cancer patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Annual Meeting*. Atlanta, GA: May 5-8, 2024.
- C.63. Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The effect of newly approved obesity medications on cardiovascular complications. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Annual Meeting*. Atlanta, GA: May 5-8, 2024.
- C.64. Baser O, Isenman L, Samayoa G, Dwivedi A, Baser E, Baser S. The effect of approved anti-obesity medications in patients with alcohol and substance use disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Annual Meeting*. Atlanta, GA: May 5-8, 2024.
- C.65. Baser O, Isenman L, Samayoa G, Dwivedi A, Baser E, Baser S. The impact of approved anti-obesity medications on osteoarthritis risk in patients with obesity: A retrospective cohort study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Annual Meeting*. Atlanta, GA: May 5-8, 2024.
- C.66. Baser O, Baser E, Yapar N, Samayoa G, Budhu A. Predictive risk score for nonalcoholic steatohepatitis (NASH) among patients in the Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Annual Meeting*. Atlanta, GA: May 5-8, 2024.
- C.67. Baser O, Isenman L, Baser E, Li W, Cigdem B. Socioeconomic status and postpartum depression among commercial health insurance enrollees. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. New Orleans, LA: April 16-19, 2024.
- C.68. Baser O, Isenman L, Dwivedi A, Samayoa S, Baser E, AlSaleh S. The effect of Ozempic vs. Wegovy vs. Mounjaro on the incidence of alcohol and substance use disorder in obese patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. New Orleans, LA: April 16-19, 2024.
- C.69. Baser O, Samayoa G, Isenman L, Baser S. Impact of Ozempic vs Wegovy on osteoarthritis risk in obese patients: A retrospective cohort study. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. New Orleans, LA: April 16-19, 2024.
- C.70. Baser O, Baser E, Samayoa G, Rodchenko R, Yapar N. The effect of approved obesity medications on obesity's cardiovascular related comorbidities. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. New Orleans, LA: April 16-19, 2024.
- C.71. Baser O, Waters H, Samayoa G, Yapar N, Gandhi H, Patel R. Open access for mental health medication: Impact on state Medicaid budgets. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. New Orleans, LA: April 16-19, 2024.

2023

- C.72. Baser O, Rodchenko K, Chen L, Yapar N. The short-run and long-run behavioral effects of vaccination enforcement in Turkey. *ISPOR Annual European Conference*. Copenhagen, DK: Nov 12-15, 2023.
- C.73. Baser O, Rodriguez N, Rodchenko K. Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from a national claims database. *ISPOR Annual European Conference*. Copenhagen, DK: November 12-15, 2023.
- C.74. Baser O, Rodchenko K, Zeng Y. Mental health disparities for young adults with arrest history: A survey-based, cross-sectional analysis. *ISPOR Annual European Conference*. Copenhagen, DK: November 12-15, 2023.
- C.75. Baser O, Baser E, Samayoa G. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide in Veteran Affairs. *Academy of Managed Care Pharmacy (AMCP) Nexus 2023*. Orlando, FL: October 16-19, 2023.
- C.76. Baser O, Baser E, Yapar N, Mete F. Use of open claims vs closed claims on health outcomes research. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.77. Baser O, Baser E, Yapar N, Rodriguez N. Relationship between body mass index and diagnosis of overweight or obesity in Veteran's Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.78. Baser O, Mete F, Baser E. Review of machine learning based disease diagnosis modeling. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.79. Baser O, Mete F, Yapar N, Baser E. Applying machine learning techniques to identify undiagnosed patients with nonalcoholic steatohepatitis (NASH). *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.80. Baser I, Rodriguez N, Azmoudeh Y. The short run and long run behavioral effects of COVID-19 vaccination enforcement. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.81. Baser O, Yuce H, Yapar N. Effect of surgical choices on the cost of breast cancer care. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Annual Meeting*. Boston, MA: May 7-10, 2023.
- C.82. Baser O, Yuce H, Rodriguez N, Yapar N. Analysis of rare events in outcomes research using Department of Defense data: Intravenous immune globulin therapy for bullous pemphigoid. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. Boston, MA: May 7-10, 2023.

2019

- C.83. Pan X, Chen CC, Wang L, Yuce H, Baser O. Real-world evidence of the economic burden and risk factors for hospitalization among patients with myeloma in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- C.84. Zhang Q, Delinger R, Wang H, Wang Y, Yuce H, Baser O, Xie L. Assessing the risk factors of heart failure among patients in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- C.85. Dieyi C, Pedarla V, Gu Y, Liu Y, Li L, Wang L, Yuce H, Baser O. Assessing the economic burden and hospitalization among patients with non-alcoholic steatohepatitis in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- C.86. Wang H, Qiang W, Delinger R, Keshishian A, Yuce H, Baser O, Xie L. Examining the risk factors of chronic obstructive pulmonary disease among patients in the Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- C.87. Okunowo O, Li L, Pedarla V, Gu Y, Wang L, Yuce H, Baser O. Assessing the economic burden and predictors of hospitalization among US veteran patients with rheumatoid arthritis: A retrospective case-control study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting*. New Orleans, LA: May 18-22, 2019.
- C.88. Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Survival rates and economic outcomes in chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
- C.89. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on metastasis and increased costs associated with progression to metastatic castrate-resistant prostate cancer. *Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
- C.90. Pedarla V, Gu Y, Wang L, Baser O. Assessing economic burden and hospitalization among asthma patients in the US Veterans Health Administration population. *American Managed Care & Specialty Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25- 28, 2019.
- C.91. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *European School of Haematology: How to Diagnose and Treat CML/MPN*. Saggart, Ireland: March 8-10, 2019

C.92. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on time to metastasis and overall survival in nonmetastatic castration-resistant prostate cancer patients. *American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium*. San Francisco, CA: February 14-16, 2019.

C.93. McNamara M, George D, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Wang L, Baser O, Huang A, Freedland SJ. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. *American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium*. San Francisco, CA: February 14-16, 2019.

2018

C.94. Pandya S, Clancy Z, Shrestha S, Wang L, Baser O. Burden of CRAB events by relapse in patients with newly diagnosed multiple myeloma not eligible for stem cell transplant. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.

C.95. Parasuraman S, Baser O, D Sturm, L Wang, S Shrestha. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.

C.96. Xie L, Sun X, Mallampati R, Wang Y, Yuce H, Baser O. Healthcare utilization and economic burden on patients with bladder cancer in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe*. Barcelona, ESP: November 10-14, 2018.

C.97. Borra S, Lin C, Wang L, Yuce H, Baser O. Assessing the economic burden and 30-day readmission rates among patients with bladder cancer in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe*. Barcelona, ESP: November 10-14, 2018.

C.98. Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K. Outcomes related to transition to once-every-three-monthly paliperidone palmitate among veterans with schizophrenia. *US Psych Congress*. Orlando, FL: October 25-28, 2018.

C.99. Szukis H, Benson C, Huang A, Amos TB, Wang L, Baser O. Economic burden of illness among US veterans with treatment-resistant depression. *US Psych Congress*. Orlando, FL: October 25-28, 2018.

C.100. Ramaswamy K, Mardekian J, Schultz N, Huang A, Wang L, Baser O, George D. Economic burden of chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide in the United States. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Orlando, FL: October 22-25, 2018.

C.101. George D, Schultz N, Huang A, Wang L, Baser O, Ramaswamy K, Mardekian J. Increased costs associated with progression to metastatic castrate-resistant prostate cancer. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Orlando, FL: October 22-25, 2018.

- C.102. Pandya S, Shrestha S, Wang L, Baser O, Clancy Z, Ni Q. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). *American Society of Clinical Oncology (ASCO) Quality Care Symposium*. Phoenix, AZ: September 28-29, 2018.
- C.103. Amin A, Bassalobre Garcia A, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in nonvalvular atrial fibrillation patients with heart failure. *European Society of Cardiology (ESC) Congress*. Munich, GER: August 25-29, 2018.
- C.104. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Standard and reduced doses of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral artery disease. *European Society of Cardiology (ESC) Congress*. Munich, GER: August 25-29, 2018.
- C.105. Amin A, Keshishian A, Zhang Q, Dina O, Dhamane A, Nadkarni A, Carda E, Liu X, Rosenblatt L, Baser O, Baker C. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress*. Munich, GER: August 25-29, 2018.
- C.106. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress*. Munich, GER: August 25-29, 2018.
- C.107. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Schuyler Jones W. Effectiveness and safety of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation according to coronary artery disease and/or peripheral artery disease. *European Society of Cardiology (ESC) Congress*. Munich, GER: August 25-29, 2018.
- C.108. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: The ARISTOPHANES study. *European Society of Cardiology (ESC) Congress*. Munich, Germany: August 25-29, 2018.
- C.109. Amin A, Keshishian A, Zhang Q, Dina O, Dhamane A, Nadkarni A, Carda E, Liu X, Rosenblatt L, Baser O, Baker C. Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress*. Munich, Germany: August 25-29, 2018.
- C.110. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: The ARISTOPHANES study. *European Society of Cardiology (ESC) Congress*. Munich, Germany: August 25-29, 2018.

- C.111. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: A dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress*. Munich, Germany: August 25-29, 2018.
- C.112. Cohen J, Beaubrun A, Bashyal R, Huang A, Huang T, Baser O. Real-world persistence for newly prescribed HIV-1 treatment: Single versus multiple tablet regimen comparison. *34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*. Prague, CZ: August 22-26, 2018. [oral presentation]
- C.113. Coleman CI, Herman WH, Pandya S, Wang L, Baser O, Cai J, Bookhart B. Body weight (BW) outcomes with canagliflozin 300 mg (CANA) vs. glucagon-like peptide-1 receptor agonists (GLP-1s) in a real-world (RW) setting. *American Diabetes Association (ADA) 78th Scientific Sessions*. Orlando, FL: June 22-26, 2018.
- C.114. Pandya S, Clancy Z, Shrestha S, Wang L, Ni Q, Baser O. Economic burden of early progression in newly diagnosed multiple myeloma patients. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL: June 1-5, 2018. [online abstract]
- C.115. Rubin DT, Long MD, Keshishian A, Baser O, Hepp Z, Wang A. The impact of intestinal complications on healthcare costs among inflammatory bowel disease patients with anti-TNF therapies. *Digestive Disease Week (DDW)*. Washington, DC: June 2-5, 2018.
- C.116. Gupta A, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with chronic obstructive pulmonary disease in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
- C.117. Xie L, Wang Y, Qiang W, Sah J, Baser O. Health care utilization and economic burden of patients with inflammatory bowel disease in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
- C.118. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Hematocrit (HCT) levels and thrombotic events (TEs) among US veterans with polycythemia vera (PV). *European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasm*. Saggart, Ireland: May 15-17, 2018.
- C.119. O'Neal W, Mendes S, Baser O, Wang L, Cramer J. Adherence and outpatient resource use with extended release oxcarbazepine (Oxtellar XR®) vs immediate-release oxcarbazepine (OXC-IR): Analysis of pooled data from four national claims databases. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. Boston, MA: April 23- 26, 2018.
- C.120. Borra S, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with breast cancer in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. Boston, MA: April 23-26, 2018.

C.121. Xie L, Baser O, Wang Y, Qiang W, Shen Y. Health care utilization and economic Burden on Patients Diagnosed with Epilepsy in the US Department of Defense Population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. Boston, MA: April 23- 26, 2018.

C.122. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in US clinical practice. *American College of Cardiology (ACC) 67th Annual Scientific Session & Expo*. Orlando, FL: March 10-12, 2018.

2017

C.123. Pandya S, Wang L, Baser O, Wan G, Lovelace B, Potenziano J, Pham AT, Kontekakis A, Huang X. The burden of hypoxic respiratory failure in preemies and neonates in the United States: 2011-2015. *Hot Topics in Neonatology*. Washington, DC: December 11-13, 2017.

C.124. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Real-world patterns of care for patients with follicular lymphoma treated with lenalidomide and rituximab (R2) in the US Medicare population. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA: December 9-12, 2017.

C.125. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among nonvalvular atrial fibrillation patients in the United States Medicare population. *American Heart Association (AHA) Scientific Sessions*. Anaheim, CA: November 11-15, 2017.

C.126. Lopes RD, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of apixaban versus other oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease. *American Heart Association (AHA) Scientific Sessions*. Anaheim, CA: November 11-15, 2017.

C.127. Ogbomo A, Lin Y, Keshishian A, Xie L, Baser O. A comparative analysis of the health care utilization and costs of patients diagnosed with and without liver cancer in the US Medicare population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.

C.128. Cinaroglu S, Baser O. The flow of EU-28 country clusters in terms of infectious and chronic diseases during a refugee crisis. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.

C.129. Zhang Q, Kariburyo MF, Xu J, Xie L, Baser O. Examining health care utilization and costs among atherosclerosis patients in the US Veteran Health Administration population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.

C.130. Vaidya N, Wang Y, Xie L, Baser O. Evaluating the economic burden and health care utilization of bacterial pneumonia in the US Department of Defense population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.

C.131. Cinaroglu S, Baser O. Adult risk factors of non-communicable disease outcomes. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.

- C.132. Cinaroglu S, Baser O. Intercontinental links among health technology assessment organizations. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4- 8, 2017.
- C.133. Cinaroglu S, Baser O. Factors related to outpatient antibiotic drug consumption in Turkey. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
- C.134. Cinaroglu S, Baser O. A fresh look at the predictors of the number of HIV cases in Turkey. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
- C.135. Ariely R, Chipps BE, Stoyanov S, Wang L, Shrestha S, Baser O. Budgetary impact model on a Medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters. *Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology*. Boston, MA: October 26-30, 2017.
- C.136. Hall E II, Wells W, Teynor M, Babb J, Huang A, Wang L, Baser O. Healthcare resource utilization and costs of spinal muscular atrophy care in the US Medicaid population. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Dallas, TX: October 16-19, 2017.
- C.137. Kerwin EM, Stoyanov S, Wang L, Shrestha S, Baser O, Ariely R. The budget impact on the adoption of short acting beta-agonist inhalers with integrated dose counters in managed care. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Dallas, TX: October 16-19, 2017.
- C.138. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Impact of coronary artery disease on clinical outcomes among patients with newly-diagnosed heart failure with systolic dysfunction: Is it changing over time? *Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting*. Dallas, TX: September 16-19, 2017.
- C.139. Benson C, Huang A, Wang L, Tandon N, Nash AI, Baser O. Clinical and economic burden of major depressive disorder among US veterans. *US Psych Congress*. New Orleans, LA: September 16-19, 2017.
- C.140. Zhang Q, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *Society of Hematologic Oncology (SOHO) Annual Meeting*. Houston, TX: September 13-16, 2017.
- C.141. Taylor K, Araujo AB, Wang L, Boystov N, Haynes GB, Pandya S, Sietsema D, Faries D, Baser O, Jones CB. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *American Society for Bone and Mineral Research (ASBMR) Annual Meeting*. Denver, CO: September 8-11, 2017.
- C.142. Ogbomo A, Keshishian A, Xie L, Lin Y, Baser O. A Descriptive analysis of the health care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, QC: August 26-30, 2017.
- C.143. Vaidya N, Xie L, Wang Y, Du J, Baser O. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, QC: August 26-30, 2017.

- C.144. Pandya S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veterans Health Administration population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, QC: August 26-30, 2017.
- C.145. Zhang Q, Xie L, Keshishian A, Lin Y, Baser O. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, QC. August 26-30, 2017. [oral presentation]
- C.146. Peacock WF, Coleman C, Wells P, Fermann GJ, Wang L, Baser O, Schein J, Crivera C. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care. *European Society of Cardiology (ESC) Congress*. Barcelona, Spain: 26-30 August 2017.
- C.147. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger J. Short and intermediate term all-cause mortality among newly-diagnosed heart failure patients in the US Medicare population. *European Society of Cardiology (ESC) Congress*. Barcelona, Spain: 26- 30 August 2017.
- C.148. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. *International Society on Thrombosis and Hemostasis (ISTH) Congress*. Berlin, Germany: July 8-13, 2017.
- C.149. Cinaroglu S, Baser O. Network among HTA ecosystem. *Health Technology Assessment international (HTAi) Annual Meeting*. Rome, Italy: June 17-21, 2017.
- C.150. Cinaroglu S, Baser O. Predictors of public health outcomes: A case study from Turkey. *Health Technology Assessment international (HTAi) Annual Meeting*. Rome, Italy: June 17-21, 2017.
- C.151. Baser O, Cinaroglu S. Determinants of the behavioral health system's efficiency in OECD countries. *Health Technology Assessment international (HTAi) Annual Meeting*. Rome, Italy: June 17-21, 2017.
- C.152. Cinaroglu S, Baser O. Worldwide clustering of surgical indicators and risk predictors of catastrophic surgical care expenditures. *Health Technology Assessment international (HTAi) Annual Meeting*. Rome, Italy: June 17-21, 2017.
- C.153. Kuritzkes BA, Pappou EP, Guo X, Yang H, Zhao B, Baser O, Kiran RP, Bentley- Hibbert S. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific and Tripartite Meeting*. Seattle, WA: June 10- 14, 2017.
- C.154. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.155. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with pneumonia in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.

- C.156. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with clostridium difficile infection in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20- 24, 2017.
- C.157. Lin Y, Ogbomo A, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with myelodysplastic syndrome in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.158. Ogbomo A, Lin Y, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with lymphoma in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.159. Vaidya N, Tan H, Xie L, Wang Y, Baser O. Evaluating the economic burden and health care utilization of rheumatoid arthritis patients in the US Department of Defense population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.160. Xie L, Vaidya N, Wang Y, Tan H, Baser O. Evaluating the economic burden and health care utilization of prostate cancer patients in the US Department of Defense population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.161. Du J, Xie L, Keshishian A, Zhang Q, Yuce H, Baser O. Assessing the hospital readmission and mortality rates among elderly patients with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.162. Xie L, Zhang Q, Baser O, McGuire M. Examining the health care resource use and economic costs associated with acute myeloid leukemia among Medicare patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
- C.163. Ganapathy V, Xie L, Keshishian A, Zhang Q, Baser O. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents. *American Thoracic Society (ATS) International Conference*. Washington, DC: May 19-24, 2017.
- C.164. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of institutionalization among newly diagnosed Alzheimer's disease patients. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
- C.165. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.

- C.166. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *Society of General Internal Medicine (SGIM) 2017 Annual Meeting*. Washington DC: April 19-22, 2017.
- C.167. Xie L, Parikh K, Abouzaid S, Pandya S, Baser O, Patel MI. Real-world treatment outcomes and costs among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *13th Hematology/Oncology Pharmacy Association (HOPA) Annual Conference*. Anaheim, CA: March 29-April 1, 2017.
- C.168. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: March 29-April 2, 2017.
- C.169. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of institutionalization among newly diagnosed AD patients. *13th International Conference on Alzheimer's & Parkinson's*. Vienna, Austria: March 29-April 2, 2017.
- C.170. Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting*. Denver, CO: March 27-30, 2017.
- C.171. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. Denver, CO: March 27-30, 2017.
- C.172. Chipps B, Ferro T, Wang L, Shrestha S, Baser O, Parikh R. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. Denver, CO: March 27-30, 2017.
- C.173. Pandya S, Abouzaid S, Xie L, Parikh K, Baser O, Patel MI. Real-world health care costs among newly diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015). *National Comprehensive Cancer Network (NCCN) 22nd Annual Conference*. Orlando, FL: March 23-25, 2017.
- C.174. Cinaroglu S, Baser O. Cross sectional analysis of predictors of self-reported chronic low back pain: An analysis of Turkey Health Survey data. *Turkish Rheumatology Congress (with International Attendance) 2017*. Antalya, Turkey: March 22-26, 2017.
- C.175. Amin A, Keshishian A, Trocio J, Dina O, Le H, Zhang Q, Baser O, Vo L. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: March 17-19, 2017.
- C.176. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US. *AMDA (Society for Post-acute and Long-term Care Medicine) Annual Conference*. Phoenix, AZ: March 16-19, 2017.

C.177. Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *American Academy of Dermatology (AAD) 2017 Annual Meeting*. Orlando, FL: March 3-7, 2017.

C.178. Shrestha S, Baser O, Zhou X, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *International Stroke Conference*. Houston, TX: February 22-24, 2017.

C.179. Cinaroglu S, Sahin B, Karabulut E, Baser O. Inequality in health care financing in Turkey: Findings from the household budget survey 2003-2013. *London School of Economics International Health Policy Conference*. London, UK: February 16-19, 2017.

C.180. Sonpavde G, Huang A, Wang L, Baser O, Miao R. First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. *Genitourinary Cancers Symposium*. Orlando, FL: February 16-18, 2017.

2016

C.181. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Time to reach coverage gap and catastrophic coverage: A Medicare Part D claims analysis among beneficiaries with chronic obstructive pulmonary disease. *American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting*. Las Vegas, NV: December 48, 2016.

C.182. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: December 3-6, 2016.

C.183. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism. *American Heart Association (AHA) Scientific Sessions*. New Orleans, LA: November 12-16, 2016.

C.184. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact. *American Heart Association (AHA) Scientific Sessions*. New Orleans, LA: November 12-16, 2016.

C.185. Kurlansky P, Baser O, Nemeth S, Tingley J, Argenziano M, Smith C. East meets West in the assessment of cardiac risk: A multicenter comparative study of the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *American Heart Association (AHA) Scientific Sessions*. New Orleans, LA: November 12-16, 2016.

C.186. Wang L, Li L, Pandya S, Baser O. Evaluating socio-demographic characteristics of patients in the United States Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Congress*. Vienna, Austria: October 29 - November 2, 2016.

- C.187. Wang L, Li L, Pandya S, Baser O. A real-world evaluation of the clinical and economic burden of United States veteran patients with post-traumatic stress disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.188. Wang L, Li L, Zhou X, Pandya S, Baser O. Evaluation of the clinical characteristics and economic burden of United States veteran patients diagnosed with the hepatitis C virus. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.189. Wang L, Li L, Zhou X, Pandya S, Baser O. Assessing the clinical and economic burden of prostate cancer in the United States veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.190. Cinaroglu S, Baser O. Spatial distribution of the total number of medical devices in Turkey: A classification analysis. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.191. Cinaroglu S, Baser O. Socio-economic status and self-rated health: Are they good predictors of income? An analysis of survey panel data from Turkey. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.192. Cinaroglu S, Baser O. Understanding the relationship between effectiveness and outcome indicators in health care. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.193. Cinaroglu S, Guzel E, Baser O. The relationship between medical innovation and health expenditures. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.194. Xie L, Zhang Q, Xin K, Wang Y, Yuce H, Özenbas D, Baser O. Health care utilization and economic burden of pancreatic cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.195. Xie L, Vaidya N, Xin K, Keshishian A, Yuce H, Özenbas D, Baser O. Evaluating the economic burden and health care utilization of lung cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
- C.196. Xie L, Vaidya N, Xin K, Kariburyo MF, Yuce H, Baser O. Evaluating the economic burden and health care utilization of breast cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.

- C.197. Murray AC, Baser O, Pappou LK, Feingold RP, Kiran. Income, geography and hospital determine gaps in assimilation of minimally invasive technology for rectal cancer surgery. *American College of Surgeons Clinical Congress*. Washington, DC: October 16- 20, 2016.
- C.198. Xie L, Zhou S, Kariburyo F, Baser O, Fan T. Clinical and economic outcomes in patients with type 2 diabetes switching from basal insulin plus rapid-acting insulin to basal insulin plus glucagon-like peptide-1: A real-world observational study. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: October 3-6, 2016.
- C.199. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O. Demographic and clinical characteristics of patients with polycythemia vera (PV) in the US veteran population. *Association of VA Hematology/Oncology (AVAHO) 12th Annual Meeting*. Dallas, TX: September 23-25, 2016.
- C.200. Parikh K, Pandya S, Abouzaid S, Baser O, Xie L, Patel MI. Treatment patterns among newly diagnosed multiple myeloma patients in the United States veteran population (2010- 2015). *ASH Meeting on Hematologic Malignancies*. Chicago, IL: September 16-17, 2016.
- C.201. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarin. *European Society of Cardiology (ESC) Congress*. Rome, Italy: 27-31 August 2016.
- C.202. Black CM, Hu X, Khandker RK, Ambegaonkar BM, Kariburyo MF, Xie L, Baser O, Yuce H. Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer's disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. *Alzheimer's Association International Conference (AAIC) Annual Conference*. Toronto, ON: July 24-28, 2016.
- C.203. Cai J, Wang Y, Baser O, Xie L, Diels J, Neslusan C, Chow W. Comparative persistence with antihyperglycemic agents (AHA) used to treat type 2 diabetes mellitus (T2DM) in the real world. *American Diabetes Association (ADA) 76th Scientific Sessions*. New Orleans, LA: June 10-14, 2016.
- C.204. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Comparing health care resource utilization and costs among obese patients in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.205. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Assessing the economic burden and health care utilization of attention deficit/hyperactivity disorder among US Medicaid patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.206. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating asthma-related expenses and health care resource utilization among children in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.

- C.207. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing the economic burden and health care resource utilization of US veterans with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.208. Ogbomo A, Zhao Y, Kariburyo MF, Xie L, Yuce H, Baser O. Retrospective analysis of the economic burden of patients diagnosed with congestive heart failure in the California Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.209. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing health care resource utilization and costs among US veterans diagnosed with asthma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.210. Keshishian A, Tan H, Xie L, Baser O. Examination of the economic burden of dyslipidemia in the Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.211. Kariburyo F, Du J, Xie L, Baser O. Examining the health care resource utilization and economic burden among rheumatoid arthritis patients with different routine assessment of patient index data 3 scores: A probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.212. Kariburyo F, Du J, Xie L, Baser O. Assessing the economic burden of rheumatoid arthritis patients with different clinical disease activity index scores: A probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.213. Tan H, Xie L, Wang Y, Yuce H, Baser O. Examine the burden of illness of US Medicare patients diagnosed with cataract. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.214. Tan H, Xie L, Baser O, Yuce H, Wang Y. Evaluating the economic burden and health care utilization of anemia in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.215. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating the economic burden and health care utilization of coronary artery disease in the US Medi-Cal population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
- C.216. Keshishian A, Du J, Xie L, Yuce H, Baser O. Demographic and socioeconomic characteristics that impact selection of oral anticoagulants among non-valvular atrial fibrillation patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.

- C.217. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among patients with chronic obstructive pulmonary disease in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.218. Bashyal R, Du H, Wang L, Yuce H, Baser O. Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.219. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among hospitalized congestive heart failure patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.220. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of alcohol dependence among US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.221. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with depressive disorder in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.222. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of bipolar disorder among U.S. veteran patients from 2011 to 2015. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.223. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with drug dependence in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.224. Bashyal R, Du H, Wang L, Yuce H, Baser O. Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
- C.225. Pesa JA, Wang L, Yuce H, Baser O. Proton pump inhibitor utilization among patients with hepatitis C virus (HCV). *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21- 25, 2016.
- C.226. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: April 2-4, 2016.

2015

- C.227. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. *American Society of Hematology (ASH) Annual Meeting and Exposition*. Orlando, FL: December 5-8, 2015. [oral presentation]
- C.228. Xie L, Wang Y, Tan H, Ogbomo A, Baser O, Yuce H. Trends in prevalence and incidence rates of type 2 diabetes mellitus in the Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
- C.229. Keshishian A, Wang Y, Xie L, Baser O, Yuce H. Examining the economic burden and health care utilization of menopausal women in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
- C.230. Baser O, Ogbomo A, Tan H, Du J, Xie L. Evaluation of the burden of opioid abuse among US veteran patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
- C.231. Xie L, Tan H, Ogbomo A, Wang Y, Baser O, Yuce H. Evaluation of the burden of Parkinson's disease in Medicare and linked long term care populations. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
- C.232. Fox KM, Wang L, Quek RGW, Gandra SR, Li L, Baser O. Long-term increased inpatient and outpatient visits associated with cardiovascular events: A large United States real world study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
- C.233. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American Heart Association (AHA) Scientific Sessions*. Orlando, FL: November 7-11, 2015.
- C.234. Masseria C, Kariburyo MF, Mardekian J, Lee TC, Ravee Y, Phatak H, Baser O, Hamilton M, Xie L. Venous thromboembolism recurrence and bleeding risk among cancer patients using a large commercial database. *American Heart Association (AHA) Scientific Sessions*. Orlando, FL: November 7-11, 2015.
- C.235. Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singha S, Patel C, Odell K, Trocio J. Comparison of short term bleeding-related health care utilization and costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. *American College of Chest Physicians CHEST Annual Meeting*. Montreal, QC, Canada: 24-28 October 2015.

- C.236. Pesa J, Wang L, Yuce H, Baser O. Comparing costs and resource utilization between patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in California Medicaid (MediCal). *US Psychiatric & Mental Health Congress*. San Diego, CA: September 10-13, 2015.
- C.237. Baser O, Lewis-Beck C, Fritschel E, Baser E, Wang L. Applied comparison of meta-analysis techniques. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 5th Latin America Conference*. Santiago, Chile: 6-8 September 2015.
- C.238. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents in the U.S. clinical practice. *American Society of Clinical Psychopharmacology (ASCP) Annual Meeting*. Miami, FL: June 22-25, 2015.
- C.239. Alley S, Nguyen C, Xie L, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents in the US clinical practice. *American Association of Nurse Practitioners (AANP) National Conference*. New Orleans, LA: June 9-14, 2015.
- C.240. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden and health care resource utilizations of U.S. Medicare patients with myeloproliferative neoplasms. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.241. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden of U.S. Medicare patients diagnosed with Non-Hodgkin's lymphoma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.242. Xie L, Kariburyo MF, Wang D, Baser O. A descriptive analysis of patient characteristics and health care burden associated with chronic obstructive pulmonary disease in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16- 20, 2015.
- C.243. Baser O, Kariburyo MF, Du J, Xie L. Comparing healthcare resource utilization and costs among schizophrenic patients who initiated typical vs atypical long-acting injectables in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.244. Xie L, Keshishian A, Du J, Baser O. Examining the fracture-related cost burden and healthcare resource utilization post-menopause in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.245. Xie L, Wang Y, Keshishian A, Baser O. Comparing the healthcare utilization and costs of early- and late-stage Alzheimer's disease patients residing in long-term care facilities. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.246. Xie L, Keshishian A, Wang Y, Baser O. Evaluating fracture-related expenses and health care resource utilization among post-menopausal women in the U.S. Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.

- C.247. Mao X, Shrestha S, Baser O, Wang L. Assessing the health care resource utilization and economic burden among U.S. cardiovascular disease patients in the Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.248. Li L, Shrestha S, Baser O, Yuce H, Wang L. Mortality and rehospitalization rates among hospitalized pneumonia patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.249. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and economic burden of patients diagnosed with rheumatoid arthritis in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.250. Li L, Shrestha S, Baser O, Yuce H, Wang L. Examining prevalence, incidence and mortality rates among opioid-dependent patients in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.251. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Health care cost burden and demographic distribution of patients diagnosed with psoriatic arthritis in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.252. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilization and costs among diabetes patients residing in long-term care facilities. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.253. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilizations and costs among migraine patients in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.254. Huang A, Shrestha S, Baser O, Yuce H, Wang L. A retrospective analysis of health care resource utilization and the economic burden among U.S. long-term care facility patients diagnosed with stroke. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.255. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and health care burden of patients diagnosed with ankylosing spondylitis in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.256. Li L, Shrestha S, Baser O, Yuce H, Wang L. Prevalence and incidence rates among alcohol-dependent patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.

- C.257. Mao X, Shrestha S, Baser O, Wang L. A retrospective analysis of the economic burden among patients diagnosed with chronic migraine using the Veterans Health Administration medical dataset. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.258. Li L, Shrestha S, Baser O, Wang L. Evaluating trends in chronic pain prevalence in the United States Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.259. Xie L, Du J, Kariburyo MF, Baser O. A descriptive analysis of patient characteristics, bleeding and recurrence risk among U.S. veteran patients diagnosed with venous thromboembolism. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
- C.260. Fox KM, Wang L, Gandra SR, Quek RGW, Li L, Baser O. Long-term economic burden associated with cardiovascular events among high-risk patients with hyperlipidemia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
- C.261. Xie L, Wang Z, Alley S, Baser O, Nguyen C. Healthcare utilization and costs of serotonin syndrome with concomitant use of serotonergic agents. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.262. Masseria C, Kariburyo MF, Mardekian J, Lee T, Phatak H, Baser O, Xie L. Clinical outcomes and treatment patterns of venous thromboembolism among cancer patients in a large commercial database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16-20, 2015.
- C.263. Velez FF, Baser O, Xie L. Adherence and persistence to anti-epileptic drugs among U.S. veterans diagnosed with epilepsy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia, PA: May 16- 20, 2015.
- C.264. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Incidence of serotonin syndrome with concomitant use of serotonergic agents in the US veteran population. *American Psychiatric Association (APA) 168th Annual Meeting*. Toronto, ON: May 16- 20, 2015.
- C.265. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *American Heart Association (AHA) Quality of Care and Outcomes Research Scientific Sessions*. Baltimore, MD: April 29 - May 1, 2015.
- C.266. Wang Z, Xie L, Alley S, Baser O, Nguyen C. Incidence of serotonin syndrome with concomitant use of serotonergic agents in the US clinical practice. *Society of General Internal Medicine (SGIM) 38th Annual Meeting*. Toronto, ON: April 22-25, 2015.
- C.267. Baser O, Griffith J, Roy S, Xie L, Ganguli A. Impact of switching among tumor necrosis factor inhibitors (TNF) on health care resource utilization and costs in patients with rheumatoid arthritis. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7-10, 2015.

C.268. Velez F, Baser O, Xie L. Cost analyses among U.S. veterans diagnosed with epilepsy and treated with antiepileptic drug monotherapy or adjunctive therapy. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7- 10, 2015.

C.269. Xie L, Vo L, Keshishian A, Price K, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7-10, 2015.

2014

C.270. Wang L, Baser O, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials. *American Society of Hematology (ASH) Annual Meeting and Exposition*. San Francisco, CA: December 6-9, 2014.

C.271. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Association of out-of- range international normalized ratio (INR) values and adverse clinical outcomes among newly initiated warfarin patients with non-valvular atrial fibrillation and comorbid diabetes. *American Heart Association (AHA) Scientific Sessions*. Chicago, IL: November 15- 19, 2014.

C.272. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of breast cancer in the Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

C.273. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of Medicaid program services for patients diagnosed with multiple sclerosis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

C.274. Li L, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden among Cushing's disease patients in the U.S. Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

C.275. Li L, Shrestha S, Baser O, Wang L. Evaluation of the economic burden of menopausal women in the U.S. Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

C.276. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of U.S. long-term care facility residents diagnosed with Parkinson's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

C.277. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of long-term care facility residents diagnosed with Alzheimer's disease in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

- C.278. Xie L, Kariburyo MF, Du J, Baser O. Examination of the burden of illness of U.S. Medicare patients diagnosed with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.279. Xie L, Kariburyo MF, Du J, Baser O. Assessing the economic burden and health care utilization of US Medicare patients diagnosed with melanoma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014. [FINALIST RESEARCH AWARD]
- C.280. Xie L, Dysinger AH, Kariburyo MF, Du J, Baser O. Evaluation of the burden of illness of U.S. Medicare patients diagnosed with hyperpotassemia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.281. Xie L, Kariburyo MF, Wang Y, Baser O. Evaluating the economic burden and health care utilizations of US veteran patients diagnosed with chronic hepatitis C. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014. [FINALIST RESEARCH AWARD]
- C.282. Xie L, Kariburyo MF, Wang Y, Baser O. Health care costs and utilization of U.S. veteran patients diagnosed with pancreatic cancer. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.283. Xie L, Kariburyo MF, Wang Y, Baser O. Comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with type 2 diabetes mellitus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.284. Xie L, Dysinger AH, Wang Y, Kariburyo MF, Baser O. Prevalence of cystic fibrosis among the U.S. national Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.285. Baser O, Kariburyo MF, Altinbas A, Baser E. Economic burden and complications of hepatitis C virus patients with and without peginterferon and ribavirin treatment in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.286. Baser O, Kariburyo MF, Baser E, Altinbas A. Cost of cirrhosis among patients diagnosed with hepatitis C virus in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.
- C.287. Baser E, Baser O, Altinbas A, Kariburyo MF. Pharmacy cost calculator for hepatitis C virus patients in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, Netherlands: 8-12 November 2014.

- C.288. Levin PA, Wei W, Gill J, Buysman E, Grabner M, Xie L, Baser O, Chu JW. Treatment patterns and outcomes in managed care patients with type 2 diabetes initiating injectable therapies: A pooled analysis from the INITIATOR Study. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Boston, MA: October 7-10, 2014.
- C.289. Wei W, Brekke LN, Buysman E, Grabner M, Ke X, Xie L, Baser O. A personalized- medicine approach to evaluate real-world treatment benefits of patients with type 2 diabetes mellitus initiating different injectable therapies. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Boston, MA: October 7-10, 2014.
- C.290. Miao R, Wei W, Xie L, Baser O. Impact of switching basal insulin analogs on clinical and economic outcomes in patients with type 2 diabetes in a national managed care plan setting. *Academy of Managed Care Pharmacy (AMCP) Nexus*. Boston, MA: October 7-10, 2014.
- C.291. Yu H, Strutton D, Roberts C, Baser O, Wang L. Clostridium difficile associated disease in the US elderly population. *54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)*. Washington, DC: September 5-9, 2014. [oral presentation]
- C.292. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large US insurance database analysis. *European Society of Cardiology (ESC) Congress*. Barcelona, Spain: August 30-September 3, 2014.
- C.293. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Therapeutically exchangeable? A real-world outcome study of switching between basal insulin analogs among T2DM patients. *American Diabetes Association (ADA) 74th Annual Scientific Sessions*. San Francisco, CA: June 13-17, 2014.
- C.294. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo MF, Edwards E, Baser O, Murrelle L. Development of a predictive questionnaire for prescription opioid-related overdose or respiratory/CNS depression. *International Conference on Opioids (ICOO)*. Boston, MA: June 8-10, 2014.
- C.295. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Variation trends in asthma prevalence in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014. [FINALIST RESEARCH AWARD]
- C.296. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Examining diabetes prevalence in the United States using a 2008-2009 Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.297. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence of hepatitis B virus infection in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
- C.298. Xie L, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Examining hepatitis C virus prevalence in the U.S Medicaid population from 2008 to 2009. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.

- C.299. Baser O, Wang L, Huang A, Wang Y, Kariburyo MF, Xie L. Examining the burden of illness of U.S. veteran patients diagnosed with bipolar disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.300. Baser O, Xie L, Huang A, Du J, Wang Y, Wang L. Evaluation of the burden of depression among U.S. veteran patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.301. Wang L, Xie L, Li L, Wang Y, Du J, Baser O. Assessing the health care burden of asthma patients in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.302. Wang L, Xie L, Li L, Kariburyo MF, Wang Y, Baser O. Evaluation of economic burden and health care utilizations for US Medicare patients with rheumatoid arthritis. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.303. Xie L, Wang L, Li L, Wang Y, Baser O. The burden of illness of osteoporosis patients in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.304. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Economic burden and health care utilizations of U.S. Medicare patients diagnosed with prostate cancer. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.305. Xie L, Wang L, Li L, Wang Y, Du J, Baser O. Evaluation of the burden of general cardiovascular disease among U.S. Medicare patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.306. Seal BS, Xie L, Rietschel P, Baser O. Compare demographic and clinical characteristics among colorectal cancer patients with a different number of treatment lines in the US veteran health administration. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.307. Seal BS, Xie L, Rietschel P, Baser O. Descriptive analysis of treatment patterns and mortality of U.S. veteran patients with colorectal cancer. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014. [Podium presentation]
- C.308. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Autism prevalence in children among the US Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014. [FINALIST RESEARCH AWARD]
- C.309. Wang L, Xie L, Dysinger AH, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Assessing Lyme disease prevalence in the US Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.

- C.310. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence and trends in cystic fibrosis among the US Medicaid population in 2008 and 2009. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
- C.311. Wang L, Dysinger AH, Xie L, Huang A, Wang Y, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients with post-traumatic stress disorder after unstable angina. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31- June 4, 2014.
- C.312. Claflin AB, Xie L, Liu X, Mardekian J, Phatak H, Tan W, Baser O. Anticoagulant use and bleeding risk in patients with venous thromboembolism: A nested case-control study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC: May 31-June 4, 2014.
- C.313. Xie L, Frech-Tamas F, Baser O. Impact of antihypertensive pill burden on patient adherence. *American Society of Hypertension (ASH) 2014 Annual Scientific Meeting and Exposition*. New York, NY: May 16-20, 2014.
- C.314. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson KN. Human immunodeficiency virus burden of illness and treatment patterns among US veteran patients. *Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo*. Tampa, FL, USA: April 1-4, 2014.
- C.315. Olufade T, Wang L, Devine S, Baser O, Lo Re V, III. Hepatic decompensation in HIV/HBV/HCV patients and the impact of HBV therapy. *Conference on Retroviruses and Opportunistic Infections (CROI)*. Boston, MA: March 3-6, 2014.

2013

- C.316. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Bleeding incidence among patients with venous thromboembolism: A large US insurance database analysis. *55th American Society of Hematology (ASH) Annual Meeting and Exposition*. New Orleans, LA: December 7-10, 2013.
- C.317. Bui CN, Spalding JR, Wang L, Baser O. Treatment timing of life-extending therapies and adherence to corticosteroids among metastatic castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use. *5th European Multidisciplinary Meeting on Urological Cancers (EMUC)*. Marseille, France: November 15-17, 2013.
- C.318. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with Alzheimer's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
- C.319. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and healthcare utilizations of US veteran patients diagnosed with the hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.

- C.320. Xie L, Wang L, Kariburyo MF, Li L, Wang Y, Baser O. Comparison of the health care costs and utilizations between patients diagnosed with the hepatitis B virus versus those without. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
- C.321. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with obesity. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
- C.322. Wang L, Dysinger AH, Xie L, Du J, Huang A, Baser O. Evaluation of the burden of illness of skin cancer among US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.323. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Evaluation of the burden of illness of colorectal cancer among U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
- C.324. Wang L, Xie L, Kariburyo MF, Li L, Wang Y, Baser O. Examining the burden of illness of U.S. veteran patients with prostate cancer. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.325. Xie L, Wang L, Kariburyo MF, Huang A, Baser O. A comparison of the economic burden and health care utilizations of US veteran patients diagnosed with diabetes. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.326. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Effects of excess use of coronary angiography and its association with mortality rates, health care costs and hospital quality in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.327. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti E. Anticoagulant use in the US hospitalized patients with acute venous thromboembolism. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.328. Wang L, Xie L, Du J, Li L, Baser O. A comparison of the economic burden and health care utilizations of US veteran patients diagnosed with hypertension. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
- C.329. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Impact of comorbidity burden on real-world healthcare costs of rheumatoid arthritis patients in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.

- C.330. Baser O, Baser E, Altinbas A, Burkan A. Effects of claims-based rheumatoid arthritis severity on biologic therapy use and health care costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.331. Baser O, Wang L, Li L, Huang A, Xie L. Application of a data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.332. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.333. Xie L, Dysinger AH, Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients diagnosed with post-traumatic stress disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.334. Xie L, Wang L, Du J, Li L, Baser O. Comparing the healthcare costs and utilizations between patients with anxiety versus those without. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.335. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and health care utilizations of US veteran patients diagnosed with schizophrenia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.336. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Using an Excel calculator to estimate ankylosing spondylitis costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.337. Baser O, Baser E, Altinbas A, Burkan A. Derivation of severity index for rheumatoid arthritis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.338. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. An Excel calculator to estimate rheumatoid arthritis costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.339. Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and healthcare utilizations of US veteran patients diagnosed with chronic kidney disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
- C.340. Ray S, Wang L, Martel MJ, Baser O. Variation in patterns of healthcare and survival among patients with brain metastases in the VHA health system. *American Society of Clinical Oncology (ASCO) Quality Care Symposium*. San Diego, CA: November 1- 2, 2013.

- C.341. Alemao E, Xie L, Wong R, Litalien G, Baser O. Analysis of non-steroidal anti-inflammatory drug burden among rheumatoid arthritis patients using the Dougados algorithm. *American College of Rheumatology (ACR) Annual Scientific Meeting*. San Diego, CA: October 25-30, 2013.
- C.342. Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. Biologic switching rates among patients with rheumatoid arthritis. *American College of Rheumatology (ACR) Annual Scientific Meeting*. San Diego, CA: October 25-30, 2013.
- C.343. Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J. Much ado about nothing? A longitudinal retrospective study of patients with type-2 diabetes treated with insulin glargine and switched to insulin detemir. *Society for Medical Decision Making (SMDM) 35th Annual Meeting*. Baltimore, MD: October 20-23, 2013.
- C.344. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson K. Burden of illness among United States veteran treatment naïve human immunodeficiency virus infected patients. *American College of Clinical Pharmacy (ACCP) Annual Meeting*. Albuquerque, NM: October 13-16, 2013.
- C.345. Xie L, Pesa J, Durkin M, Clancy Z, Baser O. Healthcare use and cost of patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in a VA population. *65th Institute on Psychiatric Services (IPS) Conference*. Philadelphia, PA: October 10-13, 2013.
- C.346. Xie L, Pesa J, Durkin M, Clancy Z, Baser O. A comparison of healthcare utilization and costs of schizophrenia patients treated with paliperidone palmitate long-acting injection or atypical oral antipsychotics within the Veterans Health Administration. *US Psychiatric and Mental Health Congress*. Las Vegas, NV: September 30-October 3, 2013.
- C.347. Dalal M, Xie L, Baser O, DiGenio A. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: Real world health care costs from a US managed care setting. *European Association for the Study of Diabetes (EASD) Annual Meeting*. Barcelona, Spain: September 23-27, 2013.
- C.348. Wang L, Lewis-Beck C, Baser E, Fritschel E, Baser O. Applied comparison of meta-analysis techniques. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 4th Latin America Conference*. Buenos Aires, Argentina: September 12-14, 2013.
- C.349. Xie L, Du J, Kariburyo MF, Dysinger AH, Wang L, Baser O. Mental disorder treatment, healthcare costs and utilizations for US veterans. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, QC: August 25-28, 2013. [Oral presentation]
- C.350. Baser O, Wang L, Li L, Xie L. Characteristics associated with initiation of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, QC: August 25-28, 2013.
- C.351. Baser O, Du J, Xie L, Dysinger AH, Wang L. Severity index for rheumatoid arthritis: Impact on healthcare costs and utilization. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, QC: August 25-28, 2013.

- C.352. Wang L, Huang A, Fritschel E, Baser O. Tumor necrosis factor treatment patterns in Medicare patients with inflammatory conditions. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, QC: August 25-28, 2013.
- C.353. Wang L, Li L, Fritschel E, Baser O. Overview of the clinical and economic burden of prostate cancer in the US veteran population. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, QC: August 25-28, 2013.
- C.354. Wang L, Wei W, Dalal M, Baser O. Treatment intensification after early failure of metformin or sulfonylurea among VA patients with type 2 diabetes. *American Diabetes Association (ADA) 73rd Scientific Sessions*. Chicago, IL: June 21-25, 2013.
- C.355. Xie L, Wei W, Thayer S, Brekke L, Buysman E, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky M, Baser O, Hu W, Cuddihy R. Insulin or GLP-1? A real-world comparative effectiveness analysis of initiating injectable treatment among patients with type 2 diabetes mellitus failing oral anti-diabetes drugs: Pilot data from the INITIATOR Study. ENDO 2013: *Endocrine Society 96th Annual Meeting & Expo*. San Francisco, CA: June 15-18, 2013.
- C.356. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Analysis of health care costs associated with ankylosing spondylitis in Turkey. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
- C.357. Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. Biologic switching rates among patients with rheumatoid arthritis. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
- C.358. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
- C.359. Barron R, Wang L, Baser O, Langeberg W, Dale DC. Chemotherapy-induced febrile neutropenia (FN) and FN prevention strategies in cancer care in the US Veterans Health Administration. 49th American Society of Clinical Oncology (ASCO) Annual Meeting: Chicago, IL: May 31-June 4, 2013.
- C.360. Xie L, Du J, Wang L, Yuce H, Baser O. Examination of treatment patterns of ankylosing spondylitis patients in the Veterans Affairs and Medicare databases using a visualization tool. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.361. Xie L, Baser O. Clinical and economic burden of U.S. veteran schizophrenia patients: A real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.362. Wang L, Zhang J, Baser O. Evaluation of the clinical and economic burden of the human immunodeficiency virus in U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.

- C.363. Wang L, Zhang J, Baser O. Evaluation of clinical, treatment characteristics and the economic burden of anxiety in U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.364. Wang L, Zhang J, Li L, Baser O. Clinical and economic burden of U.S. veteran Alzheimer's disease patients: A real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.365. Wang L, Zhang J, Baser O. Assessing the economic burden and treatment patterns of U.S. veteran chronic kidney disease patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.366. Wang L, Li L, Zhang J, Baser O. Comorbidities and economic burden of multiple sclerosis patients in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.367. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of U.S. veteran lung cancer patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.368. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of prostate cancer in the U.S. Veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.369. Wang L, Zhang J, Li L, Baser O. Clinical characteristics and treatment patterns of colorectal cancer in United States veterans. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.370. Wang L, Huang A, Baser O. Assessing the clinical and economic burden of U.S. veteran diabetes patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.371. Wang L, Huang A, Baser O. Clinical and economic burden of U.S. veteran chronic obstructive pulmonary disease patients: A real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.372. Wang L, Huang A, Li L, Baser O. Evaluation of the clinical characteristics and economic burden of U.S. veteran patients diagnosed with the hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.373. Wang L, Huang A, Baser O. Atrial fibrillation prevalence associated with geographic variation and age in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.374. Wang L, Huang A, Baser O. Geographic variation trends in Crohn's disease prevalence and demographic characteristics in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.

- C.375. Wang L, Huang A, Baser O. Assessing the geographic and demographic variation associated with psoriatic arthritis prevalence in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.376. Wang L, Huang A, Baser O. Geographic variation trends in systemic lupus erythematosus prevalence in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.377. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Ankylosing spondylitis health care costs and associated disease activity scores in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.378. Hamuryudan V, Direskeneli H, Ertenli İ, İnanç M, Karaaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Medical costs of patients with rheumatoid arthritis and its association with global disease activity in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.379. Xie L, Liu X, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti. Recurrence and risk factors in hospitalized patients with acute venous thromboembolism: A claims database analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.380. Xie L, Khandelwal N, Kariburyo F, Baser O. Comparing healthcare costs and utilizations of patients with overactive bladder who were adherent and non-adherent to their medication. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013. [FINALIST RESEARCH AWARD]
- C.381. Xie L, Du J, Kariburyo F, Baser O. Treatment, health care costs and utilizations of US veterans with mental disorders. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.382. Baser O, Du J, Dysinger AH, Wang L, Xie L. A real-world evaluation of the clinical and economic burden of U.S. veteran patients with post-traumatic stress disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.383. Xie L, Du J, Baser O. Comorbidities, medications, health care costs and utilizations of U.S. veteran patients with gastroesophageal reflux disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.384. Baser O, Du J, Kariburyo F, Xie L. A solution for under-diagnosed post-menopause: Probabilistic linkage of claims and registry data. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
- C.385. Baser O, Huang A, Li L, Wang L. Obese patients in the U.S. veteran population: A health care cost and utilization analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.

C.386. Baser O, Chan W, Wang L, Waltman-Johnson K, Xie L. Comparison of real-world cardiovascular-related healthcare costs of newly initiated valsartan/amlodipine single-pill combination angiotensin receptor blocker/calcium channel blocker free-combination therapy. *American Society of Hypertension (ASH) 28th Annual Scientific Meeting and Exposition*. San Francisco, CA: May 15-18, 2013.

C.387. Xie L, Spalding J, Baser O. Differences in test-related clinical and economic outcomes between patients who underwent single-photon emission computed tomography using regadenoson versus patients who underwent echocardiograms using dobutamine. *American Heart Association Quality of Care & Outcomes Research (AHA QCOR) Scientific Sessions*. Baltimore, MD: May 15-17, 2013.

2012

C.388. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of US veteran ankylosing spondylitis patients. *American College of Rheumatology (ACR)/ Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting*. Washington, DC: November 9-13, 2012.

C.389. Baser O, Wang L, Du J, Wang H, Xie L. Impact of severity index for rheumatoid arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *American College of Rheumatology (ACR)/ Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting*. Washington, DC: November 9-13, 2012.

C.390. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with rheumatoid arthritis prevalent cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

C.391. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with ankylosing spondylitis incident cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

C.392. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with ankylosing spondylitis prevalent cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

C.393. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with rheumatoid arthritis incident cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

C.394. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Regional variation in angiogram use for patients who underwent coronary artery bypass graft surgery. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

C.395. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High-cost patients for cardiac surgery and hospital quality in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

- C.396. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Indirect costs associated with ankylosing spondylitis in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.397. Baser O, Xie L, Huang A, Li L, Fritschel EK, Wang L. Assessing the survival rates and economic burden of prostate cancer in the U.S. veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.398. Supina D, Lewis-Beck C, McElroy S, Hodgkins P, Baser O. Health care resource utilization and costs for patients with anorexia nervosa, bulimia nervosa, and binge eating disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.399. Memiş SA, Değer C, Marmaralı B, Paralı E, Sümer F, Karakeben K, Başer O. New pricing policies after initiation of the Health Transformation Programme in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.400. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Geographic variation associated with colorectal cancer prevalence in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.401. Baser O, Wang L, Du J, Wang H, Xie L. Impact of severity index for rheumatoid arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012. [FINALIST AWARD]
- C.402. Hamuryudan V, Direskeneli H, Ertenli I, İnanç M, Karaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Indirect costs associated with rheumatoid arthritis in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.403. Wang L, Xie L, Li L, Huang A, Wang H, Baser O. Visualizing treatment patterns of veteran patients with rheumatoid arthritis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.404. Baser O, Wang L, Li L, Huang A, Wang H, Xie L. Application of data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.405. Baser O, Wang L, Lewis-Beck C, Wang H, Li L, Xie L. Demographic and socioeconomic characteristics that affect selection of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012. [FINALIST AWARD]

- C.406. Lewis-Beck C, Baser E, Baser O. An applied comparison of meta-analysis techniques using Bacille Calmette Guerin vaccine studies. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.407. Xie L, Wang L, Huang A, Li L, Fritschel EK, Baser O. Geographic variation trends in diabetes mellitus prevalence in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.408. Xie L, Wei W, Pan C, Baser O. Real-world incidence of hypoglycemia and associated costs among insulin glargine treated patients with type 2 diabetes mellitus (T2DM). *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.409. Baser E, Lewis-Beck C, Baser O. An Excel calculator tool to perform meta-analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.410. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. veteran ankylosing spondylitis patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.411. Wang L, Baser O, Huang A, Li L, Fritschel EK, Xie L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.412. Baser O, Wang L, Li T, Shu Z, Xie L. Prevalence and incidence rates of multiple sclerosis in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.413. Xie L, Du J, Altınbas S, Baser O. Compare health care utilization and costs among menopausal women with different symptoms by linking women's registry and claims data. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.414. Xie L, Lewis-Beck C, Wang H, Altınbas A, Baser O. Demographic and clinical characteristics of menopausal women in the University of Michigan Women's Registry Database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
- C.415. Baser O, Zhou S, Wei W, Ling Z, Xie L, Levin P. Adding a third agent to two oral antidiabetic drugs (OADs): Real-world economic impact and effect of treatment persistence on clinical outcomes. *48th European Association for the Study of Diabetes (EASD) Annual Meeting*. Berlin, Germany: October 1-5, 2012.
- C.416. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world practice pattern and outcomes of patients with type 2 diabetes (T2DM) initiating injectable therapy via insulin glargine disposable pen (GLA-P) or liraglutide (LIRA). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.

- C.417. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world outcomes of initiating injectable therapy with insulin glargine or liraglutide among patients with type 2 diabetes. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
- C.418. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Health outcomes of switching from vial to disposable pen among type 2 diabetes patients treated with insulin glargine. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8- 12, 2012.
- C.419. Xie L, Zhou S, Wei W, Lin J, Baser O, Levin P. Treatment patterns and A1C reduction after adding a 3rd agent to 2 oral antidiabetic drugs (OADs). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
- C.420. Wei W, Pan C, Xie L, Baser O. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012. [Oral presentation]
- C.421. Baser O, Miao R, Wei W, Xie L. Real world outcomes of adding rapid acting insulin vs. switching to analog premix insulin among patients with type 2 diabetes treated with insulin glargine. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012. Diabetes. 2012;(suppl: 2455- PO).
- C.422. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating glargine- based insulin treatment vs. analog premix insulin among patients with type 2 diabetes failing oral anti-diabetes drugs. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
- C.423. Baser O, Wang L, Xie L, Du J, Wang H. Health care outcomes research: Effectiveness of a severity index for rheumatoid arthritis. *The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology*. Berlin, Germany: June 6-9, 2012. [Abstract]
- C.424. Baser O, Wang L, Xie L, Yuce H. Treatment pattern visualization of Medicare patients diagnosed with rheumatoid arthritis and initiating tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.425. Baser O, Wang L, Xie L, Du J, Wang H. Derivation of severity index for rheumatoid arthritis and its effect on health care outcomes. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
- C.426. Baser O, Schmeichel-Mueller C, Ingham M. Using scatter plots, analysis of univariate relationship between confounders and outcomes among rheumatoid arthritis patients who initiated anti-tumor necrosis factors and subsequently switched or escalated. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.427. Baser O, Schmeichel-Mueller C, Ingham M. Analyzing the difference in health care costs of rheumatoid arthritis patients switching or dose escalating anti-TNF biologics using combined propensity score matching and multivariate regression model. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.

- C.428. Lewis-Beck C, Baser E, Baser O. A review and applied comparison of meta-analysis techniques. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.429. Baser O, Wang L, Xie L, Yuce H. Data visualization of treatment patterns of Medicare psoriatic arthritis patients who initiate tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
- C.430. Miao R, Wei W, Xie L, Baser O. Does pen help when elderly patients with type 2 diabetes initiate insulin? A real-world retrospective study of initiating insulin glargine via disposable pen vs vial. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012. [Podium presentation]
- C.431. Xie L, Joshi AV, Harnett J, Mardekian J, Schaaf D, Shah N, Baser O. Differences in health care utilization and associated costs between patients prescribed versus not prescribed opioids during an inpatient or emergency department visit. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
- C.432. Baser O, Wang L, Xie L, Yuce H. Application of data visualization tool: Treatment patterns of Medicare patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.433. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E. Venous thromboembolism prophylaxis and clinical consequences in hospitalized medically ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
- C.434. Baser O, Wang L, Xie L, Yuce H. Treatment patterns of Medicare patients with ulcerative colitis initiating tumor necrosis factor therapy: Application of a data visualization tool. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
- C.435. Baser O, Wang L, Xie L, Yuce H. Visualizing treatment patterns of Medicare patients with Crohn's disease who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.436. Wang L, Wei W, Miao R, Xie L, Baser O. Real-world health care utilization, productivity and associated costs among employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn (NPH) insulin in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.437. Baser O, Xie L, Du J, Smith Y. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women's registry and claims database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.

- C.438. Xie L, Racketta J, Bushmakina A, Mirkin S, Trocio J, Baser O. Economic impact of breast pain and bleeding among women prescribed estrogen plus progestogen hormone therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.439. Baser O, Racketta J, Bushmakina A, Komm B, Trocio J, Xie L. Clinical and economic outcomes associated with early combined estrogen and progestogen hormone therapy for post-menopausal women. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.440. Wang L, Li L, Huang A, Baser O. Assessing the clinical and economic burden of veteran breast cancer patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.441. Wang L, Li L, Huang A, Baser O. Colorectal cancer patients in the veteran population: A health care cost and utilization analysis in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.442. Wang L, Li L, Huang A, Baser O. A descriptive analysis of ovarian cancer in veteran patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.443. Baser O, Wang L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in veteran patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.444. Baser O, Wang L, Xie L, Yuce H. Using data visualization to illustrate treatment patterns of Medicare patients with diagnosis of psoriasis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
- C.445. Abouzaid S, Lewis-Beck C, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012. [FINALIST AWARD]
- C.446. Wang L, Joshi AV, Schaaf D, Mardekian J, Baser O. Prevalence of diagnosed opioid abuse in the national Veteran's Health Administration (VA) population. *American Pain Society 31st Annual Scientific Meeting*. Honolulu, HI: May 16-19, 2012.
- C.447. Baser O, Joshi AV, Schaaf D, Mardekian J, Wang L. Economic burden of diagnosed opioid abuse in the national Veteran's Health Administration (VA) population. *American Pain Society 31st Annual Scientific Meeting*. Honolulu, HI: May 16-19, 2012.
- C.448. Lin J, Xie L, Wei W, Zhou S, Miao R, Pan C, Baser O. An empirical approach to measure and predict treatment persistence among insulin-glargine treated patients with type 2 diabetes. *AMCP 24th Annual Meeting & Expo*. San Francisco, CA: April 18-20, 2012.

C.449. Baser O, Weis AJ, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid dependence treatments. *AMCP 24th Annual Meeting & Expo*. San Francisco, CA: April 18-20, 2012.

C.450. Wang L, Xie L, Du J, Li L, Huang A, Li T, Shu Z, Baser O. Claims-based severity index for rheumatoid arthritis from health care claims data. *China Outcomes Research Evidence Based Medicine (CORE) Summit*. Shanghai, PRC: March 30-31, 2012.

2011

C.451. Baser O, Wang L, Xie L. Health care cost comparisons between alcohol or opioid- dependent patients who were treated with medication and those who were not. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.452. Baser O, Wang L. Evaluation of the prophylaxis patterns and 90-day outcome events in hospitalized medically ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.453. Baser O, Wang L. Thromboprophylaxis use and venous thromboembolism, major and minor bleeding event analysis in hospitalized medically ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.454. Baser O, Wang L. Geographic variation trends in critical limb ischemia prevalence in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.455. Baser O, Wang L. Analysis of transient ischemic attack-related clinical outcomes, health care utilization and cost burden of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.456. Baser O, Wang L. Clinical outcomes and costs associated with stroke in patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.457. Baser O, Wang L. Clinical and economic burden of major bleeding in abdominal surgery patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.458. Xie L, Baser E, Baser O. Treatment patterns and associated clinical and economic outcomes of women treated with hormone therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.

C.459. Xie L, Baser E, Wang L, Baser O. Gastroesophageal reflux disease patients who switched from a branded proton pump inhibitor to a generic one and vice versa: A cost comparison. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011. [FINALIST RESEARCH AWARD]

- C.460. Wei W, Baser O, Du J, Xie L, Pan C. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer-sponsored health plans. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
- C.461. Wang L, Xie L, Baser O. Assessment of drug adherence for type 2 diabetes patients using vial or pen form insulin: A method to adjust the traditional medication possession ratio. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
- C.462. Baser O, Mody R, Morlock R, Baser E, Xie L. Comparison of daily average consumption between different proton pump inhibitors in patients with gastroesophageal reflux disease. *The American College of Gastroenterology (ACG) Annual Scientific Meeting*. Washington, DC: October 28 - November 2, 2011.
- C.463. Baser O, Mody R, Morlock R, Xie L, Baser E. Characteristics of patients who switched from twice daily (BID) protein pump inhibitors (PPI)s to once-daily (QD) dexlansoprazole or QD other PPIs. *American College of Nurse Practitioners (ACNP) 2011 Clinical Conference*. Denver, CO: October 5-9, 2011.
- C.464. Baser O, Xie L, Wei W, Chunshen P, Du J. Real-world clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs. insulin detemir disposable pen in a US managed care setting. *European Association for the Study of Diabetes (EASD) 47th Annual Meeting*. Lisbon, Portugal: September 12-16, 2011.
- C.465. Baser O, Wei W, Xie L, Baser E. Clinical and economic outcomes in patients with type two diabetes initiating insulin glargine using disposable pen vs exenatide. *European Association for the Study of Diabetes (EASD) 47th Annual Meeting*. Lisbon, Portugal: September 12-16, 2011.
- C.466. Verpillat P, Baser O, Wang L. How real-life data analysis could highlight ethnic inequalities in access to health care: Example of critical limb ischemia in the US Medicare population. *27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. Chicago, IL: August 14-17, 2011. 20 (Suppl 1):S146-S147(337).
- C.467. Levin P, Wei W, Wang L, Damon D, Baser O. Clinical characteristics, outcomes and treatment persistence in patients with T2DM adding insulin glargine to exenatide or exenatide to insulin glargine in a US Managed Care setting. *American Diabetes Association (ADA) 71st Scientific Session*. San Diego, CA: June 24-28, 2011.
- C.468. Baser O, Verpillat P, Wang L. Prevalence, incidence and outcomes of critical limb ischemia in the US Medicare population. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.469. Baser O, Du J, Xie L, Baser E. Comparison of major bleeding related mortality, health care utilization and cost of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.

- C.470. Baser O, Xie L, Du J, Wang L. Analysis of treatment patterns and costs for venous thromboembolism, major and minor bleeding events in hospitalized medically ill patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.471. Baser O, Xie L, Yuce H, Du J, Wang L. Prophylaxis use and 90-day costs for venous thromboembolism, major and minor bleeding event analysis in hospitalized medically ill patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.472. Wang L, Dysinger A, Du J, Xie L, Baser O. Treatment patterns, clinical and economic burden of venous thromboembolism in abdominal surgery patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.473. Wang L, Xie L, Baser O. Analysis of myocardial infarction related clinical outcomes, health care utilization and costs of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.474. Baser O, Xie L, Wang L, Du J. Comparison of propensity score matching and instrumental variable methods when estimating health care costs of rheumatoid arthritis patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.475. Baser O, Xie L. Applying the stratified propensity score matching method when estimating healthcare costs of rheumatoid arthritis patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.476. Baser O, Wang L, Yuce H, Xie L, Dysinger A. Differences in outcomes measures of diabetes patients using an insulin device and a conventional human insulin vial/syringe. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.477. Baser O. Excess payments from Medicare for inpatient surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.478. Baser O. Measuring drug therapy guidelines on outcomes: A tutorial. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.479. Baser O, Wang L, Xie L. Comparison of health care costs and utilizations between patients who were treated with pharmacological and non-pharmacological substance medications for alcohol dependency. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.

- C.480. Baser O, Wang L, Xie L. Comparison of health care costs and utilizations between patients who were treated with and without medication for opioid dependency. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.481. Xie L, Baser E, Wang L, Baser O. Comparison of health care utilizations between patients with gastroesophageal reflux disease who switched from a branded proton pump inhibitor to a generic proton pump inhibitor and vice versa. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
- C.482. Baser O, Mody R, Morlock R, Xie L, Baser E. Characteristics of patients who switched from twice daily (BID) proton pump inhibitors (PPI)s to once-daily (QD) dexlansoprazole or QD other PPIs. 2011 *Digestive Disease Week*. Chicago, IL: May 7-10, 2011.
- C.483. Mueller, SC, Baser O, Bolge SC, Ingham M. Healthcare costs of patients switching or dosing escalating antitumor necrosis factor therapy. *Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, MN: April 27- 29, 2011.
- C.484. Baser O, Sengupta N, Wang L. Risk of venous thromboembolism and prophylaxis use in hospitalized medically-ill US patients up to 180 days post-hospital discharge. *Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, MN: April 27-29, 2011.
- C.485. Baser O, Baser E, Wei W. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine using disposable pen versus exenatide. *Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, MN: April 27-29, 2011.

2010

- C.486. Baser O. Survival, health care utilization and cost after recurrence among patients with triple breast cancer in a US managed care setting. *33rd Annual San Antonio Breast Cancer Symposium*. San Antonio, TX: December 8-12, 2010.
- C.487. Baser O. Survival, health care utilization of patients with triple negative breast cancer in a US managed care setting. *33rd Annual San Antonio Breast Cancer Symposium*. San Antonio, TX: December 8-12, 2010.
- C.488. Baser O, Dysinger A, Baser E, Yuce H. Use of propensity score matching, standard regression analysis and instrumental variable method in outcomes research studies: A comparative analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.489. Baser O, Akin C. Claims-based severity index for rheumatoid arthritis from healthcare claims data. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.490. Baser O, Yuce H. Extending fixed effect models to censored cost data. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.

- C.491. Baser O, Wang L, Xie L. Determinants of TNF inhibitor dose escalation in patients with rheumatoid arthritis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.492. Wang L, Dysinger A, Baser O. Estimation of adverse events in 3 months after venous thromboembolism event for Medicare patients who underwent hip fracture surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.493. Baser O. Creating an efficient hospital payment system. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.494. Baser O, Akin C, Wang L, Dysinger A. Hospital quality index and its use on rates of venous thromboembolism. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010. [FINALIST RESEARCH AWARD]
- C.495. Wang L, Dysinger A, Baser O. Comparison of adverse events of Medicare patients who underwent knee replacement surgery and experienced venous thromboembolism in versus no venous thromboembolism. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.496. Baser O, Wang L, Xie L. Clinical and cost outcomes of venous thromboembolism in patients who underwent major orthopedic surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.497. Wang L, Baser O. Comparison of mortality, health care utility and cost of patients with warfarin treatment for non-valvular atrial fibrillation versus patients with other treatment. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.498. Wang L, Baser O. Estimation of stroke-related adverse events, health care utility and cost of patients with nonvalvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.499. Baser O, Wang L, Dysinger A. Analysis of anticoagulation bridging therapy in orthopedic patients: Real-world analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.500. Baser O, Wang L, Xie L, Dysinger A, Yuce H, Baser E. Deriving doctors' prescribing patterns from health care claims: An instrumental variable analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, CZ: November 2010.
- C.501. Mueller CS, Baser O, Bolge SC, et al. Clinical characteristics and health care costs of rheumatoid arthritis patients who switch anti-TNF agents. *Academy of Managed Care Pharmacy's Educational Conference*. St Louis, Missouri: October 2010.
- C.502. Baser O, Akin C. Deriving severity index for rheumatoid arthritis from healthcare claims data. *Annual European Congress of Rheumatology*. Rome, Italy: June 2010.

- C.503. Baser O. Deriving doctors' prescribing patterns from claims data: An application to TNF and non-TNF biologics. *Annual European Congress of Rheumatology*. Rome, Italy: June 2010.
- C.504. Baser O, Supina D, Sengupta N, et al. Cost of VTE events to Medicare patients undergoing TKA/THA according to discharge status. *National Association of Orthopedic Nurses Meeting*. Seattle, WA: May 15-19, 2010.
- C.505. Baser O, Wang L, Sengupta N, et al. Cost of venous thromboembolism events according to discharge status of Medicare patients after major orthopaedic surgery. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.506. Baser O, Yuce H. A method to increase sample size by removing the continuous enrollment requirement. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.507. Baser O, Yuce H. Time series analysis to examine the effect of guidelines. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.508. Baser O, Gust C. Deriving doctors' prescribing patterns from claims data: An application to TNF and non-TNF biologics. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.509. Baser O, Gust C, Akin C. Deriving severity index for rheumatoid arthritis from health care claims data. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.510. Baser O, Wang L, Gust C, Dysinger A. Examination of doctors' practice and prescribing patterns toward SSRI and SNRI. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.511. Wang L, Baser O. Analysis of "bridging therapy" in orthopedic patients in a U.S. health plan. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.512. Baser O, Dysinger A, Baser E. Comparing risk-adjustment models: Propensity score matching, standard regression analysis and instrumental variable approach. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010. [FINALIST RESEARCH AWARD]
- C.513. Baser O, Yuce H. Modeling transformed health care costs with unknown heteroskedasticity. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.514. Wang L, Baser O. Difference in outcomes measures of patients with valvular and non-valvular atrial fibrillation. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.

- C.515. Baser O, Yuce H, Wang L. Rare event bias in retrospective analysis of outcomes measures. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.516. Wang L, Baser O. Adverse event analysis for Medicare patients who underwent hip fracture surgery and suffered venous thromboembolism. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.517. Wang L, Dysinger AH, Baser O. Comparison of mortality, re-hospitalization and bleeding rates of Medicare patients who underwent knee replacement surgery. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.518. Wang L, Dysinger AH, Baser O. Estimation of adverse events related with Medicare patients who underwent hip fracture surgery and suffered VTE versus no VTE. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.519. Baser O, Akin C, Wang L, Dysinger AH. Relationship between venous thromboembolism and hospital quality. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.520. Wang L, Gust C, Baser O. Deriving doctors' prescribing patterns from claims data: An application to anticoagulant use with non-valvular atrial fibrillation. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.
- C.521. Baser O, Wang L, Supina D, Sengupta N. Cost of VTE events for Medicare patients undergoing major orthopedic surgeries according to discharge status. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, GA: May 2010.

2009

- C.522. Baser O, Dysinger AH. Comparison of risk adjustment models in outcomes research. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
- C.523. Baser O, Dysinger AH. Controlling for unobservable bias: Is the cure worse than the disease? *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
- C.524. Baser O, Wang L. Creating national weights for private insurance database. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
- C.525. Baser O, Wang L. Forecasting the number of diabetic patients in the United States in 2050. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
- C.526. Baser O. Relationship between cost and hospital quality. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.

- C.527. Baser O, Supina D, Sengupta N, Wang L. Incidence and burden of “never events” for Medicare patients undergoing total hip or total knee replacement surgery. *XXII Congress of International Society on Thrombosis and Homeostasis*. Boston, Massachusetts: July 2009.
- C.528. Baser O, Supina D, Sengupta N, et al. Impact of venous thromboembolism on US Medicare patients undergoing total hip and total knee replacement surgery. *XXII Congress International Society on Thrombosis and Homeostasis*. Boston, MA: July 11-16, 2009.
- C.529. Baser O, Supina D, Sengupta N, et al. Incidence and burden of ‘never events’ for Medicare patients undergoing total hip or total knee replacement surgery. *American Society of Health System Pharmacist Summer Meeting*. Chicago, IL: June 14-17, 2009.
- C.530. Baser O, Wang L. Forecasting the number of diabetic patients in the United States through 2025. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.531. Baser O, Dysinger A. Instrumental variable approach in outcomes research. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.532. Baser O, Wang L, Gust C, Dysinger A. Socioeconomic status and cost of care in the elderly undergoing major orthopedic surgery. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.533. Baser O, Dysinger A. Too much ado about instrumental variable approach: Is the cure worse than the disease? *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.534. Baser O, Gust C, Akin C. Comparing and validating different types of propensity score matching techniques. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
- C.535. Baser O, Yuce H, Gust C. Extending random effect models to censored cost data. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.536. Baser O. Creating a quality index to rank hospitals. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.537. Crown WH, Baser O. Short course: Retrospective database analysis. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, FL: May 2009.
- C.538. Baser O, Supina D, Sengupta N, et al. Burden of VTE ‘never events’ for Medicare patients undergoing total hip or total knee replacement surgery. *Mid America Orthopedic Association Meeting*. Lost Pines, TX: April 21-25, 2009.

2008

- C.539. Morrato EH, Newcomer JW, Kamat S, Baser O, et al. Impact of the atypical antipsychotic FDA warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. *New Clinical Drug Evaluation Unit CME Poster Session*. BEST RESEARCH POSTER. CME Institute, Physicians Postgraduate Press, Inc. *J Clin Psy*. October 2008.
- C.540. Baser O. Performance of your 5-star hospitals. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual European Congress*. Athens, Greece: November 2008.
- C.541. Morrato E, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *International Society for Pharmacoepidemiology and Therapeutic Risk Management*. August 2008.
- C.542. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *American Diabetes Association's 68th Scientific Sessions*. San Francisco, CA: June 6-10, 2008.
- C.543. Morrato EH, Newcomer JW, Kamat S, Baser O, et al. Impact of the atypical antipsychotic FDA warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. *48th Annual NCDEU Meeting*, cosponsored by the National Institute of Mental Health (NIMH) and the *American Society of Clinical Psychopharmacology (ASCP)*. Phoenix, AZ: May 27-30, 2008.
- C.544. Baser O, Gust C. Sensitivity analysis for propensity score matching. *13th Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Toronto, ON: May 2008.
- C.545. Baser O, Poling L, Schaeffer J, Maguire J, Mummidi V. Creating national weights for a large-scale, patient longitudinal database. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, ON: May 2008.
- C.546. Baser O, Wang L. A model to examine the effect of guidelines on outcomes research. *International Society for Pharmacoeconomic and Outcomes Research 13th Annual Meeting*. Toronto, ON: May 2008.
- C.547. Baser O, Yuce H. Controlling for potential censoring bias on dependent variables. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, ON: May 2008.
- C.548. Baser O, Yuce H. Inverse probability weighted random effect models for estimation of censored outcomes variables. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, ON: May 2008.
- C.549. Baser O. Medicare outlier payments for coronary artery bypass grafting. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, ON: May 2008.
- C.550. Baser O. Relationship between quality of care and excessive cost for Medicare patients undergoing lower extremity bypass surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, ON: May 2008.

C.551. Englesbe J, Fan Z, Baser O, Birkmeyer JD, Dimick JB. Developing better measures of transplant center performance. *American Transplant Congress*. May 2008.

C.552. Morrato EH, Newcomer JW, Kamat S, Baser O, et al. Trends in annual metabolic screening for patients taking second-generation antipsychotic medications. *American Psychiatric Association (APA) 161st Annual Meeting*. Washington, DC: May 3-8, 2008.

C.553. Dimick JB, Baser O, Birkmeyer JD. Variations in surgical mortality rates: Differences in quality or just statistical noise? Abstract published in *J Surg Res*. February 2008.

C.554. Morrato E, Newcomer JW, Siddhesh K, Baser O, et al. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *American Diabetic Association (ADA) 68th Scientific Sessions*. San Francisco, CA: 2008.

2007

C.555. Foley K, Kalsekar A, Baser O, Walsh JK. Health care costs of patients with insomnia: How much does the health plan and patient pay. *21st Annual Meeting of the Associated Professional Sleep Societies*. Minneapolis, MN: June 9-14, 2007.

C.556. Baser O, Foley K. An application of latent class cluster analysis in outcomes research: Identifying high-cost insomnia patients. *19th Annual Research Meeting of Academy Health*. Orlando, FL: June 3-5, 2007.

C.557. Baser O. Using propensity score matching techniques for average treatment effects: Application to triptan use. *19th Annual Research Meeting of Academy Health*. Orlando, FL: June 3-5, 2007.

C.558. Baser O. Is cure worse than the disease? *12th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Washington, DC: May 19- 23, 2007.

2006

C.559. Curtis J, Barr C, Baser O, Amonkar M, Saag K. Reduced osteoporosis-related expenditures, overall health care expenditures and health resource utilization observed for woman adherent to bisphosphonate therapy. *American College of Rheumatology (ACR) Annual Scientific Meeting*. Washington, DC: November 10-15, 2006.

C.560. Baser O. Continuous enrollment requirement: Do we really need it? *Inaugural Conference of the American Society of Health Economists*. Madison, WI: June 4- 7, 2006.

C.561. Baser O, Stephenson J. The estimation power of alternative comorbidity indexes. *18th Annual Research Meeting of Academy Health*. Seattle, WA: June 25-27, 2006.

C.562. Baser O. A method to remove continuous enrollment requirement from pharmacoeconomic studies. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.

- C.563. Baser O, Stephenson J. The estimation power of alternative comorbidity indexes. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.564. Baser O. Controlling selection bias on continuous variables. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.565. Baser O. Performance of bootstrapping in discrete choice models. *18th Annual Research Meeting of Academy Health*. Seattle, WA: June 25-27, 2006.
- C.566. Baser O. Propensity score matching with more than two categories. *18th Annual Research Meeting of Academy Health*. Seattle, WA: June 25-27, 2006.
- C.567. Krishnan AA, Foley K, Montejano L, Baser O, Long S, Walsh JK. Insomnia: Prevalence, comorbidities, costs in a treated insured population. *20th Anniversary Meeting of the Associated Professional Sleep Societies*. Salt Lake City, UT: June 17- 22, 2006.
- C.568. Baser O. Propensity score modeling with limited overlap. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.569. Baser O. Failure of regression adjustment against propensity score matching. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.570. Baser O. One solution to three problems. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.571. Baser O. Performance of bootstrapping in discrete choice models. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.572. Baser O. Propensity score matching with more than two categories. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.573. Foster S, Foley K, Baser O, Meadows E, Long S. Trends in the clinical management of fragile fracture before and after the new HEDIS osteoporosis management measures in a Medicare population. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006.
- C.574. Curtice TG, Long SR, Baser O, Montejano LB, Lobo F. Economic burden of restless legs syndrome in a privately insured population. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, PA: May 20-24, 2006. [FINALIST RESEARCH AWARD]
- C.575. Gibson TB, Mark T, Axelsen K, Mackell J, King H, Baser O, McGuigan K. The effects of statin copayments and statin adherence on medical care utilization and expenditures. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual Meeting*. Philadelphia, PA: May 20-24, 2006. [BEST CONTRIBUTED RESEARCH AWARD]

C.576. Montejano LB, Long SR, Baser O, Lobo F, Curtice TG. Restless legs syndrome: Identification of treated patients in a large claims database. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual Meeting*. Philadelphia, PA: May 20-24, 2006.

C.577. Baser O. Propensity score matching and multivariate analysis: Complement or substitute? *18th Annual Meeting of Academy of Managed Care Pharmacy (AMCP)*. Seattle, WA: April 5-8, 2006.

C.578. Gibson TB, Mark T, Axelsen K, Mackell J, King H, Baser O, McGuigan K. The effects of statin copayments and statin adherence on medical care utilization and expenditures. *American College of Cardiology 55th Annual Scientific Session*. Atlanta, GA: March 11-14, 2006.

2005

C.579. Baser O. Too much ado about propensity score matching? *6th International Health Policy Conference*. Boston, MA: October 28-30, 2005.

C.580. Ozminkowski R, Goetzel R, Shechter D, Baser O, Lapin P. Predictors of preventive service use among Medicare beneficiaries. *Academy Health Annual Research Meeting, Boston, MA: June 26-28, 2005 and 3rd National Prevention Summit*. Washington, DC: October 24-25, 2005.

C.581. Baser O, Long S. Which one is logical? Logit or rare-event logit. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 15-18, 2005.

C.582. Baser O. Choosing among different types of matching techniques. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 15-18, 2005.

C.583. Baser O. Retransformation of estimated log-transformed costs when the errors present heteroskedasticity. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 15- 18, 2005.

C.584. Baser O. Estimation of censored medical count data. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 15-18, 2005.

C.585. Long S, Robinson R, Chang S, Able S, Baser O, Swindle R. Appropriateness and variation in drug utilization across patients with depression. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 15-18, 2005.

C.586. Baser O. A test to determine possible selection bias due to censoring in medical cost estimation. *25th Annual American Economic Association Meeting*. Philadelphia, PA: January 7-9, 2005.

2004

C.587. Song X, Marder W, Baser O, Houchens B, Conklin J, Bradley R. Can health care claims data improve the estimation of the medical CPI? *Conference on Research in Income and Wealth, National Bureau of Economic Research*. Vancouver, BC: June 28-29, 2004.

C.588. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long-acting opioid medications for the treatment of chronic pain in a Medicaid population. *Academy Health Annual Research*. San Diego, CA: June 6-8, 2004.

- C.589. Baser O, Given C. Weight or not to weight? *1st Conference of the Canadian Association for Health Services and Policy Research*. Montreal, QC: May 25-28, 2004.
- C.590. Baser O, Bradley CJ, Gardiner C, Given C. Testing and correcting for non- random selection bias due to censoring: An application to medical costs. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May16-19, 2004.
- C.591. Baser O, Crown W. Choosing among different kinds of bootstrapping methods. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 16-19, 2004. [FINALIST RESEARCH AWARD]
- C.592. Baser O, Bradley CJ, Gardiner C, Given C. Censored medical cost estimation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 16-19, 2004.
- C.593. Baser O, Gardiner J, Bradley C, Yuce H, Given C. Panel analysis of censored medical cost. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 16-19, 2004.
- C.594. Baser O, Given C. Weight or not to weight? *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 16- 19, 2004.
- C.595. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long-acting opioid medications for the treatment of chronic pain in a Medicaid population. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, VA: May 16- 19, 2004.
- C.596. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long-acting opioid medications for the treatment of chronic pain in a Medicaid population. *AMCP (Academy of Managed Care Pharmacy) 16th Annual Conference*. San Francisco, CA: March 31-April 3, 2004.
- C.597. Ozminkowski JR, Baser O, Azzolini J, Fox K. Identifying high-cost asthma patients. *DATLA (Drug Alcohol Testing Industry Association) 2003 Annual Conference*. Washington, DC: January 4, 2004.

2003

- C.598. Kozma C, Luella E, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotic. *Annual Meeting of the International College of Geriatric Psychoneuropharmacology*. San Juan, PUR: December 12-14, 2003.
- C.599. Baser O, Bradley CJ, Gardiner C, Given C. Testing and correcting for non- random selection bias due to censoring: An application to medical costs. *18th Annual Meeting of Society of Medical Decision Making*. Chicago, IL: October 19, 2003.
- C.600. Ozminkowski JR, Baser O, Azzolini J, Fox K. Do you know who your high-cost asthma patient will be next year? *5th Annual Meeting of Disease Management Association of America*. Chicago, IL: October 12, 2003.

- C.601. Baser O, Gardiner J, Bradley C, Yuce H, Given C. Longitudinal analysis of censored medical cost. *Econometric Society 24th North America Meeting*. Chicago, IL: June 27, 2003.
- C.602. Baser O, Bradley C, Gardiner J, Given C. Estimation from censored medical cost. *4th World Congress, International Health Economics Association*. San Francisco, CA: June 18, 2003.
- C.603. Crown W, Berndt E, Baser O, Finkelstein S, Witt W, Haver K. Benefit plan design and prescription drug utilization among asthmatics: Do patient co-payments matter? *International Health Economics Association*. San Francisco, CA: June 14, 2003.
- C.604. Crown B, Baser O, Berndt E. Is propensity score an inferior version of instrumental variables? *International Health Economics Association*. San Francisco, CA: June 14, 2003.

2002

- C.605. Bradley C, Given C, Baser O, Gardiner J. Initial surgery determines subsequent costs of breast cancer care. Society for Medical Decision Making. Baltimore, MD: October 21, 2002.
- C.606. Baser O, Bradley C, Gardiner J, Given C. Estimation from censored medical cost. *24th Australian Conference of Health Economists*. Sydney, Australia: June 2002.
- C.607. Baser O, Given C. Full parametric estimation of censored medical cost. *24th Australian Conference of Health Economists*. Sydney, Australia: June 2002.
- C.608. Baser O, Pema E. Academic publications - Their reward, life-cycle profile, and depreciation over time: Evidence for academic economists in Midwestern universities. *Midwest Economic Association, Annual Meeting*. March 2002.

1999

- C.609. Baser O, Pema E. The longitudinal analysis of economics faculty salaries. *Red Cedar Spring Graduate Student Meetings*. Michigan State University, Spring 1999.

D. PUBLISHED PROCEEDINGS

2025

- D.1. Baser O, Yapar N, Baser E, Mohamed M, Passarelli A, Chen S, Lu Y, Rodchenko K. Comparative prevalence of suicidal ideation and self-harm history: Risperidone vs other oral atypical antipsychotics. *Value Health*. 2025;28(S12)S272.
- D.2. Baser O, Guo W, Yapar N. Does the abortion pill harm women? Serious adverse events following mifepristone abortion in US commercial and Medicaid populations. *Value Health*. 2025;28(S12)S57.
- D.3. Baser O, Rodchenko K, Yuce H, Yapar N. Effect of the Inflation Reduction Act on drug innovation. *Value Health*. 2025;28(S12)S334-5.

- D.4. Wagner S, Passarelli A, Zhu X, Baser O. Overall treatment landscape of mucosal melanoma. *Value Health*. 2025;28(S12)S77.
- D.5. Baser O, Rodchenko K, Wu L, Yapar N. Socioeconomic disparities in access to treatment for major depressive disorder: The role of accumulator and maximizer insurance plans. *Value Health*. 2025;28(S12)S358.
- D.6. Sepulveda F, Baser O, Lu Y, Endrizal A. Socioeconomic disparities in postpartum depression following abortion restrictions: A difference-in-differences analysis of Medicaid data post-Dobbs. *Value Health*. 2025;28(S12)S358.
- D.7. Baser, A Endrizal, Y Lu, F Sepulveda. Socioeconomic vulnerabilities and postpartum depression: Assessing the aftermath of Dobbs v Jackson in trigger and non-trigger states. *J Manag Care Spec Pharm*. 2025;31(10-d Suppl)S84.
- D.8. Baser O, Waters H, Rodchenko K, Sullivan M, Shurtleff M, Chen S, Wu L, Baser E, Bigley C, Patel R. The impact of copay accumulators and maximizers on treatment patterns and costs among patients with major depressive and bipolar disorders treated with branded mental health treatments. *J Manag Care Spec Pharm*. 2025;31(10-d Suppl)S11.
- D.9. Passarelli A, Yapar N, Sun Y, Rodchenko K, Baser O, Phillips A, Chen X. Improved outcomes in patients with multiple sclerosis initiating cladribine tablets compared with those denied health insurance coverage in the United States. *J Manag Care Spec Pharm*. 2025;31(10-d Suppl)S127.
- D.10. Baser O, Yapar N, Baser E, Mohamed M, Passarelli A, Chen S, Lu Y, Rodchenko K. Comparison of suicidal ideation or personal history of self harm among patients with use of Rexulti and all antipsychotics. *Value Health*. 2025;28(S6)S28-29.
- D.11. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N. Socioeconomic status and anti-obesity medications: Impact on cardiovascular risk in Medicare patients with obesity. *Value Health*. 2025;28(S6)S28.
- D.12. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N, Baser E. Machine learning algorithms for identifying undiagnosed nonalcoholic steatohepatitis: A Veterans Affairs health system study. *Value Health*. 2025;28(S6)S291.
- D.13. Baser O, Yapar N, Rodchenko K, Mohamed M, Passarelli A, Chen S, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. *Value Health*. 2025;28(S6)S36.
- D.14. Baser O, Lu Y, Sepulveda F, Yapar N, Endrizal A. Postpartum depression: Assessing the aftermath of Dobbs v. Jackson in trigger and non-trigger states. *Value Health*. 2025;28(S6)S215.
- D.15. Baser O, Rodchenko K, Mohamed M, Passarelli A, Chen S, Yapar N. Shades of blue: Investigating racial, socioeconomic, and family dynamics in depression among teen girls. *Value Health*. 2025;28(S6)S185.

D.16. Johnson D, Mollard E, Young M, Jiang X, Gannu L, Nguyen V, Mohamed M, Baser O, Tan R. Real-world treatment patterns, healthcare resource utilization and costs for Medicaid patients with a postpartum depression diagnosis. *J Manag Care Spec Pharm.* 2025;31(3-a Suppl)S53.

D.17. Waters H, Huang D, Morrissey L, Patel R, Rodchenko K, Samayoa G, Yapar N, Freedman D, Baser O. Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness. *J Manag Care Spec Pharm.* 2025;31(3-a Suppl)S46.

2024

D.18. Baser O, Mohamed M, Samayoa G, Baser E. C08 A retrospective analysis of the impact of approved anti-obesity medications on the risk of cardiovascular disease in patients with obesity. *Value Health.* 2024;27(S12)S16.

D.19. Baser O, Samayoa G, Baser E. C053 The impact of approved anti-obesity medications on the risk of obstructive sleep apnea in patients with obesity: A retrospective cohort study. *Value Health.* 2024;27(S12)S24-5.

D.20. Baser O, Mohamed M, Samayoa G, Baser E. C096 The impact of approved anti-obesity medications on the incidence of osteoarthritis, healthcare resource use and costs among patients with obesity: A retrospective cohort study. *Value Health.* 2024;27(S12)S32.

D.21. Baser O, Samayoa G, Mohamed M, Baser E. C098 Anti-obesity medications and related osteoarthritis risk among patients with obesity. *Value Health.* 2024;27(S12)S33.

D.22. Baser O, Mohamed M, Samayoa G, Baser E. C0134 The impact of approved anti-obesity medications on the incidence of obstructive sleep apnea, healthcare resource utilization and costs among patients with obesity: A retrospective cohort study. *Value Health.* 2024;27(S12)S39-40.

D.23. Baser O, Samayoa G, Baser E, Mohamed M. EE58 The impact of approved anti-obesity medications on the incidence of cardiovascular disease, healthcare resource use and costs among patients with obesity: A retrospective cohort study. *Value Health.* 2024;27(S12)S64-5.

D.24. Baser O, Baser E, Samayoa G. The cardiovascular effect of abiraterone and enzalutamide among Veterans Affairs' metastatic castration resistant prostate cancer patients. *Value Health.* 2024;27(6):S4

D.25. Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The effect of newly approved obesity medications on cardiovascular complications. *Value Health.* 2024;27(6):S50.

D.26. Baser O, Isenman L, Samayoa G, Dwivedi A, Baser E, Baser S. The effect of approved anti-obesity medications in patients with alcohol and substance use disorder. *Value Health.* 2024;27(6):S37.

D.27. Baser O, Isenman L, Samayoa G, Dwivedi A, Baser E, Baser S. The impact of approved anti-obesity medications on osteoarthritis risk in patients with obesity: A retrospective cohort study. *Value Health.* 2024;27(6):S45.

- D.28. Baser O, Baser E, Yapar N, Samayoa G, Budhu A. Predictive risk score for nonalcoholic steatohepatitis (NASH) among patients in the Department of Defense population. *Value Health*. 2024;27(6):S386.
- D.29. Baser O, Isenman L, Baser E, Li W, Cigdem B. Socioeconomic status and postpartum depression among commercial health insurance enrollees. *J Manag Care Spec Pharm*. 2024;30(4-a):S96.
- D.30. Baser O, Isenman L, Dwivedi A, Samayoa S, Baser E, AlSaleh S. The effect of Ozempic vs Wegovy vs Mounjaro on the incidence of alcohol and substance use disorder in obese patients. *J Manag Care Spec Pharm*. 2024;30(4-a):S61.
- D.31. Baser O, Samayoa G, Isenman L, Baser S. Impact of Ozempic vs Wegovy on osteoarthritis risk in obese patients: A retrospective cohort study. *J Manag Care Spec Pharm*. 2024;30(4-a):S47.
- D.32. Baser O, Baser E, Samayoa G, Rodchenko R, Yapar N. The effect of approved obesity medications on obesity's cardiovascular related comorbidities. *J Manag Care Spec Pharm*. 2024;30(4-a):S48.
- D.33. Baser O, Waters H, Samayoa G, Yapar N, Gandhi H, Patel R. Open access for mental health medication: Impact on state Medicaid budgets. *J Manag Care Spec Pharm*. 2024;30(4-a):S53.

2023

- D.34. Baser O, Rodchenko K, Chen L, Yapar N. The short-run and long-run behavioral effects of vaccination enforcement in Turkey. *Value Health*. 2023;26(12 Suppl):S1-S578.
- D.35. Baser O, Rodriguez N, Rodchenko K. Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from a national claims database. *Value Health*. 2023;26(12 Suppl):S1-S578.
- D.36. Baser O, Rodchenko K, Zeng Y. Mental health disparities for young adults with arrest history: A survey-based, cross-sectional analysis. *Value Health*. 2023;26(12 Suppl):S1- S578.
- D.37. Baser O, Baser E, Samayoa G. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide in Veteran Affairs. *J Manag Care Spec Pharm*. 2023;29(10-a Suppl)S1-S138.
- D.38. Baser O, Baser E, Yapar N, Mete F. Use of open claims vs closed claims on health outcomes research. *Value Health*. 2023;26(6 Suppl):S1-S426.
- D.39. Baser O, Baser E, Yapar N, Rodriguez N. Relationship between body mass index and diagnosis of overweight or obesity in Veteran's Administration population. *Value Health*. 2023;26(6 Suppl):S1-S426.
- D.40. Baser O, Mete F, Baser E. Review of machine learning based disease diagnosis modeling. *Value Health*. 2023;26(6 Suppl):S1-S426.
- D.41. Baser O, Mete F, Yapar N, Baser E. Applying machine learning techniques to identify undiagnosed patients with nonalcoholic steatohepatitis (NASH). *Value Health*. 2023;26(6 Suppl):S1-S426.

- D.42. Baser I, Rodriguez N, Azmoudeh Y. The short run and long run behavioral effects of COVID-19 vaccination enforcement. *Value Health*. 2023;26(6 Suppl):S1-S426.
- D.43. Yuce H, Baser O, Yapar N. Effect of surgical choices on the cost of breast cancer care. *Value Health*. 2023;26(6 Suppl):S1-S426.
- D.44. Baser O, Yuce H, Rodriguez N, Yapar N. Analysis of rare events in outcomes research using Department of Defense data: Intravenous immune globulin therapy for bullous pemphigoid. *Value Health*. 2023;26(6 Suppl):S1-S426.

2019

- D.45. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. *J Thromb Thrombolysis*. 2019;48:149–157.
- D.46. Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang AH, Wang L, Baser O, George D. Survival rates and economic outcomes in chemotherapy-naive metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *J Urol*. 2019;201(4)E242-E243:Abstract PD15-11.
- D.47. Zhang QS, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia (AML) among the elderly in the United States. *J Clin Oncol*. 2019;35(15)Abstract e18161.
- D.48. Galinier M., Deitelzweig S, Keshishian A, Li XY, Hamilton M, Masseria C, Dhamane A, Luo XM, Mardekian J, Friend K, Nadkarni A, Pan XY, Baser O, Lip G. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study. *Arch Cardiovascular Diseases Supplements*. 2019;11(1)150.
- D.49. Pan X, Chen CC, Wang L, Yuce H, Baser O. Real-world evidence of the economic burden and risk factors for hospitalization among patients with myeloma in the US Veterans Health Administration population. *Value Health*. 2019;22(S2)S67.
- D.50. Zhang Q, Delinger R, Wang H, Wang Y, Yuce H, Baser O, Xie L. Assessing the risk factors of heart failure among patients in the US Department of Defense population. *Value Health*. 2019;22(S2)S130.
- D.51. Dieyi C, Pedarla V, Gu Y, Liu Y, Li L, Wang L, Yuce H, Baser O. Assessing the economic burden and hospitalization among patients with non-alcoholic steatohepatitis in the US Veterans Health Administration population. *Value Health*. 2019;22(S2)S338– S339.
- D.52. Wang H, Qiang W, Delinger R, Keshishian A, Yuce H, Baser O, Xie L. Examining the risk factors of chronic obstructive pulmonary disease among patients in the Department of Defense population. *Value Health*. 2019;22(S2)S356.

- D.53. Okunowo O, Li L, Pedarla V, Gu Y, Wang L, Yuce H, Baser O. Assessing the economic burden and predictors of hospitalization among US veteran patients with rheumatoid arthritis: A retrospective case-control study. *Value Health*. 2019;22(S2)S377.
- D.54. Ramaswamy K, Mardekian J, Schultz N, Huang A, Wang L, Baser O, George D. Economic burden of chemotherapy naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide in the United States. *J Urol*. 2019;201(S4)e242- e243.
- D.55. Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Survival rates and economic outcomes in chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *J Urol*. 2019;201(S4)e242-e243.
- D.56. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on metastasis and increased costs associated with progression to metastatic castrate-resistant prostate cancer. *J Urol*. 2019;201(S4)e498-e499.
- D.57. Pedarla V, Gu Y, Wang L, Baser O. Assessing economic burden and hospitalization among asthma patients in the US Veterans Health Administration population. *J Manag Care Spec Pharm*. 2019;25(S3-a)S73-S74.
- D.58. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients. *J Clin Oncol*. 2019;37(7)S211.
- D.59. McNamara M, George D, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Wang L, Baser O, Huang A, Freedland SJ. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. *J Clin Oncol*. 2019;37(7)S212.

2018

- D.60. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in US clinical practice. *J Am Coll Cardiol*. 2018;71(11_Supplement)A275.
- D.61. Pandya S, Clancy Z, Shrestha S, Wang L, Baser O. Burden of CRAB events by relapse in patients with newly diagnosed multiple myeloma not eligible for stem cell transplant. *Blood*. 2018;132(S1)P4770.
- D.62. Parasuraman S, Yu JB, Paranagama DC, Shrestha S, Wang L, Baser O, Scherber RM. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *Blood*. 2018;132(S1)Abstract 175.
- D.63. George D, Schultz N, Huang A, Wang L, Baser O, Ramaswamy K, Mardekian J. Increased costs associated with progression to metastatic castrate-resistant prostate cancer. *J Manag Care Spec Pharm*. 2018;24(10-a)S26-27.

- D.64. Pandya S, Shrestha S, Wang L, Baser O, Clancy Z, Ni Q. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). *J Clin Oncol*. 2018;36(30)S194.
- D.65. Amin A, Bassalobre Garcia A, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in nonvalvular atrial fibrillation patients with heart failure. *European Heart J*. 2018;39(S1)ehy566.P6590
- D.66. Pandya S, Clancy Z, Shrestha S, Wang L, Ni Q, Baser O. Economic burden of early progression in newly diagnosed multiple myeloma patients. *J Clin Oncol*. 2018;36:15.
- D.67. Gupta A, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with chronic obstructive pulmonary disease in the US Veterans Health Administration population. *Value Health*. 2018;21(S1)S238.
- D.68. Xie L, Wang Y, Qiang W, Sah J, Baser O. Health care utilization and economic burden of patients with inflammatory bowel disease in the US Department of Defense population. *Value Health*. 2018;21(S1)S87.
- D.69. Xie L, Sun X, Mallampati R, Wang Y, Yuce H, Baser O. Healthcare utilization and economic burden on patients with bladder cancer in the US Department of Defense population. *Value Health*. 2018;21(S3)S59.
- D.70. Borra S, Lin C, Wang L, Yuce H, Baser O. Assessing the economic burden and 30-day readmission rates among patients with bladder cancer in the US Veterans Health Administration population. *Value Health*. 2018;21(S3)S34.
- D.71. Borra S, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with breast cancer in the US Veterans Health Administration population. *J Manag Care Spec Pharm*. 2018;24(4-a)S26.
- D.72. Xie L, Baser O, Wang Y, Qiang W, Shen Y. Health care utilization and economic burden on patients diagnosed with epilepsy in the US Department of Defense population. *J Manag Care Spec Pharm*. 2018;24(4-a)S64.
- D.73. Kuritzkes BA, Pappou EP, Guo X, Yang H, Zhao B, Baser O, Kiran RP, Bentley-Hibbert S. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *Int J Colorectal Dis*. 2018;33:P1019- P1028.
- D.74. Coleman CI, Herman WH, Pandya S, Wang L, Baser O, Cai J, Bookhart B. Body weight (BW) outcomes with canagliflozin 300 mg (CANA) vs. glucagon-like peptide-1 receptor agonists (GLP-1s) in a real-world (RW) setting. *Diabetes*. 2018;67(Supplement_1):1291-P.
- D.75. Rubin D, Long M, Keshishian A, Baser O, Hepp Z, Wang A. The impact of intestinal complications on healthcare costs among inflammatory bowel disease patients with anti-TNF therapies. *Gastroenterology*. 2018;154(6)S368-S369.

- D.76. Clancy Z, Pandya S, Shrestha S, Wang L, Baser O, Ni QH. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). *J Clin Oncol*. 2018;36(30)Abstract 194.
- D.77. Kuritzkes B, Huang T, Baser O, Brown AR, Kim M, Forde KA, Kiran RP. Intraoperative FiO₂ greater than or equal to 80% and risk of surgical site infection after colorectal surgery. *J Am College Surgeons*. 2018;227(4)S66-S67.
- D.78. Kuritzkes B, Cao YW, Forde KA, Baser O, Kiran RP. New barrier attire regulations in the operating room: Another mandate without basis? *J Am College Surgeons*. 2018;227(4)S109-S110.
- D.79. Pandya S, Clancy Z, Shrestha S, Wang L, Ni Q, Baser O. Economic burden of early progression in newly-diagnosed multiple myeloma patients. *J Clin Oncol*. 2018;36(S15)e20040.

2017

- D.80. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu XC, Mardekian J, Zhang QS, Baser O, Vo L. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among non-valvular atrial fibrillation patients in the United States Medicare population. *Circulation*. 2017;136(S1)Abstract 15949.
- D.81. Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *J Am Academy Dermatol*. 2017;76(6)AB127:Abstract 4907.
- D.82. Kariburyo F, Fan T, Xie L, Ogbomo A, Baser O, Levin P. Long-term impact of early and sustained A1C control on clinical and economic outcomes: US Veterans Health Administration (VHA) database analysis. *Diabetes*. 2017;66(S1)A636:Abstract 2437-PUB.
- D.83. Ogbomo A, Keshishian A, Xie L, Lin YY, Baser O. A descriptive analysis of the health-care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population. *Pharmacoepidemiology Drug Safety*. 2017;26(S2)144:Abstract 236.
- D.84. Vaidya N, Xie L, Wang YX, Du J, Baser O. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. *Pharmacoepidemiology Drug Safety*. 2017;26(S2)133-134:Abstract 217.
- D.85. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Impact of coronary artery disease on clinical outcomes among patients with newly diagnosed heart failure with systolic dysfunction: Is it changing over time? *J Cardiac Failure*. 2017;23(8)S105:Abstract 290.
- D.86. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Real-world patterns of care for patients with follicular lymphoma treated with lenalidomide and rituximab (R2) in the US Medicare population. *Blood*. 2017;130(S1)4706.
- D.87. Amin A, Keshishian A, Trocio J, Le H, Dina O, Zhang Q, Baser O, Vo L. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *J Am College Cardiol*. 2017;69(11)316:Abstract 1134M-13.

- D.88. Shrestha S, Baser O, Zhou XX, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *Stroke*. 2017;48(S1)Abstract ATMP102.
- D.89. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact. *Circulation*. 2017;134(S1)Abstract 13112.
- D.90. Al-Mazrou AM, Baser O, Kiran PR. Effect of hospital familiarity with complex procedures on overall healthcare burden. *J Am College Surgeons*. 2017;225(4)S127.
- D.91. Zhang QS, Xie L, Keshishian A, Lin YY, Baser O. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States. *Pharmacoepidemiology Drug Safety*. 2017;26(S2)40:Abstract 61.
- D.92. Amin A, Keshishian A, Trocio J, Le H, Dina O, Qisu Z, Baser O, Vo L. Real-world comparison of major bleeding and associated costs among oral anticoagulant-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *J Am College Cardiol*. 2017;69(11)439:Abstract 1189-085.
- D.93. Zhang QS, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *Clin Lymphoma Myeloma Leukemia*. 2017;17(S2)S284:Abstract AML-134.
- D.94. Fu R, Kurlansky PA, Means J, Baser O, Rohde CH. Breast cancer provider discussion law helps reverse racial and economic disparity in breast reconstruction rates in New York state: An analysis of 42,137 patients from the New York State Database. *J Am College Surgeons*. 2017;225(4)S160-S161.
- D.95. Al-Mazrou AM, Baser O, Kiran PR. Alvimopan, regardless of ileus risk, significantly impacts ileus, length of stay, and readmission after intestinal surgery. *J Am College of Surgeons*. 2017;225(4)S37.
- D.96. Pandya S, Cao YW, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veteran Health Administration population. *Pharmacoepidemiology and Drug Safety*. 2017;26(S2)135-6:Abstract 220.
- D.97. Black C, Fillit H, Xie L, Khandker R, Kariburyo F, Baser O, Yuce H, Ambegaonkar B. Rates of institutionalization among newly diagnosed AD patients. *Neurology*. 2017;88(S16)Abstract P3.099.
- D.98. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann G, Schein J, Crivera C. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *J General Internal Med*. 2017;32(S2)S281.
- D.99. Sonpavde G, Huang A, Wang L, Baser O, Miao R. First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. *J Clin Oncol*. 2017;35(6_suppl)156.
- D.100. Taylor KA, Araujo AB, Wang L, Boystov NN, Haynes GS, Pandya S, Sietsema DL, Faries D, Baser O, Jones CB. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *J Bone Miner Res*. 2017;32:S39.

- D.101. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among non-valvular atrial fibrillation patients in the United States Medicare population. *Circulation*. 2017;136(S1)A15949.
- D.102. Lopes RD, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of apixaban versus other oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease. *Circulation*. 2017;136(S1)A16487.
- D.103. Ogbomo A, Lin Y, Keshishian A, Xie L, Baser O. A comparative analysis of the health care utilization and costs of patients diagnosed with and without liver cancer in the US Medicare population. *Value Health*. 2017;20(9)PA465.
- D.104. Cinaroglu S, Baser O. The flow of EU-28 country clusters in terms of infectious and chronic diseases during a refugee crisis. *Value Health*. 2017;20(9)PA507.
- D.105. Zhang Q, Kariburyo MF, Xu J, Xie L, Baser O. Examining health care utilization and costs among atherosclerosis patients in the US Veteran Health Administration population. *Value Health*. 2017;20(9)PA629.
- D.106. Vaidya N, Wang Y, Xie L, Baser O. Evaluating the economic burden and health care utilization of bacterial pneumonia in the US Department of Defense population. *Value Health*. 2017;20(9).
- D.107. Cinaroglu S, Baser O. Adult risk factors of non-communicable disease outcomes. *Value Health*. 2017;20(9)PA644.
- D.108. Cinaroglu S, Baser O. Intercontinental links among health technology assessment organizations. *Value Health*. 2017;20(9)PA672-A673.
- D.109. Cinaroglu S, Baser O. Factors related to outpatient antibiotic drug consumption in Turkey. *Value Health*. 2017;20(9)PA658.
- D.110. Cinaroglu S, Baser O. A fresh look at the predictors of the number of HIV cases in Turkey. *Value Health*. 2017;20(9)PA794-A795.
- D.111. Ariely R, Chipps BE, Stoyanov S, Wang L, Shrestha S, Baser O. Budgetary impact model on a Medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters. *Ann Allergy Asthma Immunology*. 2017;119(5)S60.
- D.112. Hall E II, Wells W, Teynor M, Babb J, Huang A, Wang L, Baser O. Healthcare resource utilization and costs of spinal muscular atrophy care in the US Medicaid population. *J Manag Care Spec Pharm*. 2017;23(10-a)S50-51.
- D.113. Kerwin EM, Stoyanov S, Wang L, Shrestha S, Baser O, Ariely R. The budget impact on the adoption of short acting beta-agonist inhalers with integrated dose counters in managed care. *J Manag Care Spec Pharm*. 2017;23(10-a)S63.

- D.114. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Impact of coronary artery disease on clinical outcomes among patients with newly-diagnosed heart failure with systolic dysfunction: Is it changing over time? *J Cardiac Failure*. 2017;23(8)S105.
- D.115. Zhang Q, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *J Clin Oncol*. 2017;35(15)e18161.
- D.116. Taylor K, Araujo AB, Wang L, Boystov N, Haynes GB, Pandya S, Sietsema D, Faries D, Baser O, Jones CB. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *J Bone Miner Res*. 2017;32:S1.
- D.117. Peacock WF, Coleman C, Wells P, Fermann GJ, Wang L, Baser O, Schein J, Crivera C. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care. *Eur Heart J*. 2017;38(S1)ehx502.P1617.
- D.118. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger J. Short and intermediate term all-cause mortality among newly diagnosed heart failure patients in the US Medicare population. *Eur Heart J*. 2017;38(S1)ehx502.P1078.
- D.119. Cinaroglu S, Baser O. Network among HTA ecosystem. *Int J Technology Assessment Health Care*. 2017;33(S1)P235.
- D.120. Cinaroglu S, Baser O. Predictors of public health outcomes: A case study from Turkey. *Int J Technology Assessment Health Care*. 2017;33(S1)P62-P63.
- D.121. Baser O, Cinaroglu S. Determinants of the behavioral health system's efficiency in OECD countries. *Int J Technology Assessment Health Care*. 2017;33(S1)P229-P2300
- D.122. Cinaroglu S, Baser O. Worldwide clustering of surgical indicators and risk predictors of catastrophic surgical care expenditures. *J Health Sciences*. 2017;7(3)P188-P195.
- D.123. Ganapathy V, Xie L, Keshishian A, Zhang Q, Baser O. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents. *American Thoracic Society*. 2017;A37:A1412.
- D.124. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of institutionalization among newly diagnosed AD patients. *Neurology*. 2017;88(16)P3.099.
- D.125. Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Manag Care Spec Pharm*. 2017;23(3-a)S84.
- D.126. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators. *J Manag Care Spec Pharm*. 2017;23(3-a)S78-S79.

- D.127. Chipps B, Ferro T, Wang L, Shrestha S, Baser O, Parikh R. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter. *J Manag Care Spec Pharm.* 2017;23(3-a)S77-S78.
- D.128. Pandya S, Abouzaid S, Xie L, Parikh K, Baser O, Patel MI. Real-world health care costs among newly diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015). *J National Comprehensive Cancer Network.* 2017;15(5.5)E27.
- D.129. Amin A, Keshishian A, Trocio J, Dina O, Le H, Zhang Q, Baser O, Vo L. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *J Am Coll Cardiol.* 2017;69(11)P316.
- D.130. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US. *J Am Med Directors Association.* 2017;18(3)B23.
- D.131. Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *J Am Academy Dermatology.* 2017;76(6)AB127.
- D.132. Shrestha S, Baser O, Zhou X, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *Stroke.* 2017;48(S1)ATMP102.
- D.133. Sonpavde G, Huang A, Wang L, Baser O, Miao R. First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. *J Clin Oncol.* 2017;35(6)P156.

2016

- D.134. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism. *Circulation.* 2016;134(S1)Abstract 13140.
- D.135. Kurlansky P, Baser O, Nemeth S, Tingley J, Argenziano M, Smith C. East meets West in the assessment of cardiac risk: A multicenter comparative study of the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *Circulation.* 2016;134(S1)Abstract12044.
- D.136. Murray A, Baser O, Pappou E, Lee-Kong SA, Feingold DL, Kiran RP. Income, geography, and hospital determine gaps in assimilation of minimally invasive technology for rectal cancer surgery. *J Am College Surgeons.* 2016;223(4)S33.
- D.137. Xie L, Parikh K, Abouzaid S, Pandya S, Baser O, Patel MI. Real world treatment outcomes and cost among newly diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *Blood.* 2016;128(22)Abstract 5924.

- D.138. Parikh K, Pandya S, Abouzaid S, Baser O, Xie L, Patel MI. Treatment patterns among newly diagnosed multiple myeloma patients in the United States veteran population (2010- 2015). *Blood*. 2016;128(22)Abstract 5952.
- D.139. Kumar NK, Weeda ER, Wells PS, Peacock F, Fermann GJ, Wang L, Baser O, Schein J, Crivera C, Coleman CI, Kohn CG. External validation of a clinical and claims-based approach for predicting 90-day post-pulmonary embolism outcomes among US veterans. *Blood*. 2016;128(22)Abstract 533.
- D.140. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. *Blood*. 2016;128(22)3574.
- D.141. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism. *Circulation*. 2016;134(S1)A13140.
- D.142. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact. *Circulation*. 2016;134(S1)A13140.
- D.143. Kurlansky P, Baser O, Nemeth S, Tingley J, Argenziano M, Smith C. East meets West in the assessment of cardiac risk: A multicenter comparative study of the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *Circulation*. 2016;134(S1)A12044.
- D.144. Wang L, Li L, Pandya S, Baser O. Evaluating socio-demographic characteristics of patients in the United States Department of Defense population. *Value Health*. 2016;19(7)A370.
- D.145. Wang L, Li L, Pandya S, Baser O. A real-world evaluation of the clinical and economic burden of United States veteran patients with post-traumatic stress disorder. *Value Health*. 2016;19(7)A524.
- D.146. Wang L, Li L, Zhou X, Pandya S, Baser O. Evaluation of the clinical characteristics and economic burden of United States veteran patients diagnosed with the Hepatitis C virus. *Value Health*. 2016;19(7)A412.
- D.147. Wang L, Li L, Zhou X, Pandya S, Baser O. Assessing the clinical and economic burden of prostate cancer in the United States veteran population. *Value Health*. 2016;19(7)A726.
- D.148. Cinaroglu S, Baser O. Spatial distribution of the total number of medical devices in Turkey: a classification analysis. *Value Health*. 2016;19(7)A703.
- D.149. Cinaroglu S, Baser O. Socio-economic status and self-rated health: are they good predictors of income? An analysis of survey panel data from Turkey. *Value Health*. 2016;19(7)A495.
- D.150. Cinaroglu S, Baser O. Understanding the relationship between effectiveness and outcome indicators in health care. *Value Health*. 2016;19(7)A495.
- D.151. Cinaroglu S, Guzel E, Baser O. The relationship between medical innovation and health expenditures. *Value Health*. 2016;19(7)A355-A356

- D.152. Xie L, Zhang Q, Xin K, Wang Y, Yuce H, Özenbas D, Baser O. Health care utilization and economic burden of pancreatic cancer in the US Medicare population. *Value Health*. 2016;19(7)A726
- D.153. Xie L, Vaidya N, Xin K, Keshishian A, Yuce H, Özenbas D, Baser O. Evaluating the economic burden and health care utilization of lung cancer in the US Medicare population. *Value Health*. 2016;19(7)A726-A727.
- D.154. Murray AC, Baser O, Pappou LK, Feingold RP, Kiran. Income, geography and hospital determine gaps in assimilation of minimally invasive technology for rectal cancer surgery. *J Am College Surgeons*. 2016;223(4)S33.
- D.155. Xie L, Zhou S, Kariburyo F, Baser O, Fan T. Clinical and economic outcomes in patients with type 2 diabetes switching from basal insulin plus rapid-acting insulin to basal insulin plus glucagon-like peptide-1: A real-world observational study. *J Manag Care Spec Pharm*. 2016;22(10- a)S35.
- D.156. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban or warfarin. *Eur Heart J*. 2016;37(S1)P191.
- D.157. Black CM, Hu X, Khandker RK, Ambegaonkar BM, Kariburyo MF, Xie L, Baser O, Yuce H. Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer's disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. *Alzheimers Dementia*. 2016;12(7S)P254-P254.
- D.158. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Comparing health care resource utilization and costs among obese patients in the US Medicaid population. *Value Health*. 2016;19(3)A249-A250.
- D.159. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Assessing the economic burden and health care utilization of attention deficit/hyperactivity disorder among US Medicaid patients. *Value Health*. 2016;19(3)A187.
- D.160. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating asthma-related expenses and health care resource utilization among children in the US Medicaid population. *Value Health*. 2016;19(3)A114.
- D.161. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing the economic burden and health care resource utilization of US veterans with chronic obstructive pulmonary disease. *Value Health*. 2016;19(3)A114.
- D.162. Ogbomo A, Zhao Y, Kariburyo MF, Xie L, Yuce H, Baser O. Retrospective analysis of the economic burden of patients diagnosed with congestive heart failure in the California Medicaid population. *Value Health*. 2016;19(3)A46.
- D.163. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing health care resource utilization and costs among US veterans diagnosed with asthma. *Value Health*. 2016;19(3)A114.
- D.164. Keshishian A, Tan H, Xie L, Baser O. Examination of the economic burden of dyslipidemia

in the veteran's health administration population. *Value Health*. 2016;19(3)A46.

D.165. Kariburyo F, Du J, Xie L, Baser O. Examining the health care resource utilization and economic burden among rheumatoid arthritis patients with different routine assessment of patient index data 3 scores: A probabilistic matching study. *Value Health*. 2016;19(3)A231.

D.166. Kariburyo F, Du J, Xie L, Baser O. Assessing the economic burden of rheumatoid arthritis patients with different clinical disease activity index scores: a probabilistic matching study. *Value Health*. 2016;19(3)A231.

D.167. Tan H, Xie L, Wang Y, Yuce H, Baser O. Examine the burden of illness of US Medicare patients diagnosed with cataract. *Value Health*. 2016;19(3)A123-A124.

D.168. Tan H, Xie L, Baser O, Yuce H, Wang Y. Evaluating the economic burden and health care utilization of anemia in the US Medicare population. *Value Health*. 2016;19(3)A246.

D.169. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating the economic burden and health care utilization of coronary artery disease in the US Medi-Cal population. *Value Health*. 2016;19(3)A46-A47.

D.170. Keshishian A, Du J, Xie L, Yuce H, Baser O. Demographic and socioeconomic characteristics that impact selection of oral anticoagulants among non-valvular atrial fibrillation patients. *Value Health*. 2016;19(3)A55.

D.171. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among patients with chronic obstructive pulmonary disease in the US Medicare population. *Value Health*. 2016;19(3)A249-A250.

D.172. Bashyal R, Du H, Wang L, Yuce H, Baser O. Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. *Value Health*. 2016;19(3)A184.

D.173. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among hospitalized congestive heart failure patients in the US Medicare population. *Value Health*. 2016;19(3)A44.

D.174. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of alcohol dependence among US veteran patients. *Value Health*. 2016;19(3)A185.

D.175. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with depressive disorder in the US veteran population. *Value Health*. 2016;19(3)A185.

D.176. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of bipolar disorder among U.S. veteran patients from 2011 to 2015. *Value Health*. 2016;19(3)A185.

D.177. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with drug dependence in the US veteran population *Value Health*. 2016;19(3)A184-A185.

D.178. Bashyal R, Du H, Wang L, Yuce H, Baser O. Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. *Value Health*. 2016;19(3)A40.

- D.179. Pesa JA, Wang L, Yuce H, Baser O. Proton pump inhibitor utilization among patients with hepatitis C virus (HCV). *Value Health*. 2016;19(3)A213.
- D.180. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. *J Am College Cardiology*. 2016;67(13S)P668.
- D.181. Cai J, Wang YX, Baser O, Xie L, Diels J, Neslusan C, Chow W. Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world. *Diabetes*. 2016;65(S1)A303:Abstract 1155-P.
- D.182. Al-Mazrou AM, Baser O, Kiran PR. Nationwide trends in costs of healthcare and early discharge after colorectal resection. *J Am College Surgeons*. 2016;223(4)E86.

2015

- D.183. Wang ZX, Xie L, Alley S, Baser O, Nguyen C. Incidence of serotonin syndrome with concomitant use of serotonergic agents in the US clinical practice. *J General Internal Med*. 2015;30(S2)S190-S191:Abstract 2198446.
- D.184. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Comparison of short-term bleeding-related health care utilization and costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *Chest*. 2015;148(4)Abstract 65A.
- D.185. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Early comparison of major bleeding, stroke and associated medical costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *Blood*. 2015;126(23)P745.
- D.186. Xie L, Wang Y, Tan H, Ogbomo A, Baser O, Yuce H. Trends in prevalence and incidence rates of type 2 diabetes mellitus in the Medicare population. *Value Health*. 2015;18(7)A600.
- D.187. Keshishian A, Wang Y, Xie L, Baser O, Yuce H. Examining the economic burden and health care utilization of menopausal women in the US Medicaid population. *Value Health*. 2015;18(7)A736.
- D.188. Baser O, Ogbomo A, Tan H, Du J, Xie L. Evaluation of the burden of opioid abuse among US veteran patients. *Value Health*. 2015;18(7)A411.
- D.189. Xie L, Tan H, Ogbomo A, Wang Y, Baser O, Yuce H. Evaluation of the burden of Parkinson's disease in Medicare and linked long term care populations. *Value Health*. 2015;18(7)A758.
- D.190. Fox KM, Wang L, Quek RGW, Gandra SR, Li L, Baser O. Long-term increased inpatient and outpatient visits associated with cardiovascular events: A large United States real world study. *Value Health*. 2015;18(7)A377-A378.

- D.191. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *Circulation*. 2015;132(S3)A19672-A19672.
- D.192. Masseria C, Kariburyo MF, Mardekian J, Lee TC, Ravee Y, Phatak H, Baser O, Hamilton M, Xie L. Venous thromboembolism recurrence and bleeding risk among cancer patients using a large commercial database. *Circulation*. 2015;132(S3)A19936-A19936.
- D.193. Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singha S, Patel C, Odell K, Trocio J. Comparison of short-term bleeding-related health care utilization and costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. *Chest*. 2015;148(4)65A.
- D.194. Pesa J, Wang L, Yuce H, Baser O. Comparing costs and resource utilization between patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in California Medicaid (Medi-Cal). *Drugs-Real World Outcomes*. 2015;2:377-385.
- D.195. Baser O, Lewis-Beck C, Fritschel E, Baser E, Wang L. Applied comparison of meta-analysis techniques. *Value Health*. 2015;18(7)A814.
- D.196. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Epidemiology, and economic burden of serotonin syndrome with concomitant use of serotonergic agents in the US clinical practice. *Primary Care Companion for CNS Disorders*. 2015;19(6)P23092.
- D.197. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden and health care resource utilizations of US Medicare patients with myeloproliferative neoplasms. *Value Health*. 2015;18(3)A200.
- D.198. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden of U.S. Medicare patients diagnosed with non-Hodgkin's lymphoma. *Value Health*. 2015;18(3)A200.
- D.199. Xie L, Kariburyo MF, Wang D, Baser O. A descriptive analysis of patient characteristics and health care burden associated with chronic obstructive pulmonary disease in the U.S. Medicare population. *Value Health*. 2015;18(3)A173.
- D.200. Baser O, Kariburyo MF, Du J, Xie L. Comparing healthcare resource utilization and costs among schizophrenic patients who initiated typical vs atypical long-acting injectables in the US veteran population. *Value Health*. 2015;18(3)A119.
- D.201. Xie L, Keshishian A, Du J, Baser O. Examining the fracture-related cost burden and healthcare resource utilization post-menopause in the U.S. Medicare population. *Value Health*. 2015;18(3)A105.
- D.202. Xie L, Keshishian A, Wang Y, Baser O. Evaluating fracture-related expenses and health care resource utilization among post-menopausal women in the U.S. Medicaid population. *Value Health*. 2015;18(3)A113.
- D.203. Xie L, Wang Y, Keshishian A, Baser O. Comparing the healthcare utilization and costs of early- and late-stage Alzheimer's disease patients residing in long-term care facilities. *Value Health*. 2015;18(3)A118.

- D.204. Mao X, Shrestha S, Baser O, Wang L. Assessing the health care resource utilization and economic burden among U.S. cardiovascular disease patients in the Veterans Health Administration population. *Value Health*. 2015;18(3)A149.
- D.205. Li L, Shrestha S, Baser O, Yuce H, Wang L. Mortality and rehospitalization rates among hospitalized pneumonia patients in the US Medicare population. *Value Health*. 2015;18(3)A171.
- D.206. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and economic burden of patients diagnosed with rheumatoid arthritis in the U.S. Medicare population. *Value Health*. 2015;18(3)A159.
- D.207. Li L, Shrestha S, Baser O, Yuce H, Wang L. Examining prevalence, incidence and mortality rates among opioid-dependent patients in the U.S. Medicare population. *Value Health*. 2015;18(3)A116-A117.
- D.208. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Health care cost burden and demographic distribution of patients diagnosed with psoriatic arthritis in the US Medicare population. *Value Health*. 2015;18(3)A159.
- D.209. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilization and costs among diabetes patients residing in long-term care facilities. *Value Health*. 2015;18(3)A60.
- D.210. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilizations and costs among migraine patients in the U.S. Medicaid population. *Value Health*. 2015;18(3)A283.
- D.211. Huang A, Shrestha S, Baser O, Yuce H, Wang L. A retrospective analysis of health care resource utilization and the economic burden among US long-term care facility patients diagnosed with stroke. *Value Health*. 2015;18(3)A138.
- D.212. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and health care burden of patients diagnosed with ankylosing spondylitis in the U.S. Medicare population. *Value Health*. 2015;18(3)A296.
- D.213. Li L, Shrestha S, Baser O, Yuce H, Wang L. Prevalence and incidence rates among alcohol-dependent patients in the US Medicare population. *Value Health*. 2015;18(3)A116-A117.
- D.214. Mao X, Shrestha S, Baser O, Wang L. A retrospective analysis of the economic burden among patients diagnosed with chronic migraine using the Veterans Health Administration medical dataset. *Value Health*. 2015;18(3)A282-A283.
- D.215. Li L, Shrestha S, Baser O, Wang L. Evaluating trends in chronic pain prevalence in the United States Veterans Health Administration population. *Value Health*. 2015;18(3)A294.
- D.216. Xie L, Du J, Kariburyo MF, Baser O. A descriptive analysis of patient characteristics, bleeding and recurrence risk among U.S. veteran patients diagnosed with venous thromboembolism. *Value Health*. 2015;18(3)A130.

- D.217. Fox KM, Wang L, Gandra SR, Quek RGW, Li L, Baser O. Long-term economic burden associated with cardiovascular events among high-risk patients with hyperlipidemia. *Value Health*. 2015;18(3)A139-A140.
- D.218. Xie L, Wang Z, Alley S, Baser O, Nguyen C. Healthcare utilization and costs of serotonin syndrome with concomitant use of serotonergic agents. *Value Health*. 2015;18(3)A114.
- D.219. Masseria C, Kariburyo MF, Mardekian J, Lee T, Phatak H, Baser O, Xie L. Clinical outcomes and treatment patterns of venous thromboembolism among cancer patients in a large commercial database. *Value Health*. 2015;18(3)A130.
- D.220. Velez FF, Baser O, Xie L. Adherence and persistence to anti-epileptic drugs among US veterans diagnosed with epilepsy. *Value Health*. 2015;18(3)A285.
- D.221. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *Circulation Cardiovascular Quality Outcomes*. 2015;8(S2)A234-A234.
- D.222. Baser O, Griffith J, Roy S, Xie L, Ganguli A. Impact of switching among tumor necrosis factor inhibitors (TNF) on health care resource utilization and costs in patients with rheumatoid arthritis. *J Manag Care Spec Pharm*. 2015;21(4-a)S63-S64.
- D.223. Velez F, Baser O, Xie L. Cost analyses among U.S. veterans diagnosed with epilepsy and treated with anti-epileptic drug monotherapy or adjunctive therapy. *J Manag Care Spec Pharm*. 2015;21(4-a)S44.
- D.224. Xie L, Vo L, Keshishian A, Price K, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *J Manag Care Spec Pharm*. 2015;21(4-a)S50.

2014

- D.225. Wang L, Baser O, Kutikova L, Page JH, Barron RL. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials. *Blood*. 2014;124(21)4850.
- D.226. Brixner DI, Dhawan R, Miao R, Sung J, Wang L, Baser O, Mehta J. Utilization patterns of abiraterone acetate before and after chemotherapy in patients with metastatic castration-resistant prostate cancer in the Veterans Health Administration System. *J Clin Oncol*. 2014;32(15)Abstract e16014.
- D.227. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Therapeutically exchangeable? A real-world outcome study of switching between basal insulin analogs among T2DM patients. *Diabetes*. 2014;63(S1)A234.
- D.228. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Association of out-of-range international normalized ratio (INR) values and adverse clinical outcomes among newly initiated warfarin patients with non-valvular atrial fibrillation and comorbid diabetes. *Diabetes*. 2014;63(S1)A234.

- D.229. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Association of out-of-range international normalized ratio (INR) values and adverse clinical outcomes among newly initiated warfarin patients with non-valvular atrial fibrillation and comorbid diabetes. *Circulation*. 2014;130(S2)A12029.
- D.230. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of breast cancer in the Medicaid program. *Value Health*. 2014;17(7)A642.
- D.231. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of Medicaid program services for patients diagnosed with multiple sclerosis. *Value Health*. 2014;17(7)A399.
- D.232. Li L, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden among Cushing's disease patients in the U.S. Medicaid program. *Value Health*. 2014;17(7)A350.
- D.233. Li L, Shrestha S, Baser O, Wang L. Evaluation of the economic burden of menopausal women in the U.S. Medicaid program. *Value Health*. 2014;17(7)A511.
- D.234. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of U.S. long-term care facility residents diagnosed with Parkinson's disease. *Value Health*. 2014;17(7)A395.
- D.235. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of long-term care facility residents diagnosed with Alzheimer's disease in the United States. *Value Health*. 2014;17(7)A512.
- D.236. Xie L, Kariburyo MF, Du J, Baser O. Examination of the burden of illness of U.S. Medicare patients diagnosed with chronic obstructive pulmonary disease. *Value Health*. 2014;17(7)A592- A593.
- D.237. Xie L, Kariburyo MF, Du J, Baser O. Assessing the economic burden and health care utilization of U.S. Medicare patients diagnosed with melanoma. *Value Health*. 2014;17(7)A625.
- D.238. Xie L, Dysinger AH, Kariburyo MF, Du J, Baser O. Evaluation of the burden of illness of U.S. Medicare patients diagnosed with hyperpotassemia. *Value Health*. 2014;17(7)A352.
- D.239. Xie L, Kariburyo MF, Wang Y, Baser O. Evaluating the economic burden and health care utilizations of U.S. veteran patients diagnosed with chronic hepatitis C. *Value Health*. 2014;17(7)A671.
- D.240. Xie L, Kariburyo MF, Wang Y, Baser O. Health care costs and utilization of U.S. veteran patients diagnosed with pancreatic cancer. *Value Health*. 2014;17(7)A627-A628.
- D.241. Xie L, Kariburyo MF, Wang Y, Baser O. Comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with type 2 diabetes mellitus. *Value Health*. 2014;17(7)A341.
- D.242. Xie L, Dysinger AH, Wang Y, Kariburyo MF, Baser O. Prevalence of cystic fibrosis among the U.S. national Medicaid population *Value Health*. 2014;17(7)A391.
- D.243. Baser O, Kariburyo MF, Altinbas A, Baser E. Economic burden and complications of hepatitis C virus patients with and without peginterferon and ribavirin treatment in Turkey. *Value Health*. 2014;17(7)A672.

- D.244. Baser O, Kariburyo MF, Baser E, Altinbas A. Cost of cirrhosis among patients diagnosed with hepatitis C virus in Turkey. *Value Health*. 2014;17(7)A672.
- D.245. Baser E, Baser O, Altinbas A, Kariburyo MF. Pharmacy cost calculator for hepatitis C virus patients in Turkey. *Value Health*. 2014;17(7)A551.
- D.246. Levin PA, Wei W, Gill J, Buysman E, Grabner M, Xie L, Baser O, Chu JW. Treatment patterns and outcomes in managed care patients with type 2 diabetes initiating injectable therapies: A pooled analysis from the INITIATOR Study. *J Manag Care Spec Pharm*. 2014;20(10-a)S26-S27.
- D.247. Wei W, Brekke LN, Buysman E, Grabner M, Ke X, Xie L, Baser O. A personalized- medicine approach to evaluate real-world treatment benefits of patients with type 2 diabetes mellitus initiating different injectable therapies. *J Manag Care Spec Pharm*. 2014;20(10-a)S25-S26.
- D.248. Miao R, Wei W, Xie L, Baser O. Impact of switching basal insulin analogs on clinical and economic outcomes in patients with type 2 diabetes in a national managed care plan setting. *J Manag Care Spec Pharm*. 2014;20(10-a)S27.
- D.249. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large US insurance database analysis. *Circ J*. 2014;78(11):2610-8.
- D.250. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Variation trends in asthma prevalence in the U.S. Medicaid population. *Value Health*. 2014;17(3)A171.
- D.251. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Examining diabetes prevalence in the United States using a 2008-2009 Medicaid population. *Value Health*. 2014;17(3)A242.
- D.252. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence of hepatitis B virus infection in the U.S. Medicaid population. *Value Health*. 2014;17(3)A267-A268.
- D.253. Xie L, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Examining hepatitis C virus prevalence in the U.S Medicaid population from 2008 to 2009. *Value Health*. 2014;17(3)A267.
- D.254. Baser O, Wang L, Huang A, Wang Y, Kariburyo MF, Xie L. Examining the burden of illness of U.S. veteran patients diagnosed with bipolar disorder. *Value Health*. 2014;17(3)A377.
- D.255. Baser O, Xie L, Huang A, Du J, Wang Y, Wang L. Evaluation of the burden of depression among U.S. veteran patients. *Value Health*. 2014;17(3)A171.
- D.256. Wang L, Xie L, Li L, Wang Y, Du J, Baser O. Assessing the health care burden of asthma patients in the U.S. Medicare population. *Value Health*. 2014;17(3)A174.
- D.257. Wang L, Xie L, Li L, Kariburyo MF, Wang Y, Baser O. Evaluation of economic burden and health care utilizations for U.S. Medicare patients with rheumatoid arthritis. *Value Health*. 2014;17(3)A45.
- D.258. Xie L, Wang L, Li L, Wang Y, Baser O. The burden of illness of osteoporosis patients in the U.S. Medicare population. *Value Health*. 2014;17(3)A171.

- D.259. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Economic burden and health care utilizations of U.S. Medicare patients diagnosed with prostate cancer. *Value Health*. 2014;17(3)A171.
- D.260. Xie L, Wang L, Li L, Wang Y, Du J, Baser O. Evaluation of the burden of general cardiovascular disease among U.S. Medicare patients. *Value Health*. 2014;17(3)A111.
- D.261. Seal BS, Xie L, Rietschel P, Baser O. Compare demographic and clinical characteristics among colorectal cancer patients with a different number of treatment lines in the US veteran health administration. *Value Health*. 2014;17(3)A91.
- D.262. Seal BS, Xie L, Rietschel P, Baser O. Descriptive analysis of treatment patterns and mortality of U.S. veteran patients with colorectal cancer. *Value Health*. 2014;17(3)A5.
- D.263. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Autism prevalence in children among the U.S. Medicaid population. *Value Health*. 2014;17(3)A171.
- D.264. Wang L, Xie L, Dysinger AH, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Assessing Lyme disease prevalence in the U.S. Medicaid population. *Value Health*. 2014;17(3)A266-A267.
- D.265. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence and trends in cystic fibrosis among the U.S. Medicaid population in 2008 and 2009. *Value Health*. 2014;17(3)A57.
- D.266. Wang L, Dysinger AH, Xie L, Huang A, Wang Y, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients with post-traumatic stress disorder after unstable angina. *Value Health*. 2014;17(3)A118.
- D.267. Claflin AB, Xie L, Liu X, Mardekian J, Phatak H, Tan W, Baser O. Anticoagulant use and bleeding risk in patients with venous thromboembolism: A nested case-control study. *Value Health*. 2014;17(3)A107.
- D.268. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson KN. Human immunodeficiency virus burden of illness and treatment patterns among U.S. veteran patients. *J Manag Care Spec Pharm*. 2014;20(4-a)S8.

2013

- D.269. Liu, XC, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Bleeding incidence among patients with venous thromboembolism: A large US insurance database analysis. *Blood*. 2013;122(21)Abstract 2916.
- D.270. Wang L, Huang A, Fritschel E, Baser O. Tumor necrosis factor treatment patterns in Medicare patients with inflammatory conditions. *Pharmacoeconomol Drug Safety*. 2013;22(S1)118:Abstract 245.
- D.271. Bui CN, Spalding J, Wang L, Baser O. Treatment timing of life-extending therapies and adherence of corticosteroids among metastatic castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use. *J Clin Oncol*. 2013;31(15)Abstract e16080.

- D.272. Baser O, Du J, Xie L, Dysinger AH, Wang L. Severity index for rheumatoid arthritis: Impact on healthcare costs and utilization. *Pharmacoepidemiol Drug Saf.* 2013;22(S1)139:Abstract 288.
- D.273. Baser O, Wang L, Cline SK, Misurski DA, Gooch KL. Adherence to interferon- containing therapy among Veteran Affairs hepatitis C patients. *Hepatology.* 2013;58(S1)1129A-1130A:Abstract 1909
- D.274. Ray S, Wang L, Martel MJ, Baser O. Variation in patterns of healthcare and survival among patients with brain metastases in the VHA health system. *J Clin Oncol.* 2013;31(31)Abstract 204.
- D.275. Liu XC, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Persistence on warfarin therapy in patients with venous thromboembolism: A large US insurance database analysis. *Circulation.* 2013;128(22)Abstract 12664.
- D.276. Baser O, Fritschel E, Li L, Zhang J, Wang L. An overview of clinical and economic outcomes of US veteran colorectal cancer patients. *J Clin Oncol.* 2013;31(15)Abstract e14689.
- D.277. Barron RL, Wang L, Baser O, Langeberg WJ, Dale DC. Chemotherapy-induced febrile neutropenia (FN) and FN prevention strategies in cancer care in the US Veterans Health Administration (VHA). *J Clin Oncol.* 2013;31(15)Abstract 6608.
- D.278. Wang, L, Wei WH, Dalal M, Baser O. Treatment intensification after early failure of metformin or sulfonylurea among VA patients with type 2 diabetes. *Diabetes.* 2013;62(S1)A329-A330:Abstract 1258-P.
- D.279. Xie L, Du J, Kariburyo F, Dysinger AH, Wang L, Baser O. Mental disorder treatment, healthcare costs and utilizations for US Veterans. *Pharmacoepidemiol Drug Safety.* 2013;22(S1)173:Abstract 357.
- D.280. Wang L, Fritschel E, Li L, Huang A, Baser O. An examination of medical and economic outcomes of US veteran breast cancer patients. *J Clin Oncol.* 2013;31(15)Abstract e12010.
- D.281. Wang L, Li L, Fritschel E, Baser O. Overview of the clinical and economic burden of prostate cancer in the US veteran population. *Pharmacoepidemiol Drug Safety.* 2013;22(S1)413:Abstract 819.
- D.282. Baser O, Wing WC, Li W, Waltman JK, Lin X. Comparison of real-world cardiovascular-related healthcare costs of newly initiated valsartan/amlodipine single-pill combination vs angiotensin receptor blocker/calcium channel blocker free-combination therapy. *J Clin Hypertension.* 2013;15(S1).
- D.283. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson K. Burden of illness among United States veteran treatment naive human immunodeficiency virus infected patients. *Pharmacotherapy.* 2013;33(10)E212:Abstract 100.
- D.284. Fritschel E, Wang L, Li L, Zhang J, Baser O. An assessment of clinical and economic outcomes of US veteran lung cancer patients. *J Clin Oncol.* 2013;31(15)Abstract e19122.
- D.285. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Bleeding incidence among patients with venous thromboembolism: A large US insurance database analysis. *Blood.* 2013;122(21)2916.

- D.286. Bui CN, Spalding JR, Wang L, Baser O. Treatment timing of life-extending therapies and adherence to corticosteroids among metastatic castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use. *Journal of Clinical Oncology*. 2013;31(15)e16080-e16080.
- D.287. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with Alzheimer's disease. *Value Health*. 2013;16(7)A377.
- D.288. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and healthcare utilizations of US veteran patients diagnosed with the hepatitis C virus. *Value Health*. 2013;16(7)A377.
- D.289. Xie L, Wang L, Kariburyo MF, Li L, Wang Y, Baser O. Comparison of the health care costs and utilizations between patients diagnosed with the hepatitis B virus versus those without. *Value Health*. 2013;16(7)A351.
- D.290. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with obesity. *Value Health*. 2013;16(7)A377.
- D.291. Wang L, Dysinger AH, Xie L, Du J, Huang A, Baser O. Evaluation of the burden of illness of skin cancer among U.S. veteran patients. *Value Health*. 2013;16(7)A392-A393.
- D.292. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Evaluation of the burden of illness of colorectal cancer among U.S. veteran patients. *Value Health*. 2013;16(7)A392-A393.
- D.293. Wang L, Xie L, Kariburyo MF, Li L, Wang Y, Baser O. Examining the burden of illness of U.S. veteran patients with prostate cancer. *Value Health*. 2013;16(7)A402.
- D.294. Xie L, Wang L, Kariburyo MF, Huang A, Baser O. A comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with diabetes. *Value Health*. 2013;16(7)A341.
- D.295. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Effects of excess use of coronary angiography and its association with mortality rates, health care costs and hospital quality in Turkey. *Value Health*. 2013;16(7)A515.
- D.296. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti E. Anticoagulant use in the US hospitalized patients with acute venous thromboembolism. *Value Health*. 2013;16(7)A377.
- D.297. Wang L, Xie L, Du J, Li L, Baser O. A comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with hypertension. *Value Health*. 2013;16(7)A522.
- D.298. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Impact of comorbidity burden on real-world healthcare costs of rheumatoid arthritis patients in Turkey. *Value Health*. 2013;16(7)A555.
- D.299. Baser O, Baser E, Altinbas A, Burkan A. Effects of claims-based rheumatoid arthritis severity on biologic therapy use and health care costs in Turkey. *Value Health*. 2013;16(7)A555.

- D.300. Baser O, Wang L, Li L, Huang A, Xie L. Application of a data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis. *Value Health*. 2013;16(7)A557.
- D.301. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *Value Health*. 2013;16(7)A560.
- D.302. Xie L, Dysinger AH, Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients diagnosed with post-traumatic stress disorder. *Value Health*. 2013;16(7)A544-A545.
- D.303. Xie L, Wang L, Du J, Li L, Baser O. Comparing the healthcare costs and utilizations between patients with anxiety versus those without. *Value Health*. 2013;16(7)A545.
- D.304. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and health care utilizations of US veteran patients diagnosed with schizophrenia. *Value Health*. 2013;16(7)A553.
- D.305. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Using an Excel calculator to estimate ankylosing spondylitis costs in Turkey. *Value Health*. 2013;16(7)A577.
- D.306. Baser O, Baser E, Altinbas A, Burkan A. Derivation of severity index for rheumatoid arthritis. *Value Health*. 2013;16(7)A577.
- D.307. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. An Excel calculator to estimate rheumatoid arthritis costs in Turkey. *Value Health*. 2013;16(7)A581.
- D.308. Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and healthcare utilizations of US veteran patients diagnosed with chronic kidney disease. *Value Health*. 2013;16(7)A632.
- D.309. Wang L, Lewis-Beck C, Baser E, Fritschel E, Baser O. Applied comparison of meta-analysis techniques. *Value Health*. 2013;16(7)A701.
- D.310. Ray S, Wang L, Martel MJ, Baser O. Variation in patterns of healthcare and survival among patients with brain metastases in the VHA health system. *J Clin Oncol*. 2013;31(S31)204.
- D.311. Dalal M, Xie L, Baser O, DiGenio A. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: Real world health care costs from a US managed care setting. *Diabetologia*. 2013;56(S1)S897-S898.
- D.312. Xie L, Du J, Kariburyo MF, Dysinger AH, Wang L, Baser O. Mental disorder treatment, healthcare costs and utilizations for US veterans. *Pharmacoepidemiol Drug Saf*. 2013;22(S1)173.
- D.313. Baser O, Wang L, Li L, Xie L. Characteristics associated with initiation of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *Pharmacoepidemiol Drug Saf*. 2013;22(S1)498.
- D.314. Baser O, Du J, Xie L, Dysinger AH, Wang L. Severity Index for Rheumatoid Arthritis: Impact on healthcare costs and utilization. *Pharmacoepidemiol Drug Saf*. 2013;22(S1)139.

- D.315. Wang L, Huang A, Fritschel E, Baser O. Tumor necrosis factor treatment patterns in Medicare patients with inflammatory conditions. *Pharmacoepidemiol Drug Saf.* 2013;22(S1)118.
- D.316. Wang L, Li L, Fritschel E, Baser O. Overview of the clinical and economic burden of prostate cancer in the U.S. veteran population. *Pharmacoepidemiol Drug Saf.* 2013;22(S1)413.
- D.317. Wang L, Wei W, Dalal M, Baser O. Treatment intensification after early failure of metformin or sulfonylurea among VA patients with type 2 diabetes. *Diabetes.* 2013;62:A329-A330
- D.318. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Analysis of health care costs associated with ankylosing spondylitis in Turkey. *Ann Rheumatic Dis.* 2013;72(S3)A765.
- D.319. Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. Biologic switching rates among patients with rheumatoid arthritis. *Ann Rheumatic Dis.* 2013;72(S3)A561.
- D.320. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *Ann Rheumatic Dis.* 2013;72(S3)A77.
- D.321. Barron R, Wang L, Baser O, Langeberg W, Dale DC. Chemotherapy-induced febrile neutropenia (FN) and FN prevention strategies in cancer care in the US Veterans Health Administration. *J Clin Oncol.* 2013;31(S15)6608.
- D.322. Xie L, Du J, Wang L, Yuce H, Baser O. Examination of treatment patterns of ankylosing spondylitis patients in the Veterans Affairs and Medicare databases using a visualization tool. *Value Health.* 2013;16(3)A125.
- D.323. Xie L, Baser O. Clinical and economic burden of U.S. veteran schizophrenia patients: A real-world evaluation. *Value Health.* 2013;16(3)A60.
- D.324. Wang L, Zhang J, Baser O. Evaluation of the clinical and economic burden of the human immunodeficiency virus in U.S. veteran patients. *Value Health.* 2013;16(3)A80
- D.325. Wang L, Zhang J, Baser O. Evaluation of clinical, treatment characteristics and the economic burden of anxiety in U.S. veteran patients. *Value Health.* 2013;16(3)A55.
- D.326. Wang L, Zhang J, Li L, Baser O. Clinical and economic burden of U.S. veteran Alzheimer's disease patients: a real-world evaluation. *Value Health.* 2013;16(3)A101.
- D.327. Wang L, Zhang J, Baser O. Assessing the economic burden and treatment patterns of U.S. veteran chronic kidney disease patients. *Value Health.* 2013;16(3)A180.
- D.328. Wang L, Li L, Zhang J, Baser O. Comorbidities and economic burden of multiple sclerosis patients in the United States veteran population. *Value Health.* 2013;16(3)A101.
- D.329. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of U.S. veteran lung cancer patients. *Value Health.* 2013;16(3)A128.

- D.330. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of prostate cancer in the U.S. veteran population. *Value Health*. 2013;16(3)A726.
- D.331. Wang L, Zhang J, Li L, Baser O. Clinical characteristics, and treatment patterns of colorectal cancer in United States veterans. *Value Health*. 2013;16(3)A125.
- D.332. Wang L, Huang A, Baser O. Assessing the clinical and economic burden of U.S. veteran diabetes patients. *Value Health*. 2013;16(3)A156.
- D.333. Wang L, Huang A, Baser O. Clinical and economic burden of US veteran chronic obstructive pulmonary disease patients: A real-world evaluation. *Value Health*. 2013;16(3)A233.
- D.334. Wang L, Huang A, Li L, Baser O. Evaluation of the clinical characteristics and economic burden of U.S. veteran patients diagnosed with the hepatitis C virus. *Value Health*. 2013;16(3)A87- A88.
- D.335. Wang L, Huang A, Baser O. Atrial fibrillation prevalence associated with geographic variation and age in the United States veteran population. *Value Health*. 2013;16(3)A277-A278.
- D.336. Wang L, Huang A, Baser O. Geographic variation trends in Crohn's disease prevalence and demographic characteristics in the United States veteran population. *Value Health*. 2013;16(3)A212.
- D.337. Wang L, Huang A, Baser O. Assessing the geographic and demographic variation associated with psoriatic arthritis prevalence in the US veteran population. *Value Health*. 2013;16(3)A219.
- D.338. Wang L, Huang A, Baser O. Geographic variation trends in systemic lupus erythematosus prevalence in the United States veteran population. *Value Health*. 2013;16(3)A114.
- D.339. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Ankylosing spondylitis health care costs and associated disease activity scores in Turkey. *Value Health*. 2013;16(3)A125.
- D.340. Hamuryudan V, Direskeneli H, Ertenli İ, İnanç M, Karaaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Medical costs of patients with rheumatoid arthritis and its association with global disease activity in Turkey. *Value Health*. 2013;16(3)A221-A222.
- D.341. Xie L, Liu X, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti E. Recurrence and risk factors in hospitalized patients with acute venous thromboembolism: A claims database analysis. *Value Health*. 2013;16(3)A273.
- D.342. Xie L, Khandelwal N, Kariburyo F, Baser O. Comparing healthcare costs and utilizations of patients with overactive bladder who were adherent and non-adherent to their medication. *Value Health*. 2013;16(3)A182.
- D.343. Xie L, Du J, Kariburyo F, Baser O. Treatment, health care costs and utilizations of US veterans with mental disorders. *Value Health*. 2013;16(3)A60.
- D.344. Baser O, Du J, Dysinger AH, Wang L, Xie L. A real-world evaluation of the clinical and economic burden of U.S. veteran patients with post-traumatic stress disorder. *Value Health*. 2013;16(3)A60.

- D.345. Xie L, Du J, Baser O. Comorbidities, medications, health care costs and utilizations of U.S. veteran patients with gastroesophageal reflux disease. *Value Health*. 2013;16(3)A212-A213.
- D.346. Baser O, Du J, Kariburyo F, Xie L. A solution for under-diagnosed post-menopause: Probabilistic linkage of claims and registry data. *Value Health*. 2013;16(3)A30-A31.
- D.347. Baser O, Huang A, Li L, Wang L. Obese patients in the U.S. veteran population: A health care cost and utilization analysis. *Value Health*. 2013;16(3)A110.
- D.348. Baser O, Chan W, Wang L, Waltman-Johnson K, Xie L. Comparison of real-world cardiovascular-related healthcare costs of newly initiated valsartan/amlodipine single-pill combination angiotensin receptor blocker/calcium channel blocker free-combination therapy. *J Clin Hypertens*. 2013;15:S1.
- D.349. Xie L, Spalding J, Baser O. Differences in test-related clinical and economic outcomes between patients who underwent single-photon emission computed tomography using regadenoson versus patients who underwent echocardiograms using dobutamine. *Circulation Cardiovascular Quality Outcomes*. 2013;6:A240.

2012

- D.350. Wei WH, Pan CS, Xie L, Baser O. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). *Diabetes*. 2012;61:A4.
- D.351. Baser O, Miao R, Wei WH, Xie L. Real world outcomes of adding rapid acting insulin vs switching to analog premix insulin among patients with type 2 diabetes treated with insulin glargine. *Diabetes*. 2012;61:A618,A2455-PO.
- D.352. Baser O, Tangirala M, Wei WH, Xie L. Real world outcomes of initiating glargine-based insulin treatment vs. analog premix insulin among patients with type 2 diabetes failing oral antidiabetic drugs. *Diabetes*. 2012;61:A303,A1173P.
- D.353. Levin P, Wei WH, Vlajnic A, Pan CS, Xie L, Lin J, Baser O. Real-world outcomes of initiating injectable therapy with insulin glargine or liraglutide among patients with type 2 diabetes. *Diabetes*. 2012;61:A4,A11-OR.
- D.354. Lin J, Wei WH, Vlajnic A, Pan CS, Xie L, Baser O, Levin P. Real-world practice pattern and outcomes of patients with type 2 diabetes (T2DM) initiating injectable therapy via insulin glargine disposable pen (GLA-P) or liraglutide (LIRA). *Diabetes*. 2012;61:A286,A1108-P.
- D.355. Xie L, Zhou S, Wei WH, Gill J, Pan CS, Baser O. Health outcomes of switching from vial to disposable pen among type 2 diabetes patients treated with insulin glargine. *Diabetes*. 2012;61:A225-A226,A888-P.
- D.356. Xie L, Zhou S, Wei WH, Ling J, Baser O, Levin P. Treatment patterns and A1C reduction after adding a 3rd agent to 2 oral antidiabetic drugs (OADs). *Diabetes*. 2012;61:A244,A957-P.

- D.357. Baser O, Wang L, Du J, Wang H, Xie L. Impact of severity index for rheumatoid arthritis on healthcare costs and utilizations in patients with rheumatoid arthritis. *Arthritis Rheumatol.* 2012;64(10)S908:Abstract 2146.
- D.358. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. Veteran ankylosing spondylitis patients. *Arthritis Rheumatol.* 2012;64(10):S946:Abstract 2233.
- D.359. Baser O, Mody R, Xie L, Baser E, Morlock R. Comparison of daily average consumption between different proton pump inhibitors in patients with gastroesophageal reflux disease. *Am J Gastroenterol.* 2012;106(S2)S414-S415:Abstract 1112.
- D.360. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. veteran ankylosing spondylitis patients. *Value Health.* 2012;15(7)A518.
- D.361. Baser O, Wang L, Du J, Wang H, Xie L. Impact of Severity Index for Rheumatoid Arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *Value Health.* 2012;15(7)A441.
- D.362. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with rheumatoid arthritis prevalent cases in Turkey. *Value Health.* 2012;15(7)A518.
- D.363. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with ankylosing spondylitis incident cases in Turkey. *Value Health.* 2012;15(7)A443.
- D.364. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with ankylosing spondylitis prevalent cases in Turkey. *Value Health.* 2012;15(7)A441.
- D.365. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with rheumatoid arthritis incident cases in Turkey. *Value Health.* 2012;15(7)A443.
- D.366. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Regional variation in angiogram use for patients who underwent coronary artery bypass graft surgery. *Value Health.* 2012;15(7)A402.
- D.367. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High cost patients for cardiac surgery and hospital quality in Turkey. *Value Health.* 2012;15(7)A518.
- D.368. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Indirect costs associated with ankylosing spondylitis in Turkey. *Value Health.* 2012;15(7)A442.
- D.369. Baser O, Xie L, Huang A, Li L, Fritschel EK, Wang L. Assessing the survival rates and economic burden of prostate cancer in the US veteran population. *Value Health.* 2012;15(7)A518.
- D.370. Supina D, Lewis-Beck C, McElroy S, Hodgkins P, Baser O. Health care resource utilization and costs for patients with anorexia nervosa, bulimia nervosa, and binge eating disorder. *Value Health.* 2012;15(7)A343.

- D.371. Memiş SA, Değer C, Marmaralı B, Paralı E, Sümer F, Karakeben K, Başer O. New pricing policies after initiation of the Health Transformation Programme in Turkey. *Value Health*. 2012;15(7)A301.
- D.372. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Geographic variation associated with colorectal cancer prevalence in the United States. *Value Health*. 2012;15(7)A413.
- D.373. Baser O, Wang L, Du J, Wang H, Xie L. Impact of Severity Index for Rheumatoid Arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *Value Health*. 2012;15(7)A441.
- D.374. Hamuryudan V, Direskeneli H, Ertenli I, İnanç M, Karaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Indirect costs associated with rheumatoid arthritis in Turkey. *Value Health*. 2012;15(7)A443.
- D.375. Wang L, Xie L, Li L, Huang A, Wang H, Baser O. Visualizing treatment patterns of veteran patients with rheumatoid arthritis who initiated tumor necrosis factor therapy. *Value Health*. 2012;15(7)A453.
- D.376. Baser O, Wang L, Li L, Huang A, Wang H, Xie L. Application of data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *Value Health*. 2012;15(7)A453.
- D.377. Baser O, Wang L, Lewis-Beck C, Wang H, Li L, Xie L. Demographic and socioeconomic characteristics that affect selection of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *Value Health*. 2012;15(7)A454.
- D.378. Lewis-Beck C, Baser E, Baser O. An applied comparison of meta-analysis techniques using Bacille Calmette Guerin vaccine studies. *Value Health*. 2012;15(7)A486.
- D.379. Xie L, Wang L, Huang A, Li L, Fritschel EK, Baser O. Geographic variation trends in diabetes mellitus prevalence in the United States veteran population. *Value Health*. 2012;15(7)A496.
- D.380. Xie L, Wei W, Pan C, Baser O. Real-world incidence of hypoglycemia and associated costs among insulin- glargine treated patients with type 2 diabetes mellitus (T2DM). *Value Health*. 2012;15(7)A493.
- D.381. Baser E, Lewis-Beck C, Baser O. An Excel calculator tool to perform meta-analysis. *Value Health*. 2012;15(7)A487.
- D.382. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. veteran ankylosing spondylitis patients. *Value Health*. 2012;15(7)A518.
- D.383. Wang L, Baser O, Huang A, Li L, Fritschel EK, Xie L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in U.S. veteran patients. *Value Health*. 2012;15(7)A518.
- D.384. Baser O, Wang L, Li T, Shu Z, Xie L. Prevalence and incidence rates of multiple sclerosis in the United States. *Value Health*. 2012;15(7)A547.

- D.385. Xie L, Du J, Altınbas S, Baser O. Compare health care utilization and costs among menopausal women with different symptoms by linking women's registry and claims data. *Value Health*. 2012;15(7)A537.
- D.386. Xie L, Lewis-Beck C, Wang H, Altınbas A, Baser O. Demographic and clinical characteristics of menopausal women in the University of Michigan Women's Registry Database. *Value Health*. 2012;15(7)A536.
- D.387. Baser O, Zhou S, Wei W, Ling Z, Xie L, Levin P. Adding a third agent to two oral antidiabetic drugs (OADs): Real-world economic impact and effect of treatment persistence on clinical outcomes. *Diabetologia*. 2012;55:S405.
- D.388. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world practice pattern and outcomes of patients with type 2 diabetes (T2DM) initiating injectable therapy via insulin glargine disposable pen (GLA-P) or liraglutide (LIRA). *Diabetes*. 2012;61(S1)1108-P.
- D.389. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world outcomes of initiating injectable therapy with insulin glargine or liraglutide among patients with type 2 diabetes. *Diabetes*. 2012;61(S1)1173-P.
- D.390. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Health outcomes of switching from vial to disposable pen among type 2 diabetes patients treated with insulin glargine. *Diabetes*. 2012;61(S1)888-P.
- D.391. Xie L, Zhou S, Wei W, Lin J, Baser O, Levin P. Treatment patterns and A1C reduction after adding a 3rd agent to 2 oral antidiabetic drugs (OADs). *Diabetes*. 2012;61(S1)957-P.
- D.392. Wei W, Pan C, Xie L, Baser O. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). *Diabetes*. 2012;61(S1)13-OR.
- D.393. Baser O, Miao R, Wei W, Xie L. Real world outcomes of adding rapid acting insulin vs. switching to analog premix insulin among patients with type 2 diabetes treated with insulin glargine. *Diabetes*. 2012;61(S1)255-P.
- D.394. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating glargine-based insulin treatment vs. analog premix insulin among patients with type 2 diabetes failing oral antidiabetes drugs. *Diabetes*. 2012;61(S1)1173-P.
- D.395. Baser O, Wang L, Xie L, Du J, Wang H. Health care outcomes research: Effectiveness of a Severity Index for Rheumatoid Arthritis. *Ann Rheumatic Dis*. 2013;71:S3.
- D.396. Baser O, Wang L, Xie L, Yuce H. Treatment pattern visualization of Medicare patients diagnosed with rheumatoid arthritis and initiating tumor necrosis factor therapy. *Value Health*. 2012;15(4)A34.
- D.397. Baser O, Wang L, Xie L, Du J, Wang H. Derivation of severity index for rheumatoid arthritis and its effect on health care outcomes. *Value Health*. 2012;15(4)A34.

- D.398. Baser O, Schmeichel-Mueller C, Ingham M. Using scatter plots, analysis of univariate relationship between confounders and outcomes among rheumatoid arthritis patients who initiated anti-tumor necrosis factors and subsequently switched or escalated. *Value Health*. 2012;15(4)A43.
- D.399. Baser O, Schmeichel-Mueller C, Ingham M. Analyzing the difference in health care costs of rheumatoid arthritis patients switching or dose escalating anti-TNF biologics using combined propensity score matching and multivariate regression model. *Value Health*. 2012;15(4)A48.
- D.400. Lewis-Beck C, Baser E, Baser O. A review and applied comparison of meta-analysis techniques. *Value Health*. 2012;15(4)A160.
- D.401. Baser O, Wang L, Xie L, Yuce H. Data visualization of treatment patterns of Medicare psoriatic arthritis patients who initiate tumor necrosis factor therapy. *Value Health*. 2012;15(4)A34.
- D.402. Miao R, Wei W, Xie L, Baser O. Does pen help when elderly patients with type 2 diabetes initiate insulin? A real-world retrospective study of initiating insulin glargine via disposable pen vs. vial. *Value Health*. 2012;15(4)A8.
- D.403. Xie L, Joshi AV, Harnett J, Mardekian J, Schaaf D, Shah N, Baser O. Differences in health care utilization and associated costs between patients prescribed versus not prescribed opioids during an inpatient or emergency department visit. *Value Health*. 2012;15(4)A85-A86.
- D.404. Baser O, Wang L, Xie L, Yuce H. Application of data visualization tool: Treatment patterns of Medicare patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *Value Health*. 2012;15(4)A99.
- D.405. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E. Venous thromboembolism prophylaxis and clinical consequences in hospitalized medically ill patients. *Value Health*. 2012;15(4)A115.
- D.406. Baser O, Wang L, Xie L, Yuce H. Treatment patterns of Medicare patients with ulcerative colitis initiating tumor necrosis factor therapy: Application of a data visualization tool. *Value Health*. 2012;15(4)A135.
- D.407. Baser O, Wang L, Xie L, Yuce H. Visualizing treatment patterns of Medicare patients with Crohn's disease who initiated tumor necrosis factor therapy. *Value Health*. 2012;15(4)A136.
- D.408. Wang L, Wei W, Miao R, Xie L, Baser O. Real-world health care utilization, productivity and associated costs among employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn (NPH) insulin in the United States. *Value Health*. 2012;15(4)A176.
- D.409. Baser O, Xie L, Du J, Smith Y. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women's registry and claims database. *Value Health*. 2012;15(4)A194.
- D.410. Xie L, Racketta J, Bushmakina A, Mirkin S, Trocio J, Baser O. Economic impact of breast pain and bleeding among women prescribed estrogen plus progestogen hormone therapy. *Value Health*. 2012;15(4)A195.

- D.411. Baser O, Racketta J, Bushmakina A, Komm B, Trocio J, Xie L. Clinical and economic outcomes associated with early combined estrogen and progestogen hormone therapy for post-menopausal women. *Value Health*. 2012;15(4):A196.
- D.412. Wang L, Li L, Huang A, Baser O. Assessing the clinical and economic burden of veteran breast cancer patients in the United States. *Value Health*. 2012;15(4):A210.
- D.413. Wang L, Li L, Huang A, Baser O. Colorectal cancer patients in the veteran population: A health care cost and utilization analysis in the United States. *Value Health*. 2012;15(4):A211.
- D.414. Wang L, Li L, Huang A, Baser O. A descriptive analysis of ovarian cancer in veteran patients in the United States. *Value Health*. 2012;15(4):A215.
- D.415. Baser O, Wang L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in veteran patients in the United States. *Value Health*. 2012;15(4):A237- A238.
- D.416. Baser O, Wang L, Xie L, Yuce H. Using data visualization to illustrate treatment patterns of Medicare patients with diagnosis of psoriasis who initiated tumor necrosis factor therapy. *Value Health*. 2012;15(4):A250.
- D.417. Abouzaid S, Lewis-Beck C, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. *Value Health*. 2012;15(4):A34.
- D.418. Wang L, Joshi AV, Schaaf D, Mardekian J, Baser O. Prevalence of diagnosed opioid abuse in the national Veteran's Health Administration (VA) population. *J Pain*. 2012;13(4):S25.
- D.419. Baser O, Joshi AV, Schaaf D, Mardekian J, Wang L. Economic burden of diagnosed opioid abuse in the national Veteran's Health Administration (VA) population. *J Pain*. 2012;13(4):S15.

2011

- D.420. Baser O, Mody R, Morlock R, Xie L, Baser E. Characteristics of patients who switch from twice daily (BID) proton pump inhibitors (PPI) to once-daily (QD) dexlansoprazole or QD other PPIs. *Gastroenterology*. 2011;140(5):S398.
- D.421. Baser O, Mody R, Morlock R, Baser E, Xie L. Comparison of daily average consumption between different proton pump inhibitors in patients with gastroesophageal reflux disease. *Gastroenterology*. 2011;106:S414-S415.
- D.422. Baser O, Verpillat P, Wang L. How real-life data analysis could highlight ethnic inequalities in access to healthcare: Example of critical limb ischemia in the US Medicare population. *Pharmacoepidemiology And Drug Safety*. 2011;20:S146-S14, A337.
- D.423. Levin P, Wei WH, Wang L, Damon D, Baser O. Clinical characteristics and outcomes in patients with type 2 diabetes (T2D) adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting. *Diabetes*. 2011;60:A266,972-P.

- D.424. Baser O, Wang L, Xie L. Health care cost comparisons between alcohol or opioid- dependent patients who were treated with medication and those who were not. *Value Health*. 2011;14(7)A290.
- D.425. Baser O, Wang L. Evaluation of the prophylaxis patterns and 90-day outcome events in hospitalized medically- ill patients. *Value Health*. 2011;14(7)A364.
- D.426. Baser O, Wang L. Thromboprophylaxis use and venous thromboembolism, major and minor bleeding event analysis in hospitalized medically ill patients. *Value Health*. 2011;14(7)A364.
- D.427. Baser O, Wang L. Geographic variation trends in critical limb ischemia prevalence in the United States. *Value Health*. 2011;14(7)A368.
- D.428. Baser O, Wang L. Analysis of transient ischemic attack-related clinical outcomes, health care utilization and cost burden of patients with non-valvular atrial fibrillation. *Value Health*. 2011;14(7)A373.
- D.429. Baser O, Wang L. Clinical outcomes and costs associated with stroke in patients with non-valvular atrial fibrillation. *Value Health*. 2011;14(7)A373.
- D.430. Baser O, Wang L. Clinical and economic burden of major bleeding in abdominal surgery patients. *Value Health*. 2011;14(7)A372.
- D.431. Xie L, Baser E, Baser O. Treatment patterns and associated clinical and economic outcomes of women treated with hormone therapy. *Value Health*. 2011;14(7)399.
- D.432. Xie L, Baser E, Wang L, Baser O. Gastroesophageal reflux disease patients who switched from a branded proton pump inhibitor to a generic one and vice versa: A cost comparison. *Value Health*. 2011;14(7)A393.
- D.433. Wei W, Baser O, Du J, Xie L, Pan C. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer- sponsored health plans. *Value Health*. 2011;14(7)A476.
- D.434. Wang L, Xie L, Baser O. Assessment of drug adherence for type 2 diabetes patients using vial or pen form insulin: A method to adjust the traditional medication possession ratio. *Value Health*. 2011;14(7)A486.

2008

- D.435. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic testing after the FDA warning on atypical antipsychotic drugs and diabetes risk. *Pharmacoepidemiol Drug Safety*. 2008;17:S204,A464.
- D.436. Morrato EH, Newcomer JW, Ka-Mat S, Baser O , Harnett J, Cuffel B. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *Diabetes*. 2008;57:A279.
- D.437. Englesbe MJ, Fan ZH, Baser O, Birkmeyer JD, Dimick JB. Developing better measures of transplant center performance. *Am J Transplant*. 2008;8:265.

2007

D.438. Palmer L, Baser O, Arondekar B, Horblyuk R. Triple therapy with rosiglitazone (RSG) or insulin (INS) and associated medical resource use (MRU) and costs in type 2 diabetes (T2D). *Diabetes*. 2007;56:A650.

D.439. Finks JF, Ji H, Baser O, Birkmeyer JD. Effects of volume-based referral initiatives on the delivery of high-risk surgery in the US. 93rd Annual Clinical Congress of the American College of Surgeons. *J Am College Surgeons*. 2007;205(3):S75.

2006

D.440. Curtis JR, Barr CE, Baser O, Amonkar MM, Saag KG. Reduced osteoporosis-related expenditures, overall healthcare expenditures and health resource utilization observed for women adherent to bisphosphonate therapy. *Arthritis Rheumatism*. 2006;54(9):S85.

PRIVATE GRANTS FOR THE UNIVERSITIES

Columbia Data (Baser, PI)

September 2023

Bogazici University

Grant Support for Online Course Preparation

\$26,000

Goal: Online graduate teaching class preparation, including course materials and related videos for Health Economics.

Pfizer (Baser, PI)

September 2019

John D. Dingell VA Medical Center

Treatment Effects of Anticoagulant Therapies

\$300,000

Goal: Using Medicare linked Veteran Affairs dataset, we will look at the clinical and cost outcomes related with anticoagulant therapies.

Intuitive Surgical (Riva PI, Baser, co-PI)

September 2017

Columbia University

Clinical Outcomes among the Rectal Cancers

\$190,544

Patients Undergoing Laparoscopic, Robotic and Open low Anterior Resection

Goal: Using Columbia Medical Center data, the goal is to analyze clinical outcomes using propensity score matching

Novartis (Baser, PI)

December 2016

Columbia University

\$120,631

Health Care Resources Utilization and Costs among Patients diagnosed with sporadic inclusion body myositis in Medicare Population.

Goal: Using Medicare data and matching patients with sporadic inclusion body myositis and without sporadic inclusion body myositis, we analyzed health care resource utilization and costs. (<https://columbiasurgery.org/cior/ongoing-studies>)

Otsuka (Baser, PI)

April 2016

Columbia University

\$18,000

Outcome Study with Schizophrenia, Otsuka

Goal: Comparing health care costs and utilization of patients with schizophrenia using US commercial claims datasets.

Johnson & Johnson (Baser, PI)

April 2016

Columbia University

\$167,445

Comorbidities and economic burden of heart failure in the US Medicare Population

Goal: Using Medicare Population in US, estimate comorbidities and economic burden of heart failure.

Celgene (Baser, PI)

January 2017

Columbia University

\$129,676

Treatment Patterns and Adverse Events for patients newly diagnosed with Multiple Myeloma.

Goal: Using Medicare data and matching patients with patients with multiple myeloma with different treatments, we look at the adverse events.

Takeda Pharmaceutical (Baser, PI)

January 2016

Columbia University

\$6,014

Proton Pump Inhibitor Utilization among Medicaid Patients with Hepatitis C

Goal: Using Medicaid MAX dataset, we identified Hepatitis C patients and look at their use of Proton Pump Inhibitor, then categorizing by the use, we looked at the health outcomes. (<https://columbiasurgery.org/cior/ongoing-studies>)

Merck & Co (Baser, PI)

February 2016

Columbia University

\$5677

Treatment Patterns and Burden of Alzheimer Diseases in the US Medicare Population

Goal: Using Medicare data, treatment patterns of Alzheimer patients and their health outcomes analyzed. (<https://columbiasurgery.org/cior/ongoing-studies>)

Merck & Co (Baser, PI)

March 2016

Columbia University

\$135,000

Outcome Studies in Alzheimer Disease

Goal: Using Medicare data, health outcomes of Alzheimer patients are analyzed.

GOVERNMENT FUNDING

The Department of Homeland Security (DHS) (Baser, Co-PI)

2024-2025

Science and Technology Directorate (S&T) Research Grant

\$100,000

Economic Impact of COVID-19 and Optimal Vaccination Distribution at County Level in the U.S.

University of Michigan R-Grant (Baser, PI)

September 2007

University of Michigan

\$35,750 (0 CM)

Goal: To develop methods for measuring the costs of perioperative complications and the costs of down-stream complications. To identify the types of complications associated with greatest excess costs.

CURRENT MEMBERSHIP

International Society for Pharmacoeconomics and Outreach Research